PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
15039140-5	2004	22HC/RA stimulated basolateral PtdCho efflux in cells via transcriptional activation of the ATP-binding cassette transporter 1 (ABCA1) gene.	Isotretinoin	5-7	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	92-126
15039140-5	2004	22HC/RA stimulated basolateral PtdCho efflux in cells via transcriptional activation of the ATP-binding cassette transporter 1 (ABCA1) gene.	Isotretinoin	5-7	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	128-133
15039140-7	2004	ABCA1 knockdown studies using ABCA1 siRNA or the ABCA1 inhibitor, glyburide, selectively attenuated 22HC/RA-driven basolateral PtdCho efflux.	Isotretinoin	105-107	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	0-5
15138569-2	2004	13-cis retinoic acid (13-cRA) was demonstrated to reverse pre-malignant lesions of the oral cavity and to reduce the incidence of second primary tumours in patients treated radically for HNSCC.	Isotretinoin	0-20	myotubularin related protein 11	Homo sapiens	25-28
15116059-2	2004	Although isotretinoin and estradiol are metabolized largely by cytochrome P450 (CYP) 3A4 and glucuronidation, the potential for clinical drug interaction, with subsequent pharmacodynamic impact, has not been evaluated.	Isotretinoin	9-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	63-88
15007394-4	2004	RESULTS: Both experimental groups displayed an increase in adiposity with contrasting effects on TG (lowered by fenofibrate and increased by isotretinoin) and gene expression (no change in fibrate-treated rats and increased expression of ApoC-III and Hnf-4 in isotretinoin-treated group).	Isotretinoin	260-272	apolipoprotein C3	Rattus norvegicus	238-246
15067110-15	2004	Finally, we showed that the formation of A2E oxiranes is strongly suppressed by treating the abcr(-/-) mice with Accutane (isotretinoin), an inhibitor of rhodopsin regeneration.	Isotretinoin	113-121	ATP-binding cassette, sub-family A (ABC1), member 4	Mus musculus	93-97
15067110-15	2004	Finally, we showed that the formation of A2E oxiranes is strongly suppressed by treating the abcr(-/-) mice with Accutane (isotretinoin), an inhibitor of rhodopsin regeneration.	Isotretinoin	113-121	rhodopsin	Mus musculus	154-163
15067110-15	2004	Finally, we showed that the formation of A2E oxiranes is strongly suppressed by treating the abcr(-/-) mice with Accutane (isotretinoin), an inhibitor of rhodopsin regeneration.	Isotretinoin	123-135	ATP-binding cassette, sub-family A (ABC1), member 4	Mus musculus	93-97
15067110-15	2004	Finally, we showed that the formation of A2E oxiranes is strongly suppressed by treating the abcr(-/-) mice with Accutane (isotretinoin), an inhibitor of rhodopsin regeneration.	Isotretinoin	123-135	rhodopsin	Mus musculus	154-163
15263793-1	2004	INTRODUCTION: Conventional preclinical investigations have strongly recommended to combine interferon-alpha (IFN-alpha) with 13-cis retinoic acid (13-cRA, isotretinoin) for treatment of renal cell carcinoma (RCC).	Isotretinoin	125-145	myotubularin related protein 11	Homo sapiens	150-153
14750596-5	2004	Isotretinoin (Accutane) has been shown to slow the synthesis of 11-cis-retinaldehyde (11cRAL) and regeneration of rhodopsin by inhibiting 11-cis-retinol dehydrogenase (11cRDH) in the visual cycle.	Isotretinoin	0-12	rhodopsin	Mus musculus	114-123
14750596-5	2004	Isotretinoin (Accutane) has been shown to slow the synthesis of 11-cis-retinaldehyde (11cRAL) and regeneration of rhodopsin by inhibiting 11-cis-retinol dehydrogenase (11cRDH) in the visual cycle.	Isotretinoin	0-12	retinol dehydrogenase 5	Mus musculus	138-166
14750596-5	2004	Isotretinoin (Accutane) has been shown to slow the synthesis of 11-cis-retinaldehyde (11cRAL) and regeneration of rhodopsin by inhibiting 11-cis-retinol dehydrogenase (11cRDH) in the visual cycle.	Isotretinoin	0-12	retinol dehydrogenase 5	Mus musculus	170-174
14750596-5	2004	Isotretinoin (Accutane) has been shown to slow the synthesis of 11-cis-retinaldehyde (11cRAL) and regeneration of rhodopsin by inhibiting 11-cis-retinol dehydrogenase (11cRDH) in the visual cycle.	Isotretinoin	14-22	rhodopsin	Mus musculus	114-123
14750596-5	2004	Isotretinoin (Accutane) has been shown to slow the synthesis of 11-cis-retinaldehyde (11cRAL) and regeneration of rhodopsin by inhibiting 11-cis-retinol dehydrogenase (11cRDH) in the visual cycle.	Isotretinoin	14-22	retinol dehydrogenase 5	Mus musculus	138-166
14750596-5	2004	Isotretinoin (Accutane) has been shown to slow the synthesis of 11-cis-retinaldehyde (11cRAL) and regeneration of rhodopsin by inhibiting 11-cis-retinol dehydrogenase (11cRDH) in the visual cycle.	Isotretinoin	14-22	retinol dehydrogenase 5	Mus musculus	170-174
15448735-13	2004	TGF-beta1, isotretinoin and tretinoin added to the culture resulted in the lowest percentage of PCNA positive cells.	Isotretinoin	11-23	proliferating cell nuclear antigen	Homo sapiens	96-100
14666262-4	2003	The effects of a 72-h exposure to 50  M 13-cis retinoic acid on HC11 and HC11ras cell proliferation and HC11 cell differentiation were investigated by flow cytometric cell cycle analysis, and by determination of  -casein mRNA expression, respectively.	Isotretinoin	40-60	heterochromatin, Chr 11	Mus musculus	64-68
14666262-4	2003	The effects of a 72-h exposure to 50  M 13-cis retinoic acid on HC11 and HC11ras cell proliferation and HC11 cell differentiation were investigated by flow cytometric cell cycle analysis, and by determination of  -casein mRNA expression, respectively.	Isotretinoin	40-60	heterochromatin, Chr 11	Mus musculus	73-77
16767920-2	2003	We have demonstrated, in a phase IB study, that administering low-dose interleukin-2 (IL-2) and 13-cis retinoic acid (RA), there was a significant improvement of the immune function, with low toxicity, in PTS with advanced tumors that had been treated with aggressive surgery and chemotherapy (Clin Cancer Res 7: 1251-1257, 2001).	Isotretinoin	96-116	interleukin 2 receptor subunit alpha	Homo sapiens	118-120
14581068-1	2003	All-trans retinoic acid (tRA, or tretinoin) can be metabolized through stereoisomerization to 13-cis retinoic acid (13-cRA) in vivo.	Isotretinoin	94-114	myotubularin related protein 11	Homo sapiens	119-122
14501777-14	2003	Fibronectin and collagen I immunostaining was also decreased by isotretinoin.	Isotretinoin	64-76	fibronectin 1	Rattus norvegicus	0-11
12768320-1	2003	PURPOSE: Based on prior studies demonstrating the effect of 13- cis-retinoic acid and interferon alpha (CRA/IFN) in decreasing the expression of the antiapoptotic protein bcl-2, our prior clinical study of CRA/IFN with paclitaxel (TAX) administered every 3 weeks, and data demonstrating increased activity of weekly TAX against prostate cancer, we designed a phase I study of weekly TAX in combination with CRA/IFN in patients with prostate cancer and other advanced malignancies.	Isotretinoin	60-81	BCL2 apoptosis regulator	Homo sapiens	171-176
12804041-2	2003	Because of the enhancement of the antiproliferative effects of interferon-alpha2a, 13-cis-retinoic acid (13-CRA) might be of potential usefulness for immunotherapy.	Isotretinoin	83-103	interferon alpha 2	Homo sapiens	63-81
12671074-5	2003	Isotretinoin (Accutane) has been shown to slow the synthesis of 11-cis-retinaldehyde and regeneration of rhodopsin by inhibiting 11-cis-retinol dehydrogenase in the visual cycle.	Isotretinoin	0-12	rhodopsin	Mus musculus	105-114
12671074-5	2003	Isotretinoin (Accutane) has been shown to slow the synthesis of 11-cis-retinaldehyde and regeneration of rhodopsin by inhibiting 11-cis-retinol dehydrogenase in the visual cycle.	Isotretinoin	0-12	retinol dehydrogenase 5	Mus musculus	129-157
12671074-5	2003	Isotretinoin (Accutane) has been shown to slow the synthesis of 11-cis-retinaldehyde and regeneration of rhodopsin by inhibiting 11-cis-retinol dehydrogenase in the visual cycle.	Isotretinoin	14-22	rhodopsin	Mus musculus	105-114
12671074-5	2003	Isotretinoin (Accutane) has been shown to slow the synthesis of 11-cis-retinaldehyde and regeneration of rhodopsin by inhibiting 11-cis-retinol dehydrogenase in the visual cycle.	Isotretinoin	14-22	retinol dehydrogenase 5	Mus musculus	129-157
12880980-4	2003	The cytotoxic retinoid 4-HPR achieved multi-log cell kills in neuroblastoma cell lines resistant to ATRA and 13-cis-RA, and a pediatric phase I trial has shown it to be well tolerated.	Isotretinoin	109-118	haptoglobin-related protein	Homo sapiens	25-28
12804041-2	2003	Because of the enhancement of the antiproliferative effects of interferon-alpha2a, 13-cis-retinoic acid (13-CRA) might be of potential usefulness for immunotherapy.	Isotretinoin	83-103	myotubularin related protein 11	Homo sapiens	108-111
12646198-0	2003	13-cis-retinoic acid competitively inhibits 3 alpha-hydroxysteroid oxidation by retinol dehydrogenase RoDH-4: a mechanism for its anti-androgenic effects in sebaceous glands?	Isotretinoin	0-20	retinol dehydrogenase 16	Homo sapiens	102-108
12643008-1	2003	PURPOSE: Combined biological therapy with 13-cis-retinoic acid (13-cRA) and interferon alpha-2a (IFN alpha-2a) was reported to be highly effective in squamous cell carcinoma of the cervix and skin.	Isotretinoin	42-62	myotubularin related protein 11	Homo sapiens	67-70
12569141-1	2003	BACKGROUND: Altered cyclin D1 expression in advanced preinvasive lesions of the upper aerodigestive tract (UADT) is associated with an increased risk of developing cancer and histologic progression during and after combination biochemopreventive therapy (13-cis-retinoic acid, alpha-interferon, and alpha-tocopherol).	Isotretinoin	255-275	cyclin D1	Homo sapiens	20-29
12488329-7	2003	Moreover, in prostate cancer cells, the synergism between 1,25-(OH)(2)D(3) and 9-cis retinoic acid appears to be dependent on the presence of functional p53; however, 1,25-(OH)(2)D(3)-mediated induction of G(1) cell cycle accumulation and induction of apoptosis is not.	Isotretinoin	81-98	tumor protein p53	Homo sapiens	153-156
12209689-7	2002	CONCLUSIONS: The current data suggest that combined outpatient sc IFN-alpha and sc IL-2, according to the Atzpodien regimen, achieves long-term survival benefits in a subset of patients with metastatic renal cell carcinoma, both with and without 13-cis-retinoic acid and/or 5-fluorouracil.	Isotretinoin	246-266	interferon alpha 1	Homo sapiens	66-75
12209689-7	2002	CONCLUSIONS: The current data suggest that combined outpatient sc IFN-alpha and sc IL-2, according to the Atzpodien regimen, achieves long-term survival benefits in a subset of patients with metastatic renal cell carcinoma, both with and without 13-cis-retinoic acid and/or 5-fluorouracil.	Isotretinoin	246-266	interleukin 2	Homo sapiens	83-87
12164942-2	2002	In this study, we have shown that bovine serum albumin, an extracellular binding protein for 13-cis retinoic acid, plays an important part in the uptake of 13-cis retinoic acid in human sebocytes, its intracellular isomerization to all-trans retinoic acid, and the induction of its anti-proliferative effect.	Isotretinoin	93-113	albumin	Homo sapiens	41-54
12168960-2	2002	Vitamin A derivatives, including 13-cis retinoic acid (13-CRA), have been used to treat DOL and to reduce the risk of subsequent SCC.	Isotretinoin	33-53	myotubularin related protein 11	Homo sapiens	58-61
12168960-2	2002	Vitamin A derivatives, including 13-cis retinoic acid (13-CRA), have been used to treat DOL and to reduce the risk of subsequent SCC.	Isotretinoin	33-53	serpin family B member 3	Homo sapiens	129-132
12389622-1	2002	We previously reported the therapeutic efficacy of 13-cis retinoic acid (13-cRA) in some subtypes of peripheral T-cell lymphoma (PTCL).	Isotretinoin	51-71	myotubularin related protein 11	Homo sapiens	76-79
12164942-2	2002	In this study, we have shown that bovine serum albumin, an extracellular binding protein for 13-cis retinoic acid, plays an important part in the uptake of 13-cis retinoic acid in human sebocytes, its intracellular isomerization to all-trans retinoic acid, and the induction of its anti-proliferative effect.	Isotretinoin	156-176	albumin	Homo sapiens	41-54
12164942-5	2002	In parallel experiments, the anti-proliferative activity of 13-cis retinoic acid on SZ95 sebocytes was abrogated by adding 20 mg bovine serum albumin per ml into the serum-free medium.	Isotretinoin	60-80	albumin	Homo sapiens	136-149
11882655-9	2002	Recombinant enzymes with specificity for all-trans- or 9-cis-retinal were obtained, which should provide useful tools to study the relative importance of local production of all-trans- versus 9-cis-retinoic acid in development and tissue differentiation.	Isotretinoin	194-211	olfactory receptor 1742	Rattus norvegicus	52-56
12012010-2	2002	13-cis retinoic acid (RA) has immunomodulatory properties, potentially synergistic with IL-2.	Isotretinoin	0-20	interleukin 2 receptor subunit alpha	Homo sapiens	22-24
12012010-2	2002	13-cis retinoic acid (RA) has immunomodulatory properties, potentially synergistic with IL-2.	Isotretinoin	0-20	interleukin 2	Homo sapiens	88-92
11978287-1	2002	OBJECTIVE: To estimate the efficacy of isotretinoin for prevention of progression of low-grade squamous intraepithelial lesions (SIL) of the cervix to high-grade lesions or invasive cervical cancer; to estimate the regression rate of low-grade SIL with isotretinoin and the toxicity of isotretinoin in this setting; and to correlate serum CD4 levels with progression of low-grade SIL.	Isotretinoin	39-51	CD4 molecule	Homo sapiens	339-342
11955026-12	2002	Lipid response to isotretinoin was closely associated with the apoE gene.	Isotretinoin	18-30	apolipoprotein E	Homo sapiens	63-67
11911845-8	2002	The fetal form CYP3A7 was also identified as very active in either 9-cis- or 13-cis-RA metabolism.	Isotretinoin	77-86	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	15-21
11943887-2	2002	Based on these results, we conducted a phase II trial of 13-cis-retinoic acid (cRA) at 1 mg/kg/dose interferon alpha2a (IFN) at initial dose of 9 MU three times a week.	Isotretinoin	57-77	interferon alpha 2	Homo sapiens	100-118
11943887-2	2002	Based on these results, we conducted a phase II trial of 13-cis-retinoic acid (cRA) at 1 mg/kg/dose interferon alpha2a (IFN) at initial dose of 9 MU three times a week.	Isotretinoin	57-77	interferon alpha 1	Homo sapiens	120-123
11943887-2	2002	Based on these results, we conducted a phase II trial of 13-cis-retinoic acid (cRA) at 1 mg/kg/dose interferon alpha2a (IFN) at initial dose of 9 MU three times a week.	Isotretinoin	79-82	interferon alpha 2	Homo sapiens	100-118
11943887-2	2002	Based on these results, we conducted a phase II trial of 13-cis-retinoic acid (cRA) at 1 mg/kg/dose interferon alpha2a (IFN) at initial dose of 9 MU three times a week.	Isotretinoin	79-82	interferon alpha 1	Homo sapiens	120-123
11786584-4	2002	After cross-over on week 13, patients in arm 1 discontinued while patients in arm 2 added isotretinoin from weeks 14 to 25.	Isotretinoin	90-102	Jupiter microtubule associated homolog 1	Homo sapiens	78-83
11737596-10	2001	The increase of transforming growth factor (TGF)-beta1, TGF receptor II and prepro-endothelin-1 gene expression in vehicle-treated nephritic rats was significantly attenuated by isotretinoin.	Isotretinoin	178-190	transforming growth factor, beta 1	Rattus norvegicus	16-54
11737596-10	2001	The increase of transforming growth factor (TGF)-beta1, TGF receptor II and prepro-endothelin-1 gene expression in vehicle-treated nephritic rats was significantly attenuated by isotretinoin.	Isotretinoin	178-190	endothelin 1	Rattus norvegicus	83-95
11277950-1	2001	BACKGROUND: The use of Isotretinoin (Iso) for cystic acne (CA) therapy includes marked side-effects such as dyslipidemia, increased liver enzymes, and reduction of biotinidase activity.	Isotretinoin	23-35	biotinidase	Homo sapiens	164-175
11606947-1	2001	Isotretinoin (13-cis-retinoic acid) is a retinoid that has been used over the past 2 decades to treat a wide variety of dermatologic conditions, some with great success.	Isotretinoin	0-12	EH domain containing 2	Homo sapiens	78-84
11606947-1	2001	Isotretinoin (13-cis-retinoic acid) is a retinoid that has been used over the past 2 decades to treat a wide variety of dermatologic conditions, some with great success.	Isotretinoin	14-34	EH domain containing 2	Homo sapiens	78-84
11564604-2	2001	RXR also forms homodimers to mediate 9-cis retinoic acid (9-cis RA)-induced gene expression.	Isotretinoin	60-66	retinoid X receptor alpha	Homo sapiens	0-3
11747145-0	2001	Dyslipidemia and a reversible decrease in insulin sensitivity induced by therapy with 13-cis-retinoic acid.	Isotretinoin	86-106	insulin	Homo sapiens	42-49
11747145-8	2001	CONCLUSION: Treatment of acne with 13-cis-retinoic acid reduces insulin sensitivity and induces alterations in lipid metabolism resembling those of the insulin resistance syndrome.	Isotretinoin	35-55	insulin	Homo sapiens	64-71
11505395-1	2001	BACKGROUND: Interferon and 13-cis-retinoic acid (13-CRA) therapy showed clinical response rates of 30% in advanced renal cell carcinoma (RCC).	Isotretinoin	27-47	myotubularin related protein 11	Homo sapiens	52-55
11408495-2	2001	Alpha-tocopherol has chemopreventive activity in the head and neck and may decrease 13-cis-retinoic acid (13-cRA) toxicity.	Isotretinoin	84-104	myotubularin related protein 11	Homo sapiens	109-112
11497248-2	2001	In the present study, we determined the influence of high dietary concentrations of 4-hydroxyphenylretinamide (4-HPR) and 13-cis-retinoic acid (13-cis-RA) on RAR-beta mRNA expression in female mice.	Isotretinoin	122-142	retinoic acid receptor, beta	Mus musculus	158-166
11237771-3	2001	A similar effect was observed with 13-cis retinoic acid (RA), which has been used in chemoprevention of SCC.	Isotretinoin	35-55	serpin family B member 3	Homo sapiens	104-107
11181746-6	2001	On the basis of enzyme assays in vitro, ACAT activity was increased 3.0-fold by using 100 nM 1,25-(OH)(2)D(3), and 1.8-fold by using 1 microM 9-cis-RA.	Isotretinoin	143-150	acetyl-CoA acetyltransferase 1	Homo sapiens	40-44
11604994-3	2001	One such candidate may be 13-cRA (cis retinoic acid), a vitamin A derivative known to markedly regulate the differentiation and proliferation of normal and neoplastic cells.	Isotretinoin	34-51	myotubularin related protein 11	Mus musculus	29-32
11675406-3	2001	Therefore, the effects of all-trans retinoic acid and isotretinoin on the components of the TGF-beta system and extracellular matrix proteins in anti-Thy1.1-nephritis (Thy-GN) were investigated.	Isotretinoin	54-66	transforming growth factor, beta 1	Rattus norvegicus	92-100
11675406-6	2001	The increase of cortical TGF-beta 1 gene expression in Thy-GN rats was significantly attenuated with all-trans retinoic acid and even more with isotretinoin treatment as compared with untreated animals (P < 0.025).	Isotretinoin	144-156	transforming growth factor, beta 1	Rattus norvegicus	25-35
11509747-1	2001	Isotretinoin (13-cis-retinoic acid [13CRA], Accutane) is used for the treatment of dermatological diseases.	Isotretinoin	0-12	myotubularin related protein 11	Homo sapiens	38-41
11509747-1	2001	Isotretinoin (13-cis-retinoic acid [13CRA], Accutane) is used for the treatment of dermatological diseases.	Isotretinoin	14-34	myotubularin related protein 11	Homo sapiens	38-41
11489748-2	2001	In a previous Phase III study, we observed that high doses of 13-cis-retinoic acid reduced the SPT rate in this disease.	Isotretinoin	62-82	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	95-98
11435507-4	2001	Here, we examined the ability of CRA, as well as all-trans-retinoic acid (ATRA), to regulate hepatic GNMT as a potential basis for our earlier observations.	Isotretinoin	33-36	glycine N-methyltransferase	Rattus norvegicus	101-105
11435507-6	2001	Rats from each group were orally given ATRA, CRA (both at 30 micromol/kg body), or vehicle daily for 7 d. For control rats, administration of both CRA and ATRA elevated the hepatic GNMT activity 49% and 34%, respectively, compared with the control group.	Isotretinoin	45-48	glycine N-methyltransferase	Rattus norvegicus	181-185
11435507-6	2001	Rats from each group were orally given ATRA, CRA (both at 30 micromol/kg body), or vehicle daily for 7 d. For control rats, administration of both CRA and ATRA elevated the hepatic GNMT activity 49% and 34%, respectively, compared with the control group.	Isotretinoin	147-150	glycine N-methyltransferase	Rattus norvegicus	181-185
11172037-14	2001	HPLC analysis of ocular retinoids after isotretinoin and an intense bleach showed decreased levels of rhodopsin chromophore, 11-cis retinal, and the accumulation of the biosynthetic intermediates, 11-cis and all-trans retinyl esters.	Isotretinoin	40-52	rhodopsin	Rattus norvegicus	102-111
11277950-1	2001	BACKGROUND: The use of Isotretinoin (Iso) for cystic acne (CA) therapy includes marked side-effects such as dyslipidemia, increased liver enzymes, and reduction of biotinidase activity.	Isotretinoin	23-26	biotinidase	Homo sapiens	164-175
10999756-2	2000	13-cis-Retinoic acid (13-cis-RA) was comparable to all-trans-retinoic acid (RA) in inducing transglutaminase II (TGase II) in cultured human cells.	Isotretinoin	0-20	transglutaminase 2	Rattus norvegicus	113-121
11051228-0	2000	Effect of 13-cis-retinoic acid on serum prostate-specific antigen levels in patients with recurrent prostate cancer after radical prostatectomy.	Isotretinoin	10-30	kallikrein related peptidase 3	Homo sapiens	40-65
11051228-11	2000	Isotretinoin had a modest, transient effect on the serum PSA level in 4 of 11 (36%) patients with a rising serum PSA after radical prostatectomy.	Isotretinoin	0-12	kallikrein related peptidase 3	Homo sapiens	57-60
11051228-11	2000	Isotretinoin had a modest, transient effect on the serum PSA level in 4 of 11 (36%) patients with a rising serum PSA after radical prostatectomy.	Isotretinoin	0-12	kallikrein related peptidase 3	Homo sapiens	113-116
10999756-2	2000	13-cis-Retinoic acid (13-cis-RA) was comparable to all-trans-retinoic acid (RA) in inducing transglutaminase II (TGase II) in cultured human cells.	Isotretinoin	22-31	transglutaminase 2	Rattus norvegicus	113-121
10999756-3	2000	Inhaled 13-cis-RA had a significant stimulatory activity on TGase II in rat lung (P < 0.001) but not in liver tissue (P < 0.544).	Isotretinoin	8-17	transglutaminase 2	Rattus norvegicus	60-68
11066455-11	2000	It was shown in the early 1980s that 13-cis-retinoic acid (13cRA) could stimulate differentiation in bone marrow cells collected from patients with various acute leukemias, including M3.	Isotretinoin	37-57	myotubularin related protein 11	Homo sapiens	61-64
10906161-16	2000	Glomerular staining for platelet-derived growth factor B-chain was significantly reduced in anti-Thy1.1-treated nephritic rats in the presence of isotretinoin or all-trans-RA, compared with the vehicle-treated group (P < 0.001).	Isotretinoin	146-158	platelet derived growth factor subunit B	Rattus norvegicus	24-62
10951254-7	2000	De novo mRNA expression of cytochrome P450 1A1, a major xenobiotic metabolizing enzyme, in SZ95 sebocytes was induced by all-trans retinoic acid, but not by 13-cis retinoic acid.	Isotretinoin	157-177	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	27-46
10951254-9	2000	Both 13-cis retinoic acid and all-trans retinoic acid suppressed mRNA expression of cytochrome P450 1A2.	Isotretinoin	5-25	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	84-103
11107678-0	2000	[Renal carcinoma: effective modulation of low-dose interferon-alpha and interleukin-2 with medroxyprogesterone acetate and 13-cis retinoic acid].	Isotretinoin	123-143	interleukin 2	Homo sapiens	72-85
10959555-7	2000	RESULTS: ATRA and 13RA were found to have a more pronounced inhibitory effect on LFA-3 expression than did DEX, the U937 cells being the most sensitive and the KB cells the least affected.	Isotretinoin	18-22	CD58 molecule	Homo sapiens	81-86
10760826-8	2000	While the catalytic activity of all 3 G(1)-associated CDKs (CDK2, CDK4 and CDK6) was strongly inhibited in RA-treated LCLs, only CDK2-associated kinase activity was reduced in DG75 cells arrested in G(0)/G(1) by RA.	Isotretinoin	107-109	cyclin dependent kinase 2	Homo sapiens	54-58
10760826-8	2000	While the catalytic activity of all 3 G(1)-associated CDKs (CDK2, CDK4 and CDK6) was strongly inhibited in RA-treated LCLs, only CDK2-associated kinase activity was reduced in DG75 cells arrested in G(0)/G(1) by RA.	Isotretinoin	107-109	cyclin dependent kinase 2	Homo sapiens	60-64
10760826-8	2000	While the catalytic activity of all 3 G(1)-associated CDKs (CDK2, CDK4 and CDK6) was strongly inhibited in RA-treated LCLs, only CDK2-associated kinase activity was reduced in DG75 cells arrested in G(0)/G(1) by RA.	Isotretinoin	107-109	cyclin dependent kinase 4	Homo sapiens	66-70
10760826-8	2000	While the catalytic activity of all 3 G(1)-associated CDKs (CDK2, CDK4 and CDK6) was strongly inhibited in RA-treated LCLs, only CDK2-associated kinase activity was reduced in DG75 cells arrested in G(0)/G(1) by RA.	Isotretinoin	107-109	cyclin dependent kinase 6	Homo sapiens	75-79
10760826-8	2000	While the catalytic activity of all 3 G(1)-associated CDKs (CDK2, CDK4 and CDK6) was strongly inhibited in RA-treated LCLs, only CDK2-associated kinase activity was reduced in DG75 cells arrested in G(0)/G(1) by RA.	Isotretinoin	212-214	cyclin dependent kinase 2	Homo sapiens	54-58
10859533-2	2000	We investigated the effect of oral isotretinoin (13-cis-retinoic acid) on the expression of two distinct isoforms of TGF-beta, TGF-beta1 and TGF-beta2, in suction blister fluid and serum in acne patients.	Isotretinoin	35-47	transforming growth factor beta 1	Homo sapiens	117-125
10859533-2	2000	We investigated the effect of oral isotretinoin (13-cis-retinoic acid) on the expression of two distinct isoforms of TGF-beta, TGF-beta1 and TGF-beta2, in suction blister fluid and serum in acne patients.	Isotretinoin	35-47	transforming growth factor beta 1	Homo sapiens	127-136
10859533-2	2000	We investigated the effect of oral isotretinoin (13-cis-retinoic acid) on the expression of two distinct isoforms of TGF-beta, TGF-beta1 and TGF-beta2, in suction blister fluid and serum in acne patients.	Isotretinoin	35-47	transforming growth factor beta 2	Homo sapiens	141-150
10859533-2	2000	We investigated the effect of oral isotretinoin (13-cis-retinoic acid) on the expression of two distinct isoforms of TGF-beta, TGF-beta1 and TGF-beta2, in suction blister fluid and serum in acne patients.	Isotretinoin	49-69	transforming growth factor beta 1	Homo sapiens	117-125
10859533-2	2000	We investigated the effect of oral isotretinoin (13-cis-retinoic acid) on the expression of two distinct isoforms of TGF-beta, TGF-beta1 and TGF-beta2, in suction blister fluid and serum in acne patients.	Isotretinoin	49-69	transforming growth factor beta 1	Homo sapiens	127-136
10859533-2	2000	We investigated the effect of oral isotretinoin (13-cis-retinoic acid) on the expression of two distinct isoforms of TGF-beta, TGF-beta1 and TGF-beta2, in suction blister fluid and serum in acne patients.	Isotretinoin	49-69	transforming growth factor beta 2	Homo sapiens	141-150
10859533-4	2000	Six weeks of isotretinoin treatment caused a statistically significant 19% increase in suction blister fluid TGF-beta1.	Isotretinoin	13-25	transforming growth factor beta 1	Homo sapiens	109-118
10859533-11	2000	Modulation of local interstitial fluid TGF-beta1 concentration may be one mechanism by which isotretinoin and glucocorticoids mediate their effects in skin.	Isotretinoin	93-105	transforming growth factor beta 1	Homo sapiens	39-48
10944130-1	2000	PURPOSE: A randomized phase III trial was conducted to determine whether combination therapy with 13-cis-retinoic acid (13-CRA) plus interferon alfa-2a (IFNalpha2a) is superior to IFNalpha2a alone in patients with advanced renal cell carcinoma (RCC).	Isotretinoin	98-118	myotubularin related protein 11	Homo sapiens	123-126
10738115-11	2000	These results suggest that the growth inhibitory effect of 9-cis-RA on oral squamous cell carcinoma may depend on the expression levels of RARs, especially RARbeta proteins and RXRalpha proteins, and that 9-cis-RA may provide a powerful therapeutic agent for head and neck cancers.	Isotretinoin	60-67	retinoid X receptor alpha	Homo sapiens	177-185
10983416-7	2000	Level of keratin-1 (K1) mRNA was increased by 11-cis-retinoic acid and 13-cis-retinoic acid, but suppressed by 9,13-di-cis-retinoic acids while all-trans-retinoic acid and 9-cis-retinoic acid had no effect.	Isotretinoin	71-91	keratin 1	Homo sapiens	9-18
10983416-7	2000	Level of keratin-1 (K1) mRNA was increased by 11-cis-retinoic acid and 13-cis-retinoic acid, but suppressed by 9,13-di-cis-retinoic acids while all-trans-retinoic acid and 9-cis-retinoic acid had no effect.	Isotretinoin	71-91	keratin 1	Homo sapiens	20-22
10983416-8	2000	Level of keratin-10 (K10) mRNA was strongly inhibited by all-trans-retinoic acid, 9-cis-retinoic acid and 11-cis-retinoic acid as compared to 13-cis-retinoic acid and 9,13-di-cis-retinoic acids.	Isotretinoin	142-162	keratin 10	Homo sapiens	9-19
10983416-8	2000	Level of keratin-10 (K10) mRNA was strongly inhibited by all-trans-retinoic acid, 9-cis-retinoic acid and 11-cis-retinoic acid as compared to 13-cis-retinoic acid and 9,13-di-cis-retinoic acids.	Isotretinoin	142-162	keratin 10	Homo sapiens	21-24
10584127-7	1999	Treatment with both drugs (5 microM 13-cis retinoic acid, 25 IU/ml IFN-alpha) prior and post irradiation of the cells resulted in a pronounced enhancement of radiation toxicity resulting in significantly decreased SF2- and alpha-values.	Isotretinoin	36-56	serine and arginine rich splicing factor 1	Homo sapiens	214-217
10712807-4	2000	At the same concentration, 9-cis RA and cholecalciferol induced ALP of chondroblast and osteoblast cells, respectively; ATRA, 9-cis RA and cholecalciferol induced PIP of chondroblast and undifferentiated cells.	Isotretinoin	29-35	alkaline phosphatase, biomineralization associated	Canis lupus familiaris	64-67
10712807-4	2000	At the same concentration, 9-cis RA and cholecalciferol induced ALP of chondroblast and osteoblast cells, respectively; ATRA, 9-cis RA and cholecalciferol induced PIP of chondroblast and undifferentiated cells.	Isotretinoin	29-35	prolactin induced protein	Canis lupus familiaris	163-166
10606761-4	2000	Human and mouse 9cRDH and bovine 11cRDH have very similar kinetic properties towards 9-cis- and 11-cis-retinol oxidation and they respond identically to 13-cis-retinoic acid inhibition.	Isotretinoin	153-173	retinol dehydrogenase 5	Mus musculus	16-21
10606761-4	2000	Human and mouse 9cRDH and bovine 11cRDH have very similar kinetic properties towards 9-cis- and 11-cis-retinol oxidation and they respond identically to 13-cis-retinoic acid inhibition.	Isotretinoin	153-173	retinol dehydrogenase 5	Bos taurus	33-39
10588954-6	1999	Moreover, human and mouse cRDH show marked sensitivity to inhibition by 13-cis-retinoic acid, with both being inhibited by approximately 50% by 0.15 microm 13-cis-retinoic acid (for substrate concentrations of 10 microm).	Isotretinoin	72-92	retinol dehydrogenase 5	Mus musculus	26-30
10588954-6	1999	Moreover, human and mouse cRDH show marked sensitivity to inhibition by 13-cis-retinoic acid, with both being inhibited by approximately 50% by 0.15 microm 13-cis-retinoic acid (for substrate concentrations of 10 microm).	Isotretinoin	156-176	retinol dehydrogenase 5	Mus musculus	26-30
10550153-1	1999	PURPOSE: To establish the incidence of abnormalities in the expression of retinoic acid receptor-beta (RARbeta) in bronchial cells and determine the capacity of 13-cis-retinoic acid (13-CRA) to correct such abnormalities.	Isotretinoin	161-181	myotubularin related protein 11	Homo sapiens	186-189
10584127-9	1999	CONCLUSIONS: The data presented indicate that pre- and post-irradiation treatment with 13-cis retinoic acid and interferon-alpha significantly enhance the radiosensitivity of human squamous-cell carcinoma cells, SCC4, in vitro.	Isotretinoin	87-107	MAU2 sister chromatid cohesion factor	Homo sapiens	212-216
10449674-0	1999	Transforming growth factor alpha (TGF-alpha) expression in dysplastic oral leukoplakia: modulation by 13-cis retinoic acid.	Isotretinoin	102-122	tumor necrosis factor	Homo sapiens	0-32
10519672-6	1999	Proliferating cell nuclear antigen labeling indices were reduced after treatment with all-trans retinoic acid and 13-cis retinoic acid at early time points post-injury.	Isotretinoin	114-134	proliferating cell nuclear antigen	Rattus norvegicus	0-34
10604265-4	1999	Of several agents recently shown to reduce prostate-specific antigen levels in phase II studies, 13-cis-retinoic acid and interferon-alpha can reduce the expression of bcl-2 and overcome bcl-2-mediated resistance to paclitaxel in resistant cell lines.	Isotretinoin	97-117	kallikrein related peptidase 3	Homo sapiens	43-68
10604265-4	1999	Of several agents recently shown to reduce prostate-specific antigen levels in phase II studies, 13-cis-retinoic acid and interferon-alpha can reduce the expression of bcl-2 and overcome bcl-2-mediated resistance to paclitaxel in resistant cell lines.	Isotretinoin	97-117	BCL2 apoptosis regulator	Homo sapiens	168-173
10604265-4	1999	Of several agents recently shown to reduce prostate-specific antigen levels in phase II studies, 13-cis-retinoic acid and interferon-alpha can reduce the expression of bcl-2 and overcome bcl-2-mediated resistance to paclitaxel in resistant cell lines.	Isotretinoin	97-117	BCL2 apoptosis regulator	Homo sapiens	187-192
10604265-5	1999	For these reasons, our current studies test the hypothesis that reducing the expression of bcl-2 with 13-cis-retinoic acid and interferon-alpha in combination with taxanes will improve clinical results.	Isotretinoin	102-122	BCL2 apoptosis regulator	Homo sapiens	91-96
10548048-3	1999	The structure of ERABP with a mixture of all-trans and 9-cis retinoic acid has previously been reported.	Isotretinoin	56-74	lipocalin 5	Rattus norvegicus	17-22
10449674-0	1999	Transforming growth factor alpha (TGF-alpha) expression in dysplastic oral leukoplakia: modulation by 13-cis retinoic acid.	Isotretinoin	102-122	transforming growth factor alpha	Homo sapiens	34-43
10569251-3	1999	Exclusively 13-cis-retinoic acid (isotretinoin) had an effect, significantly decreasing glucocorticoid receptor affinity and increasing serum testosterone level.	Isotretinoin	12-32	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	88-111
10569251-3	1999	Exclusively 13-cis-retinoic acid (isotretinoin) had an effect, significantly decreasing glucocorticoid receptor affinity and increasing serum testosterone level.	Isotretinoin	34-46	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	88-111
10359515-0	1999	13-cis-Retinoic acid alters neural crest cells expressing Krox-20 and Pax-2 in macaque embryos.	Isotretinoin	0-20	paired box protein Pax-2	Macaca fascicularis	70-75
10432387-4	1999	METHODS: Expression of iNOS was evaluated by NO production (nitrite analysis), protein (Western blot analysis) and mRNA (RT-PCR analysis) levels in mesangial cells stimulated by a combination of lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma) in the presence and absence of all-trans-retinoic acid (ATRA) or its active metabolite, 13-cis-retinoic acid (13-cis-RA).	Isotretinoin	363-372	nitric oxide synthase 2, inducible	Mus musculus	23-27
10432387-14	1999	CONCLUSIONS: Our studies demonstrate that the retinoids ATRA and 13-cis-RA attenuate iNOS expression and activity in cytokine-stimulated murine mesangial cells.	Isotretinoin	65-74	nitric oxide synthase 2, inducible	Mus musculus	85-89
10510156-5	1999	Formation of these metabolites was inhibited significantly (>50%) by 13-cis retinoic acid, a CYP2C8 inhibitor, but not by furafylline, quinidine or ketoconazole.	Isotretinoin	72-92	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	96-102
10638174-0	1999	The role of apoptosis and bcl-2 protein in topical treatment of oral leukoplakia with isotretinoin.	Isotretinoin	86-98	BCL2 apoptosis regulator	Homo sapiens	26-31
10638174-1	1999	BACKGROUND: This study evaluates the role of bcl-2 protein, as well as, of apoptotic bodies in the topical treatment of oral leucoplakia with 13-cis-retinoic acid (isotretinoin).	Isotretinoin	142-162	BCL2 apoptosis regulator	Homo sapiens	45-50
10433621-5	1999	METHODS: Using in situ hybridization, we analyzed RARbeta messenger RNA (mRNA) expression in bronchial biopsy specimens from heavy smokers, at baseline and after 6 months of treatment with 13-cis-retinoic acid (13-cis-RA) or placebo.	Isotretinoin	189-209	retinoic acid receptor beta	Homo sapiens	50-57
10433621-11	1999	CONCLUSIONS: These results indicate that RARbeta is an independent marker of response to 13-cis-RA and may serve as an intermediate biomarker in chemoprevention trials of upper aerodigestive tract cancers.	Isotretinoin	89-98	retinoic acid receptor beta	Homo sapiens	41-48
10432387-4	1999	METHODS: Expression of iNOS was evaluated by NO production (nitrite analysis), protein (Western blot analysis) and mRNA (RT-PCR analysis) levels in mesangial cells stimulated by a combination of lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma) in the presence and absence of all-trans-retinoic acid (ATRA) or its active metabolite, 13-cis-retinoic acid (13-cis-RA).	Isotretinoin	341-361	nitric oxide synthase 2, inducible	Mus musculus	23-27
10430067-0	1999	Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2a.	Isotretinoin	109-129	retinoic acid receptor beta	Homo sapiens	17-44
10561278-8	1999	Pharmacokinetic studies demonstrated that CRA/IFNalpha caused a 33% decrease in TAX clearance and a 23% decrease in the area under the concentration-time curve values of the TAX metabolite 6-alfa-hydroxytaxol (6-HT).	Isotretinoin	42-45	interferon alpha 1	Homo sapiens	46-54
10378671-1	1999	Preclinical and clinical data have suggested antitumor efficacy in squamous cell carcinoma (SCC) of interferon (IFN)-alpha and 13-cis-retinoic acid (13-c-RA) as single agent with greater activity in combination.	Isotretinoin	127-147	myotubularin related protein 11	Homo sapiens	152-156
10367173-2	1999	PURPOSE: 9-cis retinoic acid (ALRT 1057; 9cRA) is a promising new retinoid that binds to all known retinoic acid receptors (RAR and RXR), potentially providing it with a broader spectrum of biologic activity than either 13-cis retinoic acid or all-trans retinoic acid.	Isotretinoin	220-240	myotubularin related protein 11	Homo sapiens	42-45
10334392-9	1999	The IFN-y-inducing effect of ATRA and 13-cis-retinoic acid could be abrogated by addition of anti-IL-12 antibodies, suggesting that IL-12 plays a role in the synergistic upregulation of IFN-gamma.	Isotretinoin	38-58	interferon gamma	Homo sapiens	186-195
10355579-4	1999	MATERIALS AND METHODS: The effect of ATRA and 13-cis-retinoic acid on ara-CTP accumulation and ara-C-induced apoptosis was studied.	Isotretinoin	46-66	solute carrier family 25 member 1	Homo sapiens	74-77
10472330-11	1999	Therefore, the isotretinoin treatment seems to be a good approach for cancer prevention in conditions with high predisposition to skin cancer, such as in XP-V.	Isotretinoin	15-27	DNA polymerase eta	Homo sapiens	154-158
10621853-0	1999	bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study.	Isotretinoin	41-61	BCL2 apoptosis regulator	Homo sapiens	0-5
10621853-0	1999	bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study.	Isotretinoin	63-75	BCL2 apoptosis regulator	Homo sapiens	0-5
10067845-3	1999	In the current study, we have investigated the mechanism by which 1,25-(OH)2D3 regulates AR gene expression and the involvement of AR in the 1,25-(OH)2D3- and 9-cis retinoic acid (RA)-mediated growth inhibition of LNCaP cells.	Isotretinoin	160-178	androgen receptor	Homo sapiens	131-133
10190792-9	1999	The retinoids, as a class, can inhibit the growth of resistant cell lines that overexpress bcl-2, and the combination of interferon (IFN) and cis-retinoic acid (CRA) demonstrated increased antitumor activity.	Isotretinoin	161-164	interferon alpha 1	Homo sapiens	121-131
10202838-0	1999	Drug interaction of isotretinoin and protease inhibitors: support for the cellular retinoic acid-binding protein-1 theory of lipodystrophy?	Isotretinoin	20-32	cellular retinoic acid binding protein 1	Homo sapiens	74-114
9806904-1	1998	The steric conversion of 13-cis-retinoic acid (13-cRA) to all-trans-retinoic acid (t-RA) has been proposed as an activation mechanism for the observed therapeutic and teratogenic activities of 13-cRA.	Isotretinoin	25-45	myotubularin related protein 11	Homo sapiens	50-53
9923548-1	1999	PURPOSE: The efficacy of 13-cis-retinoic acid (13-CRA) given as a single agent or in combination with tamoxifen (TAM) was determined in athymic nude mice bearing advanced s.c. MCF-7 human breast cancers.	Isotretinoin	25-45	myotubularin related protein 11	Mus musculus	50-53
10325581-0	1999	The effect of isotretinoin on biotinidase activity.	Isotretinoin	14-26	biotinidase	Homo sapiens	30-41
10325581-2	1999	OBJECTIVE: Since biotinidase is mainly produced in the liver and partial biotinidase deficiency causes dermatological manifestations, seborrheic dermatitis, alopecia etc., isotretinoin side effects in relation to biotinidase activity were studied.	Isotretinoin	172-184	biotinidase	Homo sapiens	17-28
10325581-2	1999	OBJECTIVE: Since biotinidase is mainly produced in the liver and partial biotinidase deficiency causes dermatological manifestations, seborrheic dermatitis, alopecia etc., isotretinoin side effects in relation to biotinidase activity were studied.	Isotretinoin	172-184	biotinidase	Homo sapiens	73-84
10325581-5	1999	Moreover, the effect of isotretinoin on a known plasma biotinidase activity was evaluated after incubation in vitro with various concentrations of the drug.	Isotretinoin	24-36	biotinidase	Homo sapiens	55-66
10325581-9	1999	CONCLUSION: It is suggested that isotretinoin isomers-metabolites act in the liver, resulting in low biotinidase activity.	Isotretinoin	33-45	biotinidase	Homo sapiens	101-112
9806904-1	1998	The steric conversion of 13-cis-retinoic acid (13-cRA) to all-trans-retinoic acid (t-RA) has been proposed as an activation mechanism for the observed therapeutic and teratogenic activities of 13-cRA.	Isotretinoin	25-45	myotubularin related protein 11	Homo sapiens	196-199
9711991-7	1998	P450 was induced by 13-cis-RA, 9-cis-RA, and retinal; however, retinol could not induce P450.	Isotretinoin	20-29	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-4
9740229-6	1998	The goals of this study are: (i) to identify which isozyme (s) of 17beta-HSD is active in SG; (ii) to determine if its activity differs in facial skin compared with nonacne-prone skin that may account for the regional differences in sebum production; (iii) to compare the activity of 17beta-HSD in intact glands and in SG homogenates; and (iv) to determine if 13-cis retinoic acid inhibits 17beta-HSD activity.	Isotretinoin	360-380	hydroxysteroid 17-beta dehydrogenase 13	Homo sapiens	66-76
9691099-4	1998	In men, isotretinoin treatment (80 mg/d; 5 d) resulted in elevated plasma apo C-III, but not apo E concentrations.	Isotretinoin	8-20	apolipoprotein C3	Homo sapiens	74-83
9680102-0	1998	A pilot trial of 13-cis-retinoic acid and alpha-tocopherol with recombinant human erythropoietin in myelodysplastic syndrome patients with progressive or transfusion-dependent anemias.	Isotretinoin	17-37	erythropoietin	Homo sapiens	82-96
9680102-2	1998	A pilot study was performed to determine the efficacy of 13-cis-retinoic acid (CRA) and alpha-tocopherol (AT) with increasing doses of recombinant human erythropoietin (rHuEPO) in anemic patients with primary myelodysplastic syndrome (MDS), to determine response rate and to determine the dose requirement and long-term effects of rHuEPO therapy on the transition to acute non-lymphocytic anemia and survival of these patients.	Isotretinoin	57-77	erythropoietin	Homo sapiens	153-167
9879152-0	1998	13-cis-retinoic acid and interferon-alpha 2a therapy in locally advanced squamous cell carcinoma of the cervix: p53 alteration, proliferating cell nuclear antigen expression and angiogenesis response.	Isotretinoin	0-20	tumor protein p53	Homo sapiens	112-115
9879152-0	1998	13-cis-retinoic acid and interferon-alpha 2a therapy in locally advanced squamous cell carcinoma of the cervix: p53 alteration, proliferating cell nuclear antigen expression and angiogenesis response.	Isotretinoin	0-20	proliferating cell nuclear antigen	Homo sapiens	128-162
9879152-1	1998	OBJECTIVE: To evaluate prognostic importance of p53, PCNA and vascularization alteration in patients with locally advanced cervical squamous cell carcinoma (SCC) after combination therapy with 13-cis-retinoic acid (13cRA) and interferon-alpha 2a (IFN-alpha 2a).	Isotretinoin	193-213	serpin family B member 3	Homo sapiens	157-160
9717711-10	1998	Nine-cis-retinoic acid up-regulates RXRalpha transcripts at stages 19.5-22.0 within a few hours, augmenting but not expanding the expression pattern.	Isotretinoin	5-22	retinoid X receptor alpha	Gallus gallus	36-44
9693115-3	1998	Although both proteins interact with retinoids, RBP exhibits a broad specificity, binding retinol, retinoic acid and retinaldehyde with roughly equal affinities, whereas ERABP is specific for all-trans- and 9-cis-retinoic acids.	Isotretinoin	208-227	retinol binding protein 4	Rattus norvegicus	48-51
9693115-3	1998	Although both proteins interact with retinoids, RBP exhibits a broad specificity, binding retinol, retinoic acid and retinaldehyde with roughly equal affinities, whereas ERABP is specific for all-trans- and 9-cis-retinoic acids.	Isotretinoin	208-227	lipocalin 5	Rattus norvegicus	170-175
9676837-7	1998	With lung cancer cell lines, 0.5-4 microM concentrations of 13-cis-retinoic acid reduced hnRNP A2/B1 overexpression by immunocytochemistry.	Isotretinoin	60-80	heterogeneous nuclear ribonucleoprotein A2/B1	Homo sapiens	89-100
9625816-1	1998	The synergistic anti-tumor effect of 13-cis retinoic acid (13-cRA) and interferon-alpha/beta (IFN-alpha/beta) was investigated using a highly metastatic mouse renal cell carcinoma cell subline (RenCa/F).	Isotretinoin	37-57	myotubularin related protein 11	Mus musculus	62-65
9815762-8	1997	High p53 protein expression (LI >/= 0.2) was detected in 25% of the lesions at baseline and in 18% of the lesions after isotretinoin therapy.	Isotretinoin	123-135	tumor protein p53	Homo sapiens	5-8
9463728-6	1997	While total ADH activity was increased from 84 +/- 78 mU/1 to 206 +/- 70 mU/1 (mean +/- SD, P < 0.02) after 1 week of treatment, there were no further significant changes after 4 weeks of treatment with cRA.	Isotretinoin	206-209	aldo-keto reductase family 1 member A1	Homo sapiens	12-15
9815590-0	1997	Effect of 13-cis-retinoic acid and alpha-interferon on transforming growth factor beta1 in patients with rising prostate-specific antigen.	Isotretinoin	10-30	transforming growth factor beta 1	Homo sapiens	55-87
9815590-0	1997	Effect of 13-cis-retinoic acid and alpha-interferon on transforming growth factor beta1 in patients with rising prostate-specific antigen.	Isotretinoin	10-30	kallikrein related peptidase 3	Homo sapiens	112-137
9815590-1	1997	The objective of this study was to test the hypothesis that 13-cis-retinoic acid (CRA) and alpha-interferon (IFN-alpha) have antitumor activity in patients with early recurrence of prostate cancer measured by rising prostate-specific antigen (PSA) after local therapy, and that this activity is associated with the increase of plasma transforming growth factor beta1 (TGF-beta1).	Isotretinoin	60-80	kallikrein related peptidase 3	Homo sapiens	216-247
9815590-1	1997	The objective of this study was to test the hypothesis that 13-cis-retinoic acid (CRA) and alpha-interferon (IFN-alpha) have antitumor activity in patients with early recurrence of prostate cancer measured by rising prostate-specific antigen (PSA) after local therapy, and that this activity is associated with the increase of plasma transforming growth factor beta1 (TGF-beta1).	Isotretinoin	60-80	transforming growth factor beta 1	Homo sapiens	334-366
9815590-1	1997	The objective of this study was to test the hypothesis that 13-cis-retinoic acid (CRA) and alpha-interferon (IFN-alpha) have antitumor activity in patients with early recurrence of prostate cancer measured by rising prostate-specific antigen (PSA) after local therapy, and that this activity is associated with the increase of plasma transforming growth factor beta1 (TGF-beta1).	Isotretinoin	60-80	transforming growth factor beta 1	Homo sapiens	368-377
9815590-1	1997	The objective of this study was to test the hypothesis that 13-cis-retinoic acid (CRA) and alpha-interferon (IFN-alpha) have antitumor activity in patients with early recurrence of prostate cancer measured by rising prostate-specific antigen (PSA) after local therapy, and that this activity is associated with the increase of plasma transforming growth factor beta1 (TGF-beta1).	Isotretinoin	82-85	kallikrein related peptidase 3	Homo sapiens	216-247
9815590-1	1997	The objective of this study was to test the hypothesis that 13-cis-retinoic acid (CRA) and alpha-interferon (IFN-alpha) have antitumor activity in patients with early recurrence of prostate cancer measured by rising prostate-specific antigen (PSA) after local therapy, and that this activity is associated with the increase of plasma transforming growth factor beta1 (TGF-beta1).	Isotretinoin	82-85	transforming growth factor beta 1	Homo sapiens	334-366
9815590-1	1997	The objective of this study was to test the hypothesis that 13-cis-retinoic acid (CRA) and alpha-interferon (IFN-alpha) have antitumor activity in patients with early recurrence of prostate cancer measured by rising prostate-specific antigen (PSA) after local therapy, and that this activity is associated with the increase of plasma transforming growth factor beta1 (TGF-beta1).	Isotretinoin	82-85	transforming growth factor beta 1	Homo sapiens	368-377
9403338-1	1997	Pharmacokinetics and pharmacodynamics of 13-cis-retinoic acid (13-cRA) administered at doses that suppress experimental autoimmune encephalomyelitis (EAE) have been investigated in rats.	Isotretinoin	41-61	myotubularin related protein 11	Homo sapiens	66-69
9815762-13	1997	Eighty-three percent of patients having low p53 expression had up-regulation of RAR-beta mRNA after isotretinoin therapy, compared with 22% of patients with high p53 expression (P = 0.003).	Isotretinoin	100-112	tumor protein p53	Homo sapiens	44-47
9815762-13	1997	Eighty-three percent of patients having low p53 expression had up-regulation of RAR-beta mRNA after isotretinoin therapy, compared with 22% of patients with high p53 expression (P = 0.003).	Isotretinoin	100-112	retinoic acid receptor beta	Homo sapiens	80-88
9815762-14	1997	We correlated baseline p53 protein expression with RAR-beta modulation and clinical responses to isotretinoin therapy.	Isotretinoin	97-109	tumor protein p53	Homo sapiens	23-26
9815762-15	1997	The patients with low p53 protein expression at baseline and up-regulation of RAR-beta after isotretinoin therapy achieved a 70% rate of major response.	Isotretinoin	93-105	retinoic acid receptor beta	Homo sapiens	78-86
9815762-17	1997	The patients with high p53 protein expression and either no change or down-regulation of RAR-beta had a response rate of only 14% to isotretinoin therapy.	Isotretinoin	133-145	tumor protein p53	Homo sapiens	23-26
9815762-17	1997	The patients with high p53 protein expression and either no change or down-regulation of RAR-beta had a response rate of only 14% to isotretinoin therapy.	Isotretinoin	133-145	retinoic acid receptor beta	Homo sapiens	89-97
10851460-2	1997	More recently, clinical and pre-clinical results provide evidence for an antiproliferative effect of 13-cis-retinoic acid (13cRA) in interferon-alpha (IFN-alpha) treated renal cell carcinoma patients.	Isotretinoin	101-121	interferon alpha 1	Homo sapiens	151-160
9560303-0	1998	Inhibition of activation-induced apoptosis of thymocytes by all-trans- and 9-cis-retinoic acid is mediated via retinoic acid receptor alpha.	Isotretinoin	77-94	retinoic acid receptor alpha	Homo sapiens	111-139
9488639-4	1998	All-trans-RA, 13-cis-RA and 9-cis-RA at 10(-8) mol/l to 10(-5) mol/l inhibited the GM-CSF-dependent cell growth.	Isotretinoin	14-23	colony stimulating factor 2	Homo sapiens	83-89
9516858-10	1997	Treatment of these rats with the somatostatin analogue octreotide seemed to upregulate in vivo receptor expression of somatostatin and vasoactive intestinal peptide more effectively than 13-cis retinoic acid.	Isotretinoin	187-207	somatostatin	Rattus norvegicus	33-45
10851460-2	1997	More recently, clinical and pre-clinical results provide evidence for an antiproliferative effect of 13-cis-retinoic acid (13cRA) in interferon-alpha (IFN-alpha) treated renal cell carcinoma patients.	Isotretinoin	123-128	interferon alpha 1	Homo sapiens	151-160
10851460-3	1997	The manner in which 13cRA augments antitumor effects and modulates biologic and clinical responses of renal cell carcinoma to IFN-alpha remains elusive.	Isotretinoin	20-25	interferon alpha 1	Homo sapiens	126-135
10851460-4	1997	In the present study, we report induction of apoptosis and objective tumor regression in response to 13cRA in advanced renal cell carcinoma patients refractory to IFN-alpha.	Isotretinoin	101-106	interferon alpha 1	Homo sapiens	163-172
9815762-10	1997	Expression of RAR-beta mRNA was detected in 40% of the patients at baseline and increased to 90% of the patients after isotretinoin therapy (P < 0.	Isotretinoin	119-131	retinoic acid receptor beta	Homo sapiens	14-22
9589358-2	1997	The present study assessed the effect of 13-cis-retinoic acid (13-CRA) treatment in 13 chronic cervicitis and 52 cervical intraepithelial neoplasia patients.	Isotretinoin	41-61	myotubularin related protein 11	Homo sapiens	66-69
9174604-2	1997	We here provide evidence that the vitamin A metabolites all-trans and 13-cis retinoic acid up-regulate CD43 on human leukemic (HMC-1) mast cells, as determined by flow cytometry, Western blot analysis, and by semiquantitative reverse transcriptase-polymerase chain reaction.	Isotretinoin	70-90	sialophorin	Homo sapiens	103-107
9067580-2	1997	Incubation of these cells for 48 h with either 13-cis retinoid acid (13-cis RA) or all-trans retinoic acid (ATRA) resulted in marked inhibition of cell growth, determined by 3H-thymidine incorporation, and in down-regulation of CD25 expression, determined by flow cytometry.	Isotretinoin	69-78	interleukin 2 receptor subunit alpha	Homo sapiens	228-232
8952316-1	1996	We observed the effects of the retinoic acid (13-cis retinoic acid; 13-cis RA, and all-trans retinoic acid; ATRA) for the cell growth and the expression of CD 25 on peripheral blood mononuclear cells (PBMC) from 17 patients with adult T cell leukemia (ATL).	Isotretinoin	46-66	interleukin 2 receptor subunit alpha	Homo sapiens	156-161
8980637-5	1996	Retinoic acid and 13-cis-retinoic acid produced transient, but significant, depressions of both serum retinol and RBP concentrations, when the individual retinoids were administered orally to rats.	Isotretinoin	18-38	retinol binding protein 4	Rattus norvegicus	114-117
8912706-13	1996	Finally treatment of the keratinocytes with retinoids including etretinate, Ro13-7410, etarotene, Ro40-8757, 13-cisretinoic acid, and acitretin blocked the PMA induction of ODC mRNA, suggesting this in vitro model could be a valuable screening assay for predicting biological activity in humans.	Isotretinoin	109-128	ornithine decarboxylase 1	Homo sapiens	173-176
9816131-5	1996	EGFr expression was examined as a marker of bronchial metaplasia and response to 13cRA treatment.	Isotretinoin	81-86	epidermal growth factor receptor	Homo sapiens	0-4
8856073-5	1996	When present at a concentration of 60, 80, or 100 microM, 13-cis-retinoic acid was a significantly more potent activator of CETP activity than all the other derivatives studied (P < 0.01 in all cases).	Isotretinoin	58-78	cholesteryl ester transfer protein	Homo sapiens	124-128
8856073-6	1996	In contrast to observations made with reconstituted mixtures, only 13-cis-retinoic acid, but not palmitic acid, was able to induce a significant, concentration-dependent stimulation of CETP activity in total human plasma.	Isotretinoin	67-87	cholesteryl ester transfer protein	Homo sapiens	185-189
8856073-8	1996	In support of a key role of the negatively charged carboxylic group of 13-cis-retinoic acid in upregulating CETP activity, cholesteryl ester transfer rates correlated positively with the electrophoretic mobility of LDL (r = 0.98; P < 0.0002) and HDL (r = 0.96; P < 0.0008) in total plasma supplemented with the carboxylated compound.	Isotretinoin	71-91	cholesteryl ester transfer protein	Homo sapiens	108-112
8856073-9	1996	It is concluded that 13-cis-retinoic acid can upregulate the CETP-mediated cholesteryl ester transfer reaction both in reconstituted mixtures containing isolated lipoproteins and purified CETP, and in total normolipidemic human plasma.	Isotretinoin	21-41	cholesteryl ester transfer protein	Homo sapiens	61-65
8856073-9	1996	It is concluded that 13-cis-retinoic acid can upregulate the CETP-mediated cholesteryl ester transfer reaction both in reconstituted mixtures containing isolated lipoproteins and purified CETP, and in total normolipidemic human plasma.	Isotretinoin	21-41	cholesteryl ester transfer protein	Homo sapiens	188-192
8949994-5	1996	We report two patients with recurrent squamous cell carcinoma (SCC) of the cervix who had small-volume progressive metastatic disease, and were treated with a combination of IFN-alpha and 13-cis-retinoic acid.	Isotretinoin	188-208	serpin family B member 3	Homo sapiens	63-66
8816844-17	1996	These results show that selective loss of RAR beta mRNA expression occurs in the early stages of carcinogenesis and may be involved in HN cancer development; and demonstrate that RAR beta is induced by 13-cis-RA in humans.	Isotretinoin	202-211	retinoic acid receptor beta	Homo sapiens	179-187
9816270-0	1996	Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid.	Isotretinoin	137-157	retinoic acid receptor beta	Homo sapiens	14-41
8765055-7	1996	NT2/D1-R cells were cross-resistant to 9-cis retinoic acid (9-cis RA), a ligand activating the RAR and RXR pathways, but retained maturation response to HMBA.	Isotretinoin	61-68	retinoic acid receptor alpha	Homo sapiens	95-98
8676899-1	1996	The purpose of this study was to investigate the influence of benzylisothiocyanate (BIT) and 13-cis-retinoic acid (RA) upon the genotoxic potential of benzo[a]pyrene (BaP) to induce micronucleus formation in the bone marrow of mice.	Isotretinoin	93-113	prohibitin 2	Mus musculus	167-170
8676899-1	1996	The purpose of this study was to investigate the influence of benzylisothiocyanate (BIT) and 13-cis-retinoic acid (RA) upon the genotoxic potential of benzo[a]pyrene (BaP) to induce micronucleus formation in the bone marrow of mice.	Isotretinoin	115-117	prohibitin 2	Mus musculus	167-170
8676899-9	1996	The results showed that both BIT and RA significantly reduced the frequency of micronucleus formation in the bone marrow of the BaP treated animals.	Isotretinoin	37-39	prohibitin 2	Mus musculus	128-131
8833201-8	1996	Using ribonuclease protection assays, we found that NHE-1 transcripts are induced as cells differentiate in vitro and in response to 13-cis-RA.	Isotretinoin	133-142	solute carrier family 9 member A1	Homo sapiens	52-57
8625298-0	1996	13-cis-retinoic acid with alpha-2a-interferon enhances radiation cytotoxicity in head and neck squamous cell carcinoma in vitro.	Isotretinoin	0-20	interferon alpha 2	Homo sapiens	26-45
8601734-3	1996	Application of 0.1% all-trans, 0.1% 9-cis, and 0.1% 13-cis retinoic acid to human skin for 2 d resulted in induction of only all-trans retinoic acid 4-hydroxylase activity.	Isotretinoin	52-72	cytochrome P450 family 26 subfamily A member 1	Homo sapiens	135-162
7723796-0	1995	Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin.	Isotretinoin	97-109	retinoic acid receptor beta	Homo sapiens	15-42
8815586-7	1996	The stimulation of C6 cell-line by cRA in vitro is dose-dependent and reached a maximum for 3 and 30 microM at the 72nd h. So cRA-treated C6 glioma cells produce t-PA which appears to be the major species associated with the fibrinolytic activity-induced intra-tumoral haemorrhage after exposure to retinoid treatment.	Isotretinoin	35-38	plasminogen activator, tissue type	Rattus norvegicus	162-166
7619051-8	1995	Two of these other retinoids, 13-cis-retinoic acid and Ro13-7410, inhibited EGF binding the most (35-46%, P < 0.001); several others (etarotene, Ro40-8757 and etretinate) were less effective (7-16%), but significantly decreased EGF binding (P < 0.05), and two retinoids (Ro15-0778 and acitretin) showed no significant effect on EGF binding.	Isotretinoin	30-50	epidermal growth factor	Homo sapiens	76-79
7669643-10	1995	The decline in PAI levels appears to reflect the resolving cutaneous inflammation following treatment with isotretinoin, rather than a direct effect of isotretinoin on the synthesis or release of PAI.	Isotretinoin	107-119	serpin family E member 1	Homo sapiens	15-18
9816270-3	1996	This study examined the antiproliferative effects of 13-cis-retinoic acid (cRA) on 12 renal cancer cell lines and correlated these findings with the basal and induced expression of RAR-alpha, -beta and -gamma.	Isotretinoin	53-73	retinoic acid receptor alpha	Homo sapiens	181-208
9816270-3	1996	This study examined the antiproliferative effects of 13-cis-retinoic acid (cRA) on 12 renal cancer cell lines and correlated these findings with the basal and induced expression of RAR-alpha, -beta and -gamma.	Isotretinoin	75-78	retinoic acid receptor alpha	Homo sapiens	181-208
7547391-0	1995	In situ hybridization analysis of CRABP II expression in sebaceous follicles from 13-cis retinoic acid-treated acne patients.	Isotretinoin	82-102	cellular retinoic acid binding protein 2	Homo sapiens	34-42
7547391-1	1995	The aim of this study was to investigate the effects of 13-cis retinoic acid treatment on cellular retinoic acid binding protein II (CRABP II) mRNA expression in sebaceous follicles from acne patients, using in situ hybridization.	Isotretinoin	56-76	cellular retinoic acid binding protein 2	Homo sapiens	90-131
7547391-1	1995	The aim of this study was to investigate the effects of 13-cis retinoic acid treatment on cellular retinoic acid binding protein II (CRABP II) mRNA expression in sebaceous follicles from acne patients, using in situ hybridization.	Isotretinoin	56-76	cellular retinoic acid binding protein 2	Homo sapiens	133-141
7547391-7	1995	These findings indicate a selective activity of 13-cis retinoic acid on CRABP II mRNA expression in the sebaceous glands of acne patients.	Isotretinoin	48-68	cellular retinoic acid binding protein 2	Homo sapiens	72-80
7636535-1	1995	PURPOSE: A phase II trial of interferon alfa-2a (IFN) and 13-cis-retinoic acid (CRA) was conducted in patients with renal cell carcinoma (RCC).	Isotretinoin	58-78	LUC7 like 3 pre-mRNA splicing factor	Homo sapiens	80-83
7723796-9	1995	The levels of retinoic acid receptor-beta mRNA increased in the specimens from 18 of the 22 patients who had responses to isotretinoin and in 8 of the 17 specimens from the patients without responses (P = 0.04).	Isotretinoin	122-134	retinoic acid receptor beta	Homo sapiens	14-41
7723796-10	1995	CONCLUSIONS: The expression of retinoic acid receptor-beta mRNA is selectively lost in premalignant oral lesions and can be restored by treatment with isotretinoin.	Isotretinoin	151-163	retinoic acid receptor beta	Homo sapiens	31-58
7705672-1	1995	The combination of 13-cis-retinoic acid (13-cRA) and interferon (IFN)-alpha 2a has been reported to be highly active in previously untreated squamous carcinoma of the cervix.	Isotretinoin	19-39	myotubularin related protein 11	Homo sapiens	44-47
7752598-4	1995	All-trans retinoic acid (ATRA, Tretinoin) and 13-cis retinoid acid (cRA, Isotretinoin) are the most important isomers.	Isotretinoin	73-85	LUC7 like 3 pre-mRNA splicing factor	Homo sapiens	46-66
7647031-3	1995	Addition of 13-cis-retinoic acid to small cell lung cancer cells cultured using serum-free, hormonally defined medium resulted in a 5-8-fold increase in the level of the retinoic acid receptor-beta mRNAs; in medium containing serum, the increase in expression of the retinoic acid receptor-beta mRNAs was less pronounced, usually no more than 2-fold.	Isotretinoin	12-32	retinoic acid receptor beta	Homo sapiens	170-197
7647031-3	1995	Addition of 13-cis-retinoic acid to small cell lung cancer cells cultured using serum-free, hormonally defined medium resulted in a 5-8-fold increase in the level of the retinoic acid receptor-beta mRNAs; in medium containing serum, the increase in expression of the retinoic acid receptor-beta mRNAs was less pronounced, usually no more than 2-fold.	Isotretinoin	12-32	retinoic acid receptor beta	Homo sapiens	267-294
7714084-0	1995	Effect of oral isotretinoin treatment on skin androgen receptor levels in male acneic patients.	Isotretinoin	15-27	androgen receptor	Homo sapiens	46-63
7714084-6	1995	These data clearly showed that skin androgen receptor was sensitive to oral isotretinoin administration in acneic patients.	Isotretinoin	76-88	androgen receptor	Homo sapiens	36-53
7625852-0	1995	Influence of aging, localization, glucocorticoids and isotretinoin on matrix metalloproteases 2 (MMP-2) and 9 (MMP-9) in suction blister fluids.	Isotretinoin	54-66	matrix metallopeptidase 9	Homo sapiens	111-116
7805028-8	1995	An inverse relationship occurred between the levels of accumulated p53 protein and response to isotretinoin (P = 0.006).	Isotretinoin	95-107	tumor protein p53	Homo sapiens	67-70
8165591-0	1993	Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans.	Isotretinoin	10-22	plasminogen activator, tissue type	Homo sapiens	37-70
7605422-2	1994	In vitro, isotretinoin (13-cis-retinoic acid) attenuates both the spontaneous proliferation of leukemic peripheral-blood progenitor cells (granulocyte-macrophage colony-forming units) and their selective hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF).	Isotretinoin	10-22	colony stimulating factor 2	Homo sapiens	224-272
7605422-2	1994	In vitro, isotretinoin (13-cis-retinoic acid) attenuates both the spontaneous proliferation of leukemic peripheral-blood progenitor cells (granulocyte-macrophage colony-forming units) and their selective hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF).	Isotretinoin	10-22	colony stimulating factor 2	Homo sapiens	274-280
7798613-2	1994	Biologic activity was shown by the induction of cellular retinoic acid-binding protein type 2 (CRABP 2) mRNA and protein; the rank order for CRABP-2 increase was retinoic acid > retinaldehyde > 9 cis retinoic acid > retinol > beta carotene.	Isotretinoin	202-219	cellular retinoic acid binding protein 2	Homo sapiens	48-93
7798613-2	1994	Biologic activity was shown by the induction of cellular retinoic acid-binding protein type 2 (CRABP 2) mRNA and protein; the rank order for CRABP-2 increase was retinoic acid > retinaldehyde > 9 cis retinoic acid > retinol > beta carotene.	Isotretinoin	202-219	cellular retinoic acid binding protein 2	Homo sapiens	95-102
7798613-2	1994	Biologic activity was shown by the induction of cellular retinoic acid-binding protein type 2 (CRABP 2) mRNA and protein; the rank order for CRABP-2 increase was retinoic acid > retinaldehyde > 9 cis retinoic acid > retinol > beta carotene.	Isotretinoin	202-219	cellular retinoic acid binding protein 2	Homo sapiens	141-148
7967513-12	1994	CK14 and CK16 were also expressed, suggestive of squamous metaplasia in culture, which could be inhibited with 13-cis-retinoic acid.	Isotretinoin	111-131	keratin 14	Homo sapiens	0-4
7967513-12	1994	CK14 and CK16 were also expressed, suggestive of squamous metaplasia in culture, which could be inhibited with 13-cis-retinoic acid.	Isotretinoin	111-131	keratin 16	Homo sapiens	9-13
7812199-2	1994	13-Cis retinoic acid (13-CRA) may have moderate effect on 20-30% of patients with MDS.	Isotretinoin	0-20	myotubularin related protein 11	Homo sapiens	25-28
8188744-4	1994	Among other retinoids tested, 13-cis retinoic acid, which binds neither RAR nor RXR, also increases the potency of the ricin A chain immunotoxin.	Isotretinoin	30-50	retinoic acid receptor alpha	Homo sapiens	72-75
8301142-9	1994	13-cis-retinoic acid, retinol, retinaldehyde, all-trans etretin, Ro 13-6298, and 9-cis retinoic acid also inhibited IL-1-induced IL-6 production.	Isotretinoin	0-20	interleukin 1 alpha	Homo sapiens	116-120
8301142-9	1994	13-cis-retinoic acid, retinol, retinaldehyde, all-trans etretin, Ro 13-6298, and 9-cis retinoic acid also inhibited IL-1-induced IL-6 production.	Isotretinoin	0-20	interleukin 6	Homo sapiens	129-133
8012274-7	1994	These investigations demonstrate for the first time that 13-cis-RA inhibits the growth of human prostatic cancer cells, and this inhibition is associated with an increase in hRXR alpha nuclear receptor gene expression and alterations in phosphorous metabolites detected by 31P MR spectroscopy.	Isotretinoin	57-66	retinoid X receptor alpha	Homo sapiens	174-178
7625852-0	1995	Influence of aging, localization, glucocorticoids and isotretinoin on matrix metalloproteases 2 (MMP-2) and 9 (MMP-9) in suction blister fluids.	Isotretinoin	54-66	matrix metallopeptidase 2	Homo sapiens	70-95
8555652-5	1995	Furthermore, inhibitors of TRX reductase, 13-cis-retinoic acid (13-cis-RA) and azelaic acid, inhibited the DNA synthesis of these cells.	Isotretinoin	64-73	thioredoxin	Homo sapiens	27-30
7605422-2	1994	In vitro, isotretinoin (13-cis-retinoic acid) attenuates both the spontaneous proliferation of leukemic peripheral-blood progenitor cells (granulocyte-macrophage colony-forming units) and their selective hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF).	Isotretinoin	24-44	colony stimulating factor 2	Homo sapiens	224-272
7605422-2	1994	In vitro, isotretinoin (13-cis-retinoic acid) attenuates both the spontaneous proliferation of leukemic peripheral-blood progenitor cells (granulocyte-macrophage colony-forming units) and their selective hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF).	Isotretinoin	24-44	colony stimulating factor 2	Homo sapiens	274-280
7523313-3	1994	The present study was designed to elucidate the role of 13-cis-retinoic acid (RA) in regulation of PSA and the tumorigenic potential of the human prostate cancer cell line LNCaP.	Isotretinoin	56-76	kallikrein related peptidase 3	Homo sapiens	99-102
7523313-3	1994	The present study was designed to elucidate the role of 13-cis-retinoic acid (RA) in regulation of PSA and the tumorigenic potential of the human prostate cancer cell line LNCaP.	Isotretinoin	78-80	kallikrein related peptidase 3	Homo sapiens	99-102
8165591-0	1993	Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans.	Isotretinoin	10-22	plasminogen activator, tissue type	Homo sapiens	72-76
8165591-6	1993	Mean PAI-1 antigen and PAI activity in 9 a.m. plasma samples were non-significantly higher during isotretinoin than during placebo treatment.	Isotretinoin	98-110	serpin family E member 1	Homo sapiens	5-10
8165591-6	1993	Mean PAI-1 antigen and PAI activity in 9 a.m. plasma samples were non-significantly higher during isotretinoin than during placebo treatment.	Isotretinoin	98-110	serpin family E member 1	Homo sapiens	5-8
8382035-7	1993	Retinoid analogs competed with the binding of CD 367 to CRABP-I and CRABP-II in the following order: (p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8- tetramethyl-2-naphtyl)-1-propenyl]-benzoic acid (TTNPB) > 4-oxo-RA > 4-OH-RA > 13-cis-RA = 9-cis-RA.	Isotretinoin	231-237	C-type lectin domain family 4 member A	Homo sapiens	46-52
8457712-1	1993	The combination of interferon (IFN)-alpha 2a and 13-cis-retinoic acid (13-cRA) has demonstrated significant antitumor activity in patients with advanced squamous cell cancer of the skin and cervix.	Isotretinoin	49-69	myotubularin related protein 11	Homo sapiens	74-77
8288320-0	1993	Long-term administration of 13-cis retinoic acid in common variable immunodeficiency: circulating interleukin-6 levels, B-cell surface molecule display, and in vitro and in vivo B-cell antibody production.	Isotretinoin	28-48	interleukin 6	Homo sapiens	98-111
8319203-6	1993	Inhibition of intestinal LRAT by HPR and 13-cis-retinoic acid was enhanced by preincubation prior to assay, whereas inhibition of the other activities was not.	Isotretinoin	41-61	lecithin retinol acyltransferase	Homo sapiens	25-29
8382035-7	1993	Retinoid analogs competed with the binding of CD 367 to CRABP-I and CRABP-II in the following order: (p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8- tetramethyl-2-naphtyl)-1-propenyl]-benzoic acid (TTNPB) > 4-oxo-RA > 4-OH-RA > 13-cis-RA = 9-cis-RA.	Isotretinoin	231-237	cellular retinoic acid binding protein 1	Homo sapiens	56-63
1569455-7	1992	Additionally, the combination of 13-cis-retinoic acid (cRA) with interferon alpha (IFN alpha) has produced high objective response rates for patients with squamous cell carcinomas of the head and neck and of the cervix.	Isotretinoin	33-53	LUC7 like 3 pre-mRNA splicing factor	Homo sapiens	55-58
1425698-7	1992	The inhibition of thioredoxin reductase activity by 13-cis-retinoic acid resulted in a decrease in the regeneration of glyceraldehyde-3-phosphate dehydrogenase in the H2O2-treated endothelial cells.	Isotretinoin	52-72	thioredoxin	Homo sapiens	18-29
1425698-7	1992	The inhibition of thioredoxin reductase activity by 13-cis-retinoic acid resulted in a decrease in the regeneration of glyceraldehyde-3-phosphate dehydrogenase in the H2O2-treated endothelial cells.	Isotretinoin	52-72	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	119-159
8439447-1	1993	13-cis-Retinoic acid (13-CRA), a water-soluble vitamin A analog and 5"-lipoxygenase inhibitor, was tested in vitro for effects on excess oxidative metabolism and DNA damage in mitogen-stimulated lymphocytes from patients with systemic lupus erythematosus (SLE), because other 5"-lipoxygenase enzyme inhibitors were shown to lower the excess oxidative metabolism in SLE cells.	Isotretinoin	0-20	myotubularin related protein 11	Homo sapiens	25-28
8439447-1	1993	13-cis-Retinoic acid (13-CRA), a water-soluble vitamin A analog and 5"-lipoxygenase inhibitor, was tested in vitro for effects on excess oxidative metabolism and DNA damage in mitogen-stimulated lymphocytes from patients with systemic lupus erythematosus (SLE), because other 5"-lipoxygenase enzyme inhibitors were shown to lower the excess oxidative metabolism in SLE cells.	Isotretinoin	0-20	arachidonate 5-lipoxygenase	Homo sapiens	68-83
1535214-5	1992	All-trans retinoic acid and 13-cis retinoic acid had a greater ability to induce IL-1 production than the two aromatic retinoids, etretinate and acitretin.	Isotretinoin	28-48	interleukin 1 complex	Mus musculus	81-85
1734084-2	1992	A large body of preclinical and clinical data supports the use of combination therapy with 13-cis-retinoic acid (13-cRA) and IFN-alpha in patients with squamous cell carcinoma of the skin.	Isotretinoin	91-111	myotubularin related protein 11	Homo sapiens	116-119
1734085-5	1992	PURPOSE: In view of the preclinical and clinical evidence that supports testing of the novel combination of 13-cis-retinoic acid (13-cRA) plus interferon-alpha (IFN-alpha) in cervical squamous cell carcinoma, we conducted a phase II study of this regimen in locally advanced disease.	Isotretinoin	108-128	myotubularin related protein 11	Homo sapiens	133-136
1329444-6	1992	To clarify the role of ADF/thioredoxin system in the viral transformation, we tested the effect of 13-cis-retinoic acid (RA), which is a competitive inhibitor of thioredoxin reductase, on the growth of ADF high producing cells.	Isotretinoin	99-119	peroxiredoxin 5	Homo sapiens	162-183
1329444-6	1992	To clarify the role of ADF/thioredoxin system in the viral transformation, we tested the effect of 13-cis-retinoic acid (RA), which is a competitive inhibitor of thioredoxin reductase, on the growth of ADF high producing cells.	Isotretinoin	99-119	thioredoxin	Homo sapiens	202-205
1329444-6	1992	To clarify the role of ADF/thioredoxin system in the viral transformation, we tested the effect of 13-cis-retinoic acid (RA), which is a competitive inhibitor of thioredoxin reductase, on the growth of ADF high producing cells.	Isotretinoin	121-123	peroxiredoxin 5	Homo sapiens	162-183
1329444-8	1992	RA dose-dependently reduced the cell number and viability of ADF high producing lymphoid cells.	Isotretinoin	0-2	thioredoxin	Homo sapiens	61-64
1329444-10	1992	It is suggested that RA has an inhibitory effect on the activation and the growth of cells producing ADF and that inhibition of the ADF/thioredoxin system may be a new therapeutic approach for retrovirus-related disorders.	Isotretinoin	21-23	thioredoxin	Homo sapiens	101-104
1329444-10	1992	It is suggested that RA has an inhibitory effect on the activation and the growth of cells producing ADF and that inhibition of the ADF/thioredoxin system may be a new therapeutic approach for retrovirus-related disorders.	Isotretinoin	21-23	thioredoxin	Homo sapiens	132-135
1329444-10	1992	It is suggested that RA has an inhibitory effect on the activation and the growth of cells producing ADF and that inhibition of the ADF/thioredoxin system may be a new therapeutic approach for retrovirus-related disorders.	Isotretinoin	21-23	thioredoxin	Homo sapiens	136-147
1918383-2	1991	In this study, we demonstrate that 13-cis-retinoic acid (13-cRA), a retinoid well tolerated in human therapy, can suppress T cell-mediated immunity in rats.	Isotretinoin	35-55	myotubularin related protein 11	Homo sapiens	60-63
1673838-1	1991	We report that all-trans and 13-cis-retinoic acid as well as the synthetic compound CH-55 enhance tissue transglutaminase activity as they increase NIH-3T3 cell adhesiveness.	Isotretinoin	29-49	transglutaminase 2, C polypeptide	Mus musculus	98-121
1828174-1	1991	The N-formylmethionyl-leucyl-phenylalanine (f-MLP)-induced metabolic burst activity of peripheral blood neutrophils isolated from acne patients undergoing treatment with 13-cis-retinoic acid at a dose of 1.0 mg/kg/day was investigated using a luminol-enhanced chemiluminescence assay.	Isotretinoin	170-190	cysteine and glycine rich protein 3	Homo sapiens	46-49
1898963-5	1991	Additions of two agonists, 1,25(OH)2D3 (1.2 x 10(-9) M) and 13-Cis retinoic acid (0.2 x 10(-9) M), to dye-loaded keratinocytes induced rapid release of [Ca++]i, respectively, followed by gradual return to the prestimulated state.	Isotretinoin	60-80	carbonic anhydrase 1	Mus musculus	153-159
1988285-5	1991	Similar to RA, 13-cis-RA and 3,5-di-tert-butyl-4-chalcone carboxylic acid, a synthetic retinoid, also increased PHA-L binding to gp130; they also enhanced cell adhesiveness and inhibited cell growth.	Isotretinoin	15-24	interleukin 6 signal transducer	Mus musculus	129-134
2172028-4	1990	Both 13-cis-retinoic acid and 3,4-didehydro-all trans-retinoic acid also induced expression of RAR-beta but were only effective at concentrations 100-fold greater than all trans-retinoic acid.	Isotretinoin	5-25	retinoic acid receptor, beta	Mus musculus	95-103
2064786-1	1991	13-cis-Retinoic acid is a stereospecific suicide inhibitor of thioredoxin reductase.	Isotretinoin	0-20	peroxiredoxin 5	Homo sapiens	62-83
2064786-2	1991	[3H]-labeled 13-cis-retinoic acid has been used to covalently label thioredoxin reductase in human keratinocytes.	Isotretinoin	13-33	peroxiredoxin 5	Homo sapiens	68-89
2064786-5	1991	The inhibition of thioredoxin reductase by 13-cis-retinoic acid may explain the known cytostatic and teratogenic properties attributed to this retinoid.	Isotretinoin	43-63	peroxiredoxin 5	Homo sapiens	18-39
2204541-0	1990	13-cis retinoic acid augments the production of macrophages in mouse bone marrow cultures stimulated with interleukin 3.	Isotretinoin	0-20	interleukin 3	Mus musculus	106-119
1698888-6	1990	The apparently uncoupled expression of K6 and K16 appeared also to be concentration dependent when 13-cis retinoic acid at concentrations of 10(-9), 10(-8), and 10(-7) M was analyzed.	Isotretinoin	99-119	keratin 16	Homo sapiens	46-49
34901184-0	2021	Isotretinoin Associated Rhabdomyolysis: Monitoring Creatine Kinase and Educating Patients.	Isotretinoin	0-12	cytidine/uridine monophosphate kinase 1	Homo sapiens	51-66
34869449-12	2021	Intriguingly, the SRI expression was negatively correlated with drug sensitivity of fluorouracil, paclitaxel, docetaxel, and isotretinoin.	Isotretinoin	125-137	sorcin	Homo sapiens	18-21
2252043-1	1990	PURPOSE: The purpose of this study was to determine the response and tolerance to long-term treatment using 13-cis-retinoic acid (13-CRA) in transfusion-dependent patients with the myelodysplastic syndrome (MDS) and to determine the effects of therapy on the natural history of the disease.	Isotretinoin	108-128	myotubularin related protein 11	Homo sapiens	133-136
19525031-0	2009	Retinoic acid 4-hydroxylase inducibility and clinical response to isotretinoin in patients with acne.	Isotretinoin	66-78	cytochrome P450 family 26 subfamily A member 1	Homo sapiens	0-27
19525031-2	2009	The CYP26 enzyme acts specifically on tRA, but not 13-cis RA (isotretinoin), a retinoid used to treat severe acne.	Isotretinoin	62-74	cytochrome P450 family 26 subfamily A member 1	Homo sapiens	4-9
34992430-5	2021	Purpose: To evaluate the impact of LEP gene rs7799039 polymorphism in acne patients" clinical response lipid profile and liver enzymes following 6 months oral isotretinoin therapy in Egyptian AV patients.	Isotretinoin	159-171	leptin	Homo sapiens	35-38
34992430-10	2021	Results: Six month administration of oral isotretinoin in Egyptian AV patients is associated with significantly elevated aspartate transaminase (AST) in CC and AC genotypes (P<0.001).	Isotretinoin	42-54	solute carrier family 17 member 5	Homo sapiens	121-143
34992430-10	2021	Results: Six month administration of oral isotretinoin in Egyptian AV patients is associated with significantly elevated aspartate transaminase (AST) in CC and AC genotypes (P<0.001).	Isotretinoin	42-54	solute carrier family 17 member 5	Homo sapiens	145-148
34992430-15	2021	Conclusion: LEP rs7799039 gene had an impact on the clinical response, lipid profile and liver enzymes in AV patients treated with oral isotretinoin.	Isotretinoin	136-148	leptin	Homo sapiens	12-15
34992430-16	2021	LEP rs7799039 CC genotype is predicted to be the treatment candidate for 6 month oral isotretinoin.	Isotretinoin	86-98	leptin	Homo sapiens	0-3
34893965-5	2022	We next demonstrated that chronic 13-cis-RA application increased neural activity in the dentate gyrus (DG) using c-Fos immunostaining, which may be critically involved in some aspects of depression-like behavior.	Isotretinoin	34-43	FBJ osteosarcoma oncogene	Mus musculus	114-119
34901184-3	2021	We present 2 patients with hyperCKemia: a 16-year-old male on isotretinoin whose CK levels were elevated (7,325 U/L) when rhabdomyolysis symptoms were present, and an asymptomatic 18-year-old male with elevated CK levels (35,000 U/L) before starting isotretinoin.	Isotretinoin	62-74	cytidine/uridine monophosphate kinase 1	Homo sapiens	81-83
34853752-17	2021	Conclusion The findings of this study indicate that oral isotretinoin can cause an elevation in ALT, AST, total cholesterol, and triglyceride levels but the incidence of these laboratory abnormalities is low and the elevation was not associated with significant morbidity, and therefore the practice of monthly laboratory monitoring for all patients while on isotretinoin needs to be revised as there is no strong evidence for such practice.	Isotretinoin	57-69	solute carrier family 17 member 5	Homo sapiens	101-104
34387230-1	2021	BACKGROUND: This study aimed to investigate the presence of physeal abnormality and its effect on growth in children with high-risk neuroblastoma treated by intensive multimodal treatment with/without 13-cis-retinoic acid (13-CRA).	Isotretinoin	201-221	myotubularin related protein 11	Homo sapiens	226-229
34641286-0	2021	Isotretinoin and Thalidomide Down-Regulate c-MYC Gene Expression and Modify Proteins Associated with Cancer in Hepatic Cells.	Isotretinoin	0-12	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	43-48
34641286-5	2021	The objective of this work was to evaluate the effect of the drugs isotretinoin and thalidomide on c-MYC expression and cancer-related proteins in an HCC cellular model.	Isotretinoin	67-79	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	99-104
34641286-10	2021	We demonstrated that in HepG2 cells, isotretinoin and thalidomide reduced c-MYC mRNA expression levels, but this decrease in expression was linked to the regulation of P1 and P1-P2 c-MYC promoter activity in isotretinoin only.	Isotretinoin	37-49	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	74-79
34641286-13	2021	In conclusion, isotretinoin and thalidomide down-regulate c-MYC mRNA expression and this is partially due to P1 or P2 promoter activity, suggesting that these drugs could be promising options for modulating the expression of oncogenes and tumor suppressor genes in HCC.	Isotretinoin	15-27	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	58-63
35353124-0	2022	Isotretinoin Impairs the Secretory Function of Meibomian Gland Via the PPARgamma Signaling Pathway.	Isotretinoin	0-12	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	71-80
34266686-0	2021	Evaluation of CPK levels during acne treatment with oral isotretinoin.	Isotretinoin	57-69	phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha	Homo sapiens	14-17
34224824-5	2021	Isotretinoin is associated with pro-apoptotic signaling in sebaceous glands through upregulated expression of p53, forkhead box O transcription factors (FOXO1, FOXO3), and tumor necrosis factor-related apoptosis inducing ligand (TRAIL).	Isotretinoin	0-12	tumor protein p53	Homo sapiens	110-113
34224824-5	2021	Isotretinoin is associated with pro-apoptotic signaling in sebaceous glands through upregulated expression of p53, forkhead box O transcription factors (FOXO1, FOXO3), and tumor necrosis factor-related apoptosis inducing ligand (TRAIL).	Isotretinoin	0-12	forkhead box O1	Homo sapiens	153-158
34224824-5	2021	Isotretinoin is associated with pro-apoptotic signaling in sebaceous glands through upregulated expression of p53, forkhead box O transcription factors (FOXO1, FOXO3), and tumor necrosis factor-related apoptosis inducing ligand (TRAIL).	Isotretinoin	0-12	forkhead box O3	Homo sapiens	160-165
34224824-5	2021	Isotretinoin is associated with pro-apoptotic signaling in sebaceous glands through upregulated expression of p53, forkhead box O transcription factors (FOXO1, FOXO3), and tumor necrosis factor-related apoptosis inducing ligand (TRAIL).	Isotretinoin	0-12	TNF superfamily member 10	Homo sapiens	172-227
34224824-5	2021	Isotretinoin is associated with pro-apoptotic signaling in sebaceous glands through upregulated expression of p53, forkhead box O transcription factors (FOXO1, FOXO3), and tumor necrosis factor-related apoptosis inducing ligand (TRAIL).	Isotretinoin	0-12	TNF superfamily member 10	Homo sapiens	229-234
34224824-6	2021	Two literature searches including clinical and experimental studies respectively support the hypothesis that isotretinoin s toxicological mode of action on the pituitary-ovarian axis might be caused by over-expressed p53/FOXO1 signaling resulting in gonadotropin suppression and granulosa cell apoptosis.	Isotretinoin	109-121	tumor protein p53	Homo sapiens	217-220
34224824-6	2021	Two literature searches including clinical and experimental studies respectively support the hypothesis that isotretinoin s toxicological mode of action on the pituitary-ovarian axis might be caused by over-expressed p53/FOXO1 signaling resulting in gonadotropin suppression and granulosa cell apoptosis.	Isotretinoin	109-121	forkhead box O1	Homo sapiens	221-226
35468045-6	2022	Furthermore, we discovered an FDA-approved drug, 13-cis retinoic acid, is capable of alleviating these mitophagic defects and neurobehavioral abnormalities in Kansl1 heterozygous mice by promoting autophagosome-lysosome fusion via directly binding to STX17 and SNAP29.	Isotretinoin	49-69	KAT8 regulatory NSL complex subunit 1	Mus musculus	159-165
35468045-6	2022	Furthermore, we discovered an FDA-approved drug, 13-cis retinoic acid, is capable of alleviating these mitophagic defects and neurobehavioral abnormalities in Kansl1 heterozygous mice by promoting autophagosome-lysosome fusion via directly binding to STX17 and SNAP29.	Isotretinoin	49-69	syntaxin 17	Mus musculus	251-256
35468045-6	2022	Furthermore, we discovered an FDA-approved drug, 13-cis retinoic acid, is capable of alleviating these mitophagic defects and neurobehavioral abnormalities in Kansl1 heterozygous mice by promoting autophagosome-lysosome fusion via directly binding to STX17 and SNAP29.	Isotretinoin	49-69	synaptosomal-associated protein 29	Mus musculus	261-267
34340266-1	2021	Aims: to evaluate changes in clinical periodontal parameters, salivary levels of MMP-8 and MMP-9, in individuals taking Isotretinoin (INN), and compare with individuals not taking the medication and to compare findings among different stages of periodontal disease and healthy periodontium.	Isotretinoin	120-132	matrix metallopeptidase 8	Homo sapiens	81-86
34340266-1	2021	Aims: to evaluate changes in clinical periodontal parameters, salivary levels of MMP-8 and MMP-9, in individuals taking Isotretinoin (INN), and compare with individuals not taking the medication and to compare findings among different stages of periodontal disease and healthy periodontium.	Isotretinoin	120-132	matrix metallopeptidase 9	Homo sapiens	91-96
34471574-5	2021	A 20-year-old female patient was diagnosed with acne vulgaris and started treatment with systemic isotretinoin (20 mg once daily) for one month.	Isotretinoin	98-110	immunoglobulin kappa variable 1-27	Homo sapiens	0-4
35545255-0	2022	Isotretinoin and its metabolites alter mRNA of multiple enzyme and transporter genes in vitro but downregulation of OATP1B1 does not translate to the clinic.	Isotretinoin	0-12	solute carrier organic anion transporter family member 1B1	Homo sapiens	116-123
35545255-8	2022	Based on the EC50 and Emax-values and the known circulating concentrations of 13cisRA and its metabolites after isotretinoin dosing, a 55% decrease in OATP1B1 activity was predicted in vivo In vivo DDI potential was evaluated clinically in subjects dosed with isotretinoin for up to 20 weeks using coproporphyrin-I (CP-I) as an OATP1B1 biomarker.	Isotretinoin	112-124	solute carrier organic anion transporter family member 1B1	Homo sapiens	151-158
35545255-8	2022	Based on the EC50 and Emax-values and the known circulating concentrations of 13cisRA and its metabolites after isotretinoin dosing, a 55% decrease in OATP1B1 activity was predicted in vivo In vivo DDI potential was evaluated clinically in subjects dosed with isotretinoin for up to 20 weeks using coproporphyrin-I (CP-I) as an OATP1B1 biomarker.	Isotretinoin	260-272	solute carrier organic anion transporter family member 1B1	Homo sapiens	151-158
35429216-2	2022	Oral isotretinoin used in the management of moderate-to-severe acne binds to the retinoid receptor which can form a heterodimer with vitamin D receptor (VDR) and may decrease the level of vitamin D by increasing catabolism.	Isotretinoin	5-17	vitamin D receptor	Homo sapiens	133-151
35429216-2	2022	Oral isotretinoin used in the management of moderate-to-severe acne binds to the retinoid receptor which can form a heterodimer with vitamin D receptor (VDR) and may decrease the level of vitamin D by increasing catabolism.	Isotretinoin	5-17	vitamin D receptor	Homo sapiens	153-156
35426210-0	2022	Lip mesotherapy with dexpanthenol in the treatment of isotretinoin-induced cheilitis.	Isotretinoin	54-66	SMG1 nonsense mediated mRNA decay associated PI3K related kinase	Homo sapiens	0-3
35353124-7	2022	Furthermore, isotretinoin treatment did not cause the upregulation of FoxO1 and inflammation related genes but significantly suppressed the expression of PPARgamma pathway.	Isotretinoin	13-25	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	154-163
35353124-9	2022	Isotretinoin causes meibomian gland dysfunction, affecting meibocyte differentiation and qualitative and quantitative changes in the meibum, through PPARgamma pathway.	Isotretinoin	0-12	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	149-158
35177641-6	2022	Moreover, we discovered that the FDA-approved drug 13-cis retinoic acid can reverse these mitophagic defects and neurobehavioral abnormalities in Kansl1+/- mice by promoting autophagosome-lysosome fusion.	Isotretinoin	51-71	KAT8 regulatory NSL complex subunit 1	Mus musculus	146-152
35324825-4	2022	The aim of this study was to investigate the clinical and histological effects of isotretinoin on ARCI in a golden retriever dog with confirmed mutation in the PNPLA 1 gene.	Isotretinoin	82-94	patatin like phospholipase domain containing 1	Canis lupus familiaris	160-167
2522491-4	1989	Retinoic acid and 13-cis retinoic acid (13-cRA) produced significant increases in the percentage of cells with markers for total T-helper cells, with a minimal effect on percentage of lymphocytes with markers for NK cells.	Isotretinoin	18-38	myotubularin related protein 11	Homo sapiens	43-46
2547418-0	1989	Isotretinoin differs from other synthetic retinoids in its modulation of human cellular retinoic acid binding protein (CRABP).	Isotretinoin	0-12	cellular retinoic acid binding protein 1	Homo sapiens	79-117
2547418-0	1989	Isotretinoin differs from other synthetic retinoids in its modulation of human cellular retinoic acid binding protein (CRABP).	Isotretinoin	0-12	cellular retinoic acid binding protein 1	Homo sapiens	119-124
2543582-3	1989	We found increased CRABP after daily application during 4 days of natural or synthetic retinoids (RA, acitretin, isotretinoin, Ro137410, retinol), that have either a high affinity to CRABP or can be transformed into RA.	Isotretinoin	113-125	cellular retinoic acid binding protein 1	Homo sapiens	19-24
2543582-3	1989	We found increased CRABP after daily application during 4 days of natural or synthetic retinoids (RA, acitretin, isotretinoin, Ro137410, retinol), that have either a high affinity to CRABP or can be transformed into RA.	Isotretinoin	113-125	cellular retinoic acid binding protein 1	Homo sapiens	183-188
35002402-1	2022	Aims: To evaluate and compare changes in salivary flow rate and salivary levels of TIMP-1 and TIMP-2 in individuals taking oral Isotretinoin (INN) with those who do not take INN.	Isotretinoin	128-140	TIMP metallopeptidase inhibitor 1	Homo sapiens	83-89
35002402-1	2022	Aims: To evaluate and compare changes in salivary flow rate and salivary levels of TIMP-1 and TIMP-2 in individuals taking oral Isotretinoin (INN) with those who do not take INN.	Isotretinoin	128-140	TIMP metallopeptidase inhibitor 2	Homo sapiens	94-100
2719682-0	1989	The stereospecific suicide inhibition of human melanoma thioredoxin reductase by 13-cis-retinoic acid.	Isotretinoin	81-101	peroxiredoxin 5	Homo sapiens	56-77
2719682-1	1989	13-cis retinoic acid has been shown to be a stereospecific suicide inhibitor of thioredoxin reductase purified from human melanoma tissue.	Isotretinoin	0-20	peroxiredoxin 5	Homo sapiens	80-101
2719682-3	1989	The covalent addition of 13-cis retinoic acid to the thiolate active site of thioredoxin reductase produces a thioether enzyme-inhibitor complex.	Isotretinoin	25-45	peroxiredoxin 5	Homo sapiens	77-98
2922761-14	1989	13cisRA and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma osteocalcin, an effect that correlated with retinoid-induced bone effects.	Isotretinoin	0-7	bone gamma-carboxyglutamate protein	Rattus norvegicus	76-87
3566730-5	1987	reconstitution of holo-RBP using apo-RBP from delipidized serum was achieved only after its incubation with natural all-trans-retinoids such as retinol, 3-dehydroretinol and retinoic acid but not with synthetic analogs of retinoic acid (13-cis-retinoic acid, TMMP, 13-cis-TMMP, TTNPB).	Isotretinoin	237-257	retinol binding protein 4	Homo sapiens	23-26
3655940-7	1987	When vitamin A-deficient rats were repleted with 13-cis retinoic acid for 3 or 5 d, both the ceruloplasmin activity and synthesis were significantly stimulated when compared to the nonrepleted, deficient rats.	Isotretinoin	49-69	ceruloplasmin	Rattus norvegicus	93-106
2575317-0	1989	13-cis retinoic acid and dexamethasone modulate the gene expression of epidermal growth factor receptor and fibroblast proteoglycan 40 core protein in human skin fibroblasts.	Isotretinoin	0-20	epidermal growth factor receptor	Homo sapiens	71-103
2575317-3	1989	13-cis-RA at a concentration of 10(-7) M markedly reduced the levels of the EGF receptor and PG40 mRNAs, the decreases being 33 and 56%, respectively.	Isotretinoin	0-9	epidermal growth factor receptor	Homo sapiens	76-88
2575317-3	1989	13-cis-RA at a concentration of 10(-7) M markedly reduced the levels of the EGF receptor and PG40 mRNAs, the decreases being 33 and 56%, respectively.	Isotretinoin	0-9	decorin	Homo sapiens	93-97
2575317-5	1989	Simultaneous treatment of the fibroblasts with 13-cis-RA and dexamethasone resulted in similar decreases in EGF receptor and PG40 mRNAs as with 13-cis-RA alone.	Isotretinoin	47-56	epidermal growth factor receptor	Homo sapiens	108-120
2575317-5	1989	Simultaneous treatment of the fibroblasts with 13-cis-RA and dexamethasone resulted in similar decreases in EGF receptor and PG40 mRNAs as with 13-cis-RA alone.	Isotretinoin	47-56	decorin	Homo sapiens	125-129
3278754-2	1988	Sixty-eight evaluable patients with MDS were randomized to receive a single, daily oral dose of either 13-cis retinoic acid (13-CRA, 100 mg/m2) or matching placebo.	Isotretinoin	103-123	myotubularin related protein 11	Homo sapiens	128-131
3655940-1	1987	Ceruloplasmin, a copper-containing acute phase plasma protein, has been shown to be regulated by 13-cis retinoic acid in rats.	Isotretinoin	97-117	ceruloplasmin	Rattus norvegicus	0-13
3655940-2	1987	Ceruloplasmin activity was significantly increased within 24 h and remained elevated for at least 72 h after a single injection of 13-cis retinoic acid.	Isotretinoin	131-151	ceruloplasmin	Rattus norvegicus	0-13
3475136-7	1987	Growth of the cells in the presence of dimethyl sulfoxide, cis-retinoic acid, or dibutyryl cyclic adenosine monophosphate results in granulocytic maturation as determined by morphology, histochemical staining characteristics, and incorporation of 35S-methionine into the neutrophil primary granule proteinases elastase and cathepsin G.	Isotretinoin	59-76	cathepsin G	Homo sapiens	323-334
2958204-5	1987	Reduction occurred in HDL-C (p less than 0.05) and HDL2-C (p less than 0.01) while HDL3-C remained unchanged, indicating that the effect of isotretinoin is on the HDL2-C subfraction.	Isotretinoin	140-152	junctophilin 3	Homo sapiens	163-167
3566730-5	1987	reconstitution of holo-RBP using apo-RBP from delipidized serum was achieved only after its incubation with natural all-trans-retinoids such as retinol, 3-dehydroretinol and retinoic acid but not with synthetic analogs of retinoic acid (13-cis-retinoic acid, TMMP, 13-cis-TMMP, TTNPB).	Isotretinoin	237-257	retinol binding protein 4	Homo sapiens	37-40
3755868-1	1986	The effects of two retinoids, all-trans-retinoic acid (t-RA) and 13-cis-retinoic acid (c-RA) were studied in a model of osteoclast precursors.	Isotretinoin	65-85	LUC7 like 3 pre-mRNA splicing factor	Homo sapiens	87-91
3747550-4	1986	The inhibition by all trans-retinoic acid of ornithine decarboxylase induced by cellotape stripping was dose dependent as was found to be the case for arotinoid, retinol, Ro-10-1670, motretinid, 13-cis-retinoic acid, etretinate, and vitamin A.	Isotretinoin	195-215	ornithine decarboxylase 1	Rattus norvegicus	45-68
3320577-1	1987	Responses have been reported in patients with myelodysplastic syndromes (MDS) after low-dose cytarabine (Ara-C) or 13-cis-retinoic acid (13-CRA) therapy.	Isotretinoin	115-135	myotubularin related protein 11	Homo sapiens	140-143
2870901-5	1986	A specific high performance liquid chromatography method based on the assay of generated isotretinoin in beta-glucuronidase-treated bile was developed for the determination of isotretinoin glucuronide in bile samples.	Isotretinoin	89-101	glucuronidase, beta	Rattus norvegicus	105-123
6609094-0	1984	Influence of 13-cis retinoic acid and of arotinoid on the cytochrome P-450 system in rat liver.	Isotretinoin	13-33	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	58-74
3857634-3	1985	13-cis-Retinoic acid (160 mg/kg, orally) given daily increased serum ceruloplasmin 2.2 and 2.7 times that found in nontreated arthritic rats when given alone and with zinc (2 mg/kg, intraperitoneally), respectively.	Isotretinoin	0-20	ceruloplasmin	Rattus norvegicus	69-82
3866117-9	1985	Expression of alkaline leukocyte phosphatase following 13-cis retinoic acid exposure may be a useful indicator for cells amenable to 13-cis retinoic acid or Ara-C treatment.	Isotretinoin	55-75	ATP binding cassette subfamily C member 6	Homo sapiens	157-160
6237253-3	1984	Oral vitamin A therapy was not beneficial, but oral use of 13-cis-retinoic acid (Accutane: Roche), at 0.25 mg/kg BID, resulted in recovery within a month.	Isotretinoin	59-79	BH3 interacting domain death agonist	Canis lupus familiaris	113-116
6237253-3	1984	Oral vitamin A therapy was not beneficial, but oral use of 13-cis-retinoic acid (Accutane: Roche), at 0.25 mg/kg BID, resulted in recovery within a month.	Isotretinoin	81-89	BH3 interacting domain death agonist	Canis lupus familiaris	113-116
33730072-0	2021	Treatment of 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 inhibits TNF-alpha-mediated expression of MMP-9 protein and cell invasion through the suppression of JNK pathway and microRNA 221 in human pancreatic adenocarcinoma cancer cells.	Isotretinoin	13-33	tumor necrosis factor	Homo sapiens	72-81
6580843-4	1983	The patient"s WBC count increased and her angiotensin-converting enzyme level decreased during the first two months of isotretinoin therapy; both returned to pretreatment levels during the third month of therapy.	Isotretinoin	119-131	angiotensin I converting enzyme	Homo sapiens	42-71
6580071-1	1983	13-cis-Retinoic acid (13-cRA) induces maturation and differentiation of neoplastic myeloid cell lines in vitro.	Isotretinoin	0-20	myotubularin related protein 11	Homo sapiens	25-28
6409606-1	1983	Tumor promoters are known to induce ODC activity in mouse skin and that this induction can be inhibited by the application of 13-cis-retinoic acid.	Isotretinoin	126-146	ornithine decarboxylase, structural 1	Mus musculus	36-39
6578203-1	1983	The results reported here provide information on the effects of 13-cis retinoic acid (13-cRA) on the IgG and IgM responses in BALB/c mice.	Isotretinoin	64-84	myotubularin related protein 11	Mus musculus	89-92
7039822-1	1982	13-cis-Retinoic acid (13-CRA) is a synthetic analog of vitamin A effective reversing preneoplastic lesions in both humans and animals.	Isotretinoin	0-20	myotubularin related protein 11	Homo sapiens	25-28
6958659-1	1982	The results reported here are an extension of our previously reported studies on the adjuvant effects of 13-cis-retinoic acid (13-cRA).	Isotretinoin	105-125	myotubularin related protein 11	Mus musculus	130-133
6791164-4	1981	13-cis-Retinoic acid inhibited this ornithine decarboxylase induction when painted on the skin 1 hr before these natural products.	Isotretinoin	0-20	ornithine decarboxylase, structural 1	Mus musculus	36-59
7061156-1	1982	Pretreatment of Balb/c mice per os with 13-cis retinoic acid (13-cRA) in gelatin beadlets potentiated the production of a secondary IgE response to ovalbumin (OA) without a detectable primary response.	Isotretinoin	40-60	myotubularin related protein 11	Mus musculus	65-68
7371022-5	1980	ANFT-induced ornithine decarboxylase activity was principally localized in the bladder epithelium and was inhibited in a linear dose-response relationship by the synthetic retinoid, 13-cis-retinoic acid.	Isotretinoin	182-202	ornithine decarboxylase, structural 1	Mus musculus	13-36
31498706-3	2021	Objective: The purpose of this study was to assess the management and clinical outcome of acne patients with abnormal aspartate transaminase (AST) and alanine aminotransferase (ALT) when receiving isotretinoin.	Isotretinoin	197-209	solute carrier family 17 member 5	Homo sapiens	118-140
31498706-3	2021	Objective: The purpose of this study was to assess the management and clinical outcome of acne patients with abnormal aspartate transaminase (AST) and alanine aminotransferase (ALT) when receiving isotretinoin.	Isotretinoin	197-209	solute carrier family 17 member 5	Homo sapiens	142-145
31498706-3	2021	Objective: The purpose of this study was to assess the management and clinical outcome of acne patients with abnormal aspartate transaminase (AST) and alanine aminotransferase (ALT) when receiving isotretinoin.	Isotretinoin	197-209	glutamic--pyruvic transaminase	Homo sapiens	151-175
33919763-1	2021	(1) Background: 13-cis-retinoic acid (13-CRA) is a key component of neuroblastoma treatment protocols.	Isotretinoin	16-36	myotubularin related protein 11	Homo sapiens	41-44
33730072-0	2021	Treatment of 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 inhibits TNF-alpha-mediated expression of MMP-9 protein and cell invasion through the suppression of JNK pathway and microRNA 221 in human pancreatic adenocarcinoma cancer cells.	Isotretinoin	13-33	matrix metallopeptidase 9	Homo sapiens	105-110
33730072-0	2021	Treatment of 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 inhibits TNF-alpha-mediated expression of MMP-9 protein and cell invasion through the suppression of JNK pathway and microRNA 221 in human pancreatic adenocarcinoma cancer cells.	Isotretinoin	13-33	mitogen-activated protein kinase 8	Homo sapiens	164-167
33730072-5	2021	In this study, our results demonstrated that co-treatment of 13-cis retinoic acid (13-cis RA) and 1,25-dihydroxyvitamin D3 (1,25-VD3) significantly inhibited TNF-alpha mediated cell invasion in PDAC in vitro.	Isotretinoin	61-81	tumor necrosis factor	Homo sapiens	158-167
33730072-5	2021	In this study, our results demonstrated that co-treatment of 13-cis retinoic acid (13-cis RA) and 1,25-dihydroxyvitamin D3 (1,25-VD3) significantly inhibited TNF-alpha mediated cell invasion in PDAC in vitro.	Isotretinoin	83-92	tumor necrosis factor	Homo sapiens	158-167
33658110-1	2021	13-cis-retinoic acid (13-cRA) is a safe treatment for severe acne, as it has immunomodulatory effects such as enhancing the antigen-presenting activity of epidermal Langerhans cells (LCs) and T-cell activity.	Isotretinoin	0-20	myotubularin related protein 11	Homo sapiens	25-28
33039483-0	2021	Choosing Between Isotretinoin and Acitretin for Epidermal Growth Factor Receptor Inhibitor and Small Molecule Tyrosine Kinase Inhibitor Acneiform Eruptions.	Isotretinoin	17-29	epidermal growth factor receptor	Homo sapiens	48-80
33601383-8	2021	13-cis-retinoic acid and all-trans-retinoic acid regulated IL-6 release.	Isotretinoin	0-20	interleukin 6	Homo sapiens	59-63
32982373-9	2020	Expression of GATA2 (2.73 fold, P=0.024512), C4BPA (35.87 folds, P=0.038073), and CCR5 (2.48 folds, P=0.004681) increased in the ISO-induced acne flare-up patients.	Isotretinoin	129-132	GATA binding protein 2	Homo sapiens	14-19
32982373-13	2020	GATA2, C4BPA, CCR5, DEFA3, ELANE, MMP9, and RPS4Y1 might be susceptible to genes that could participate in the ISO-induced aggravation of acne.	Isotretinoin	111-114	GATA binding protein 2	Homo sapiens	0-5
32982373-10	2020	Meanwhile, the expression of DEFA3 (0.18 fold, P=0.041934), ELANE (0.14 fold, P=0.030767), MMP9 (0.41 fold, P=0.013383), and RPS4Y1 (0.00018 fold, P=0.000986) decreased when compared with ISO-ineffective patients.	Isotretinoin	188-191	defensin alpha 3	Homo sapiens	29-34
32982373-13	2020	GATA2, C4BPA, CCR5, DEFA3, ELANE, MMP9, and RPS4Y1 might be susceptible to genes that could participate in the ISO-induced aggravation of acne.	Isotretinoin	111-114	complement component 4 binding protein alpha	Homo sapiens	7-12
32982373-13	2020	GATA2, C4BPA, CCR5, DEFA3, ELANE, MMP9, and RPS4Y1 might be susceptible to genes that could participate in the ISO-induced aggravation of acne.	Isotretinoin	111-114	C-C motif chemokine receptor 5	Homo sapiens	14-18
32409685-4	2020	Although MYC amplification is rare in neuroblastoma at diagnosis, we report transcriptional activation of MYC medicated by the transcription factor OCT4, functionally replacing MYCN in 13-cisRA-resistant progressive disease neuroblastoma in large panels of patient-derived cell lines and xenograft models.	Isotretinoin	185-193	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	106-109
32982373-13	2020	GATA2, C4BPA, CCR5, DEFA3, ELANE, MMP9, and RPS4Y1 might be susceptible to genes that could participate in the ISO-induced aggravation of acne.	Isotretinoin	111-114	defensin alpha 3	Homo sapiens	20-25
32982373-13	2020	GATA2, C4BPA, CCR5, DEFA3, ELANE, MMP9, and RPS4Y1 might be susceptible to genes that could participate in the ISO-induced aggravation of acne.	Isotretinoin	111-114	elastase, neutrophil expressed	Homo sapiens	27-32
32982373-13	2020	GATA2, C4BPA, CCR5, DEFA3, ELANE, MMP9, and RPS4Y1 might be susceptible to genes that could participate in the ISO-induced aggravation of acne.	Isotretinoin	111-114	matrix metallopeptidase 9	Homo sapiens	34-38
32982373-13	2020	GATA2, C4BPA, CCR5, DEFA3, ELANE, MMP9, and RPS4Y1 might be susceptible to genes that could participate in the ISO-induced aggravation of acne.	Isotretinoin	111-114	ribosomal protein S4 Y-linked 1	Homo sapiens	44-50
32995446-0	2020	Isotretinoin for the treatment of severe acneiform eruptions associated with the MEK inhibitor trametinib.	Isotretinoin	0-12	mitogen-activated protein kinase kinase 7	Homo sapiens	81-84
32685503-9	2020	Using isotretinoin for 1 week, LCN2, PTGES, and GDF15 were upregulated and might mediate sebocytes apoptosis and thus decreased sebum production; CCL2 originated from activated TNF signaling pathway and S100A7 could be related with "acne-flare".	Isotretinoin	6-18	lipocalin 2	Homo sapiens	31-35
32685503-9	2020	Using isotretinoin for 1 week, LCN2, PTGES, and GDF15 were upregulated and might mediate sebocytes apoptosis and thus decreased sebum production; CCL2 originated from activated TNF signaling pathway and S100A7 could be related with "acne-flare".	Isotretinoin	6-18	prostaglandin E synthase	Homo sapiens	37-42
32685503-9	2020	Using isotretinoin for 1 week, LCN2, PTGES, and GDF15 were upregulated and might mediate sebocytes apoptosis and thus decreased sebum production; CCL2 originated from activated TNF signaling pathway and S100A7 could be related with "acne-flare".	Isotretinoin	6-18	growth differentiation factor 15	Homo sapiens	48-53
32685503-9	2020	Using isotretinoin for 1 week, LCN2, PTGES, and GDF15 were upregulated and might mediate sebocytes apoptosis and thus decreased sebum production; CCL2 originated from activated TNF signaling pathway and S100A7 could be related with "acne-flare".	Isotretinoin	6-18	C-C motif chemokine ligand 2	Homo sapiens	146-150
32685503-9	2020	Using isotretinoin for 1 week, LCN2, PTGES, and GDF15 were upregulated and might mediate sebocytes apoptosis and thus decreased sebum production; CCL2 originated from activated TNF signaling pathway and S100A7 could be related with "acne-flare".	Isotretinoin	6-18	tumor necrosis factor	Homo sapiens	177-180
32685503-9	2020	Using isotretinoin for 1 week, LCN2, PTGES, and GDF15 were upregulated and might mediate sebocytes apoptosis and thus decreased sebum production; CCL2 originated from activated TNF signaling pathway and S100A7 could be related with "acne-flare".	Isotretinoin	6-18	S100 calcium binding protein A7	Homo sapiens	203-209
32685503-10	2020	While treating with isotretinoin for 8 weeks, key genes were downregulated, including HMGCS1, HMGCR, FDFT1, MVD, IDI1, and FDPS, which may be associated with decreased sebum synthesis; HMGCS1, HMGCR, and FDFT1 also probably associated with apoptosis of sebocytes.	Isotretinoin	20-32	3-hydroxy-3-methylglutaryl-CoA synthase 1	Homo sapiens	86-92
32685503-10	2020	While treating with isotretinoin for 8 weeks, key genes were downregulated, including HMGCS1, HMGCR, FDFT1, MVD, IDI1, and FDPS, which may be associated with decreased sebum synthesis; HMGCS1, HMGCR, and FDFT1 also probably associated with apoptosis of sebocytes.	Isotretinoin	20-32	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	94-99
32685503-10	2020	While treating with isotretinoin for 8 weeks, key genes were downregulated, including HMGCS1, HMGCR, FDFT1, MVD, IDI1, and FDPS, which may be associated with decreased sebum synthesis; HMGCS1, HMGCR, and FDFT1 also probably associated with apoptosis of sebocytes.	Isotretinoin	20-32	farnesyl-diphosphate farnesyltransferase 1	Homo sapiens	101-106
32685503-10	2020	While treating with isotretinoin for 8 weeks, key genes were downregulated, including HMGCS1, HMGCR, FDFT1, MVD, IDI1, and FDPS, which may be associated with decreased sebum synthesis; HMGCS1, HMGCR, and FDFT1 also probably associated with apoptosis of sebocytes.	Isotretinoin	20-32	mevalonate diphosphate decarboxylase	Homo sapiens	108-111
32685503-10	2020	While treating with isotretinoin for 8 weeks, key genes were downregulated, including HMGCS1, HMGCR, FDFT1, MVD, IDI1, and FDPS, which may be associated with decreased sebum synthesis; HMGCS1, HMGCR, and FDFT1 also probably associated with apoptosis of sebocytes.	Isotretinoin	20-32	isopentenyl-diphosphate delta isomerase 1	Homo sapiens	113-117
32685503-10	2020	While treating with isotretinoin for 8 weeks, key genes were downregulated, including HMGCS1, HMGCR, FDFT1, MVD, IDI1, and FDPS, which may be associated with decreased sebum synthesis; HMGCS1, HMGCR, and FDFT1 also probably associated with apoptosis of sebocytes.	Isotretinoin	20-32	farnesyl diphosphate synthase	Homo sapiens	123-127
32685503-10	2020	While treating with isotretinoin for 8 weeks, key genes were downregulated, including HMGCS1, HMGCR, FDFT1, MVD, IDI1, and FDPS, which may be associated with decreased sebum synthesis; HMGCS1, HMGCR, and FDFT1 also probably associated with apoptosis of sebocytes.	Isotretinoin	20-32	3-hydroxy-3-methylglutaryl-CoA synthase 1	Homo sapiens	185-191
32685503-10	2020	While treating with isotretinoin for 8 weeks, key genes were downregulated, including HMGCS1, HMGCR, FDFT1, MVD, IDI1, and FDPS, which may be associated with decreased sebum synthesis; HMGCS1, HMGCR, and FDFT1 also probably associated with apoptosis of sebocytes.	Isotretinoin	20-32	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	193-198
32685503-10	2020	While treating with isotretinoin for 8 weeks, key genes were downregulated, including HMGCS1, HMGCR, FDFT1, MVD, IDI1, and FDPS, which may be associated with decreased sebum synthesis; HMGCS1, HMGCR, and FDFT1 also probably associated with apoptosis of sebocytes.	Isotretinoin	20-32	farnesyl-diphosphate farnesyltransferase 1	Homo sapiens	204-209
32409685-0	2020	MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma.	Isotretinoin	78-86	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-3
32409685-0	2020	MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma.	Isotretinoin	78-86	POU class 5 homeobox 1	Homo sapiens	41-45
32409685-3	2020	MYCN expression is downregulated by 13-cisRA, a differentiating agent that is a component of neuroblastoma therapy.	Isotretinoin	36-44	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	0-4
32325076-1	2020	OBJECTIVE: To explore the pharmacokinetic interaction between isotretinoin, a cytochrome P-450 (CYP) inducer and potent teratogen, and the etonogestrel contraceptive implant.	Isotretinoin	62-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	78-94
32325076-1	2020	OBJECTIVE: To explore the pharmacokinetic interaction between isotretinoin, a cytochrome P-450 (CYP) inducer and potent teratogen, and the etonogestrel contraceptive implant.	Isotretinoin	62-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	96-99
32729248-6	2020	Vorinostat and isotretinoin are the top ACE2 up/downregulators, respectively, in cell lines.	Isotretinoin	15-27	angiotensin converting enzyme 2	Homo sapiens	40-44
32391951-2	2020	We therefore aimed to examine the effects of isotretinoin treatment on changes in insulin resistance and serum levels of adiponectin in patients with acne.	Isotretinoin	45-57	insulin	Homo sapiens	82-89
32391951-2	2020	We therefore aimed to examine the effects of isotretinoin treatment on changes in insulin resistance and serum levels of adiponectin in patients with acne.	Isotretinoin	45-57	adiponectin, C1Q and collagen domain containing	Homo sapiens	121-132
32391951-8	2020	Our study concluded that isotretinoin treatment for patients with acne resulted in an increased serum level of adiponectin but did not have a substantial impact on the status of insulin resistance.	Isotretinoin	25-37	adiponectin, C1Q and collagen domain containing	Homo sapiens	111-122
32409685-4	2020	Although MYC amplification is rare in neuroblastoma at diagnosis, we report transcriptional activation of MYC medicated by the transcription factor OCT4, functionally replacing MYCN in 13-cisRA-resistant progressive disease neuroblastoma in large panels of patient-derived cell lines and xenograft models.	Isotretinoin	185-193	POU class 5 homeobox 1	Homo sapiens	148-152
32409685-4	2020	Although MYC amplification is rare in neuroblastoma at diagnosis, we report transcriptional activation of MYC medicated by the transcription factor OCT4, functionally replacing MYCN in 13-cisRA-resistant progressive disease neuroblastoma in large panels of patient-derived cell lines and xenograft models.	Isotretinoin	185-193	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	177-181
32409685-8	2020	OCT4 or MK2 knockdown decreased c-MYC expression and restored the sensitivity to 13-cisRA.	Isotretinoin	81-89	POU class 5 homeobox 1	Homo sapiens	0-4
32409685-8	2020	OCT4 or MK2 knockdown decreased c-MYC expression and restored the sensitivity to 13-cisRA.	Isotretinoin	81-89	MAPK activated protein kinase 2	Homo sapiens	8-11
32306454-4	2020	Recent research demonstrated that IGF-1 levels decrease after three months of isotretinoin.	Isotretinoin	78-90	insulin like growth factor 1	Homo sapiens	34-39
32354609-14	2020	13-cis-RA increased autophagy in SZ95 sebocytes, partly via FoxO1 activation, and inhibition of autophagy abolished the sebosuppressive effect of 13-cis-RA.	Isotretinoin	0-9	forkhead box O1	Homo sapiens	60-65
31562833-2	2020	demonstrated that isotretinoin (13-cis-retinoic acid, 13CRA) induced acnegenic changes in SEB-1 cultured human sebocytes1 .	Isotretinoin	18-30	myotubularin related protein 11	Homo sapiens	56-59
32393134-3	2020	We present a case with an unusual appearance of epitheliolysis of the small bowel and colon due to a toxic reaction.Case report: A 19 year old male was diagnosed with ulcerative colitis (UC) after treatment with tetracyclines followed by isotretinoin due to acne vulgaris.	Isotretinoin	238-250	immunoglobulin kappa variable 2-28	Homo sapiens	129-133
32411191-0	2020	The Association between Adiponectin Single Nucleotide Polymorphisms and Side Effects of Isotretinoin in Acne Patients.	Isotretinoin	88-100	adiponectin, C1Q and collagen domain containing	Homo sapiens	24-35
32411191-4	2020	Aim: In this study, the effect of genetic polymorphisms, rs2241766 and rs1501299, of the adiponectin gene was investigated in relation to the side effects of isotretinoin-treated young adult acne patients (n = 230).	Isotretinoin	158-170	adiponectin, C1Q and collagen domain containing	Homo sapiens	89-100
32411191-10	2020	Conclusions: Current findings showed that rs1501299 of the ADIPOQ gene might be associated with changes in HDL level in acne patients following treatment with isotretinoin.	Isotretinoin	159-171	adiponectin, C1Q and collagen domain containing	Homo sapiens	59-65
31639246-2	2019	As isotretinoin therapy is known to alter some of S100 peptides, these could be important specific targets for acne therapy and may have an important role in clinical remission.	Isotretinoin	3-15	S100 calcium binding protein A1	Homo sapiens	50-54
31857701-0	2020	Immunomodulator polyinosinic-polycytidylic acid enhances the inhibitory effect of 13-cis-retinoic acid on neuroblastoma through a TLR3-related immunogenic-apoptotic response.	Isotretinoin	82-102	toll like receptor 3	Homo sapiens	130-134
31857701-4	2020	In MYCN-amplified SK-N-DZ cells, 13cRA induced significant upregulation of toll-like receptor 3 (TLR3) and mitochondrial antiviral-signaling protein (MAVS) expression in a time-dependent manner.	Isotretinoin	33-38	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	3-7
31857701-4	2020	In MYCN-amplified SK-N-DZ cells, 13cRA induced significant upregulation of toll-like receptor 3 (TLR3) and mitochondrial antiviral-signaling protein (MAVS) expression in a time-dependent manner.	Isotretinoin	33-38	toll like receptor 3	Homo sapiens	75-95
31857701-4	2020	In MYCN-amplified SK-N-DZ cells, 13cRA induced significant upregulation of toll-like receptor 3 (TLR3) and mitochondrial antiviral-signaling protein (MAVS) expression in a time-dependent manner.	Isotretinoin	33-38	toll like receptor 3	Homo sapiens	97-101
31857701-4	2020	In MYCN-amplified SK-N-DZ cells, 13cRA induced significant upregulation of toll-like receptor 3 (TLR3) and mitochondrial antiviral-signaling protein (MAVS) expression in a time-dependent manner.	Isotretinoin	33-38	mitochondrial antiviral signaling protein	Homo sapiens	107-148
31857701-4	2020	In MYCN-amplified SK-N-DZ cells, 13cRA induced significant upregulation of toll-like receptor 3 (TLR3) and mitochondrial antiviral-signaling protein (MAVS) expression in a time-dependent manner.	Isotretinoin	33-38	mitochondrial antiviral signaling protein	Homo sapiens	150-154
32158247-11	2020	Results: Using human primary sebocytes, we found that biguanides, isotretinoin and azithromycin induced an acute dose and time-dependent increase in [14C]-acetate labeling of neutral lipids, while AICAR, an AMPK activator, inhibited this DNL response.	Isotretinoin	66-78	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	207-211
32064346-4	2020	We then identified isotretinoin and bexarotene, two FDA-approved RXRA agonists, which exert cardioprotective effects.	Isotretinoin	19-31	retinoid x receptor, gamma a	Danio rerio	65-69
31522242-3	2019	We conducted a phase I study of belinostat combined with 50-100 mg/m2/day 13-cis-retinoic acid (13-cRA) in patients with advanced solid tumors.	Isotretinoin	74-94	myotubularin related protein 11	Homo sapiens	99-102
31419517-2	2019	The three CYP26 family enzymes, CYP26A1, CYP26B1 and CYP26C1 have all been shown to metabolize all-trans-retinoic acid (atRA) it"s 9-cisRA and 13-cisRA isomers and primary metabolites 4-OH-RA and 4-oxo-RA with high efficiency.	Isotretinoin	133-138	cytochrome P450 family 26 subfamily A member 1	Homo sapiens	10-15
31419517-2	2019	The three CYP26 family enzymes, CYP26A1, CYP26B1 and CYP26C1 have all been shown to metabolize all-trans-retinoic acid (atRA) it"s 9-cisRA and 13-cisRA isomers and primary metabolites 4-OH-RA and 4-oxo-RA with high efficiency.	Isotretinoin	133-138	cytochrome P450 family 26 subfamily A member 1	Homo sapiens	32-39
31419517-2	2019	The three CYP26 family enzymes, CYP26A1, CYP26B1 and CYP26C1 have all been shown to metabolize all-trans-retinoic acid (atRA) it"s 9-cisRA and 13-cisRA isomers and primary metabolites 4-OH-RA and 4-oxo-RA with high efficiency.	Isotretinoin	133-138	cytochrome P450 family 26 subfamily B member 1	Homo sapiens	41-48
31419517-2	2019	The three CYP26 family enzymes, CYP26A1, CYP26B1 and CYP26C1 have all been shown to metabolize all-trans-retinoic acid (atRA) it"s 9-cisRA and 13-cisRA isomers and primary metabolites 4-OH-RA and 4-oxo-RA with high efficiency.	Isotretinoin	133-138	cytochrome P450 family 26 subfamily C member 1	Homo sapiens	53-60
31419517-2	2019	The three CYP26 family enzymes, CYP26A1, CYP26B1 and CYP26C1 have all been shown to metabolize all-trans-retinoic acid (atRA) it"s 9-cisRA and 13-cisRA isomers and primary metabolites 4-OH-RA and 4-oxo-RA with high efficiency.	Isotretinoin	146-151	cytochrome P450 family 26 subfamily A member 1	Homo sapiens	10-15
31419517-2	2019	The three CYP26 family enzymes, CYP26A1, CYP26B1 and CYP26C1 have all been shown to metabolize all-trans-retinoic acid (atRA) it"s 9-cisRA and 13-cisRA isomers and primary metabolites 4-OH-RA and 4-oxo-RA with high efficiency.	Isotretinoin	146-151	cytochrome P450 family 26 subfamily A member 1	Homo sapiens	32-39
31419517-2	2019	The three CYP26 family enzymes, CYP26A1, CYP26B1 and CYP26C1 have all been shown to metabolize all-trans-retinoic acid (atRA) it"s 9-cisRA and 13-cisRA isomers and primary metabolites 4-OH-RA and 4-oxo-RA with high efficiency.	Isotretinoin	146-151	cytochrome P450 family 26 subfamily B member 1	Homo sapiens	41-48
31419517-2	2019	The three CYP26 family enzymes, CYP26A1, CYP26B1 and CYP26C1 have all been shown to metabolize all-trans-retinoic acid (atRA) it"s 9-cisRA and 13-cisRA isomers and primary metabolites 4-OH-RA and 4-oxo-RA with high efficiency.	Isotretinoin	146-151	cytochrome P450 family 26 subfamily C member 1	Homo sapiens	53-60
31639246-9	2019	By comparing the mean S100a7a protein level before and after isotretinoin therapy in the study group, a highly significant statistical difference was also found (p = .001).	Isotretinoin	61-73	S100 calcium binding protein A7A	Homo sapiens	22-29
31639246-10	2019	The current study showed a downregulatory effect of isotretinoin therapy on the S100a7a peptide mean level.	Isotretinoin	52-64	S100 calcium binding protein A7A	Homo sapiens	80-87
31364786-0	2019	Plasma dermcidin levels in acne patients, and the effect of isotretinoin treatment on dermcidin levels.	Isotretinoin	60-72	dermcidin	Homo sapiens	86-95
31365169-5	2019	We demonstrated that TERT expression is reduced during 13-cis retinoic acid-induced NB differentiation and that this inversely correlated with increased expression of AT-rich interaction domain 1A (ARID1A), a subunit of the SWItch/sucrose nonfermentable chromatin remodeling complex.	Isotretinoin	58-75	telomerase reverse transcriptase	Homo sapiens	21-25
31358541-12	2019	CONCLUSIONS: Hu14.18-IL2 given in combination with GM-CSF and isotretinoin is safe and tolerable.	Isotretinoin	62-74	interleukin 2	Homo sapiens	21-24
32010406-4	2019	In the end, the authors concluded that robust trials with more patients are needed to establish the efficacy of Vit B12 and folic acid in the treatment of isotretinoin induced musculoskeletal pain.	Isotretinoin	155-167	vitrin	Homo sapiens	112-115
31358541-0	2019	Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children"s Oncology Group Phase II Study.	Isotretinoin	66-78	interleukin 2	Homo sapiens	47-50
31364786-4	2019	The aim of this study was to determine the relationship between DCD expression and acne vulgaris and the effect of oral isotretinoin treatment on DCD levels.	Isotretinoin	120-132	dermcidin	Homo sapiens	146-149
31364786-11	2019	Additionally, pretreatment DCD levels were significantly increased after 6 months of isotretinoin treatment in the patient group (28.60 +- 20.12 vs. 35.07 +- 24.02, p = .012).	Isotretinoin	85-97	dermcidin	Homo sapiens	27-30
31364786-15	2019	Moreover, it was shown that isotretinoin treatment may improve acne vulgaris by increasing DCD levels.	Isotretinoin	28-40	dermcidin	Homo sapiens	91-94
31380129-0	2019	Prolonged Serum Alanine Aminotransferase Elevation Associated with Isotretinoin Administration.	Isotretinoin	67-79	glutamic--pyruvic transaminase	Homo sapiens	16-40
31380129-4	2019	We describe a 16-year-old male in whom alanine aminotransferase (ALT) rose from a baseline of 13 to 288 U/L after 20 weeks of treatment with 1.0-1.4 mg/kg of oral isotretinoin daily.	Isotretinoin	163-175	glutamic--pyruvic transaminase	Homo sapiens	39-63
30761880-1	2019	The aim of this study was to assess the association of AV with insulin resistance and adipocytokine levels and to evaluate the effect of isotretinoin on insulin resistance and adipocytokine levels.	Isotretinoin	137-149	insulin	Homo sapiens	153-160
31101494-5	2019	RELMalpha expression required dietary vitamin A and was induced by the therapeutic vitamin A analog isotretinoin, which protected against skin infection in a RELMalpha-dependent manner.	Isotretinoin	100-112	resistin like alpha	Mus musculus	0-9
31101494-5	2019	RELMalpha expression required dietary vitamin A and was induced by the therapeutic vitamin A analog isotretinoin, which protected against skin infection in a RELMalpha-dependent manner.	Isotretinoin	100-112	resistin like alpha	Mus musculus	158-167
30761880-5	2019	Isotretinoin therapy maintained lower mean resistin levels (P = 0.016), higher mean RBP4 levels (P = 0.040), but not affected the mean adiponectin and leptin levels (P = 0.113, P = 0.125, respectively).	Isotretinoin	0-12	retinol binding protein 4	Homo sapiens	84-88
31080813-8	2019	Results: Isotretinoin treatment significantly decreased Ferriman-Gallwey score, free testosterone, insulin level, hemoglobin level, acne score, and ovarian volume.	Isotretinoin	9-21	insulin	Homo sapiens	99-106
31080813-10	2019	Conclusion: Isotretinoin treatment may have beneficial effects on free testosterone, insulin, acne score, and Ferriman-Gallwey score.	Isotretinoin	12-24	insulin	Homo sapiens	85-92
30761880-6	2019	Conclusions: All data suggests that five months of isotretinoin therapy in AV patients causes insulin resistance and the increase in in-sulin resistance is not dependent on age, BMI, BFM, and lipid levels of these patients.	Isotretinoin	51-63	insulin	Homo sapiens	94-101
30240097-5	2018	Our in vivo study demonstrates a significant increase in the nucleo-cytoplasmic ratio of non-phosphorylated FoxO1 and FoxO3 during isotretinoin treatment of acne patients.	Isotretinoin	131-143	forkhead box O3	Homo sapiens	118-123
30155683-3	2019	13-cis-RA-induced depressive-like behavior and DO symptoms were associated with increased corticotropin-releasing factor (CRF) level in the plasma, prefrontal cortex (PFC), hippocampus (Hp), Barrington"s nucleus (BN), and urinary bladder.	Isotretinoin	0-9	corticotropin releasing hormone	Rattus norvegicus	90-120
30155683-5	2019	Blebbistatin exerted antidepressant-like effect and attenuated changes in the cystometric parameters as well as the central and peripheral levels of CRF, BDNF, and NGF that were induced by 13-cis-RA, while it did not affect urine production, mean, systolic or diastolic blood pressure, or heart rate.	Isotretinoin	189-198	brain derived neurotrophic factor	Homo sapiens	154-158
30240097-6	2018	Translational and presented experimental evidence indicates that upregulation of nuclear FoxO1 and FoxO3 proteins is involved in isotretinoin-induced pro-apoptotic signalling in sebocytes confirming the scientific hypothesis of isotretinoin-mediated upregulation of FoxO expression.	Isotretinoin	129-141	forkhead box O1	Homo sapiens	89-94
30240097-0	2018	Effect of oral isotretinoin on the nucleo-cytoplasmic distribution of FoxO1 and FoxO3 proteins in sebaceous glands of patients with acne vulgaris.	Isotretinoin	15-27	forkhead box O1	Homo sapiens	70-75
30240097-0	2018	Effect of oral isotretinoin on the nucleo-cytoplasmic distribution of FoxO1 and FoxO3 proteins in sebaceous glands of patients with acne vulgaris.	Isotretinoin	15-27	forkhead box O3	Homo sapiens	80-85
30240097-6	2018	Translational and presented experimental evidence indicates that upregulation of nuclear FoxO1 and FoxO3 proteins is involved in isotretinoin-induced pro-apoptotic signalling in sebocytes confirming the scientific hypothesis of isotretinoin-mediated upregulation of FoxO expression.	Isotretinoin	129-141	forkhead box O3	Homo sapiens	99-104
30240097-2	2018	It has been hypothesized that upregulation of nuclear FoxO transcription factors and p53 mediate isotretinoin-induced sebocyte apoptosis in vivo.	Isotretinoin	97-109	tumor protein p53	Homo sapiens	85-88
30240097-6	2018	Translational and presented experimental evidence indicates that upregulation of nuclear FoxO1 and FoxO3 proteins is involved in isotretinoin-induced pro-apoptotic signalling in sebocytes confirming the scientific hypothesis of isotretinoin-mediated upregulation of FoxO expression.	Isotretinoin	228-240	forkhead box O1	Homo sapiens	89-94
30240097-3	2018	It is the aim of our study to analyse the distribution of the pro-apoptotic transcription factors FoxO1 and FoxO3 in the nuclear and cytoplasmic compartments of human sebocytes in vivo before and during isotretinoin treatment of acne patients.	Isotretinoin	203-215	forkhead box O1	Homo sapiens	98-103
30240097-6	2018	Translational and presented experimental evidence indicates that upregulation of nuclear FoxO1 and FoxO3 proteins is involved in isotretinoin-induced pro-apoptotic signalling in sebocytes confirming the scientific hypothesis of isotretinoin-mediated upregulation of FoxO expression.	Isotretinoin	228-240	forkhead box O3	Homo sapiens	99-104
30144329-7	2018	Isotretinoin enhanced FoxO1, p53 and p21 but inhibited p-FoxO1 and involucrin expression in HPKs.	Isotretinoin	0-12	forkhead box O1	Homo sapiens	22-27
30240097-5	2018	Our in vivo study demonstrates a significant increase in the nucleo-cytoplasmic ratio of non-phosphorylated FoxO1 and FoxO3 during isotretinoin treatment of acne patients.	Isotretinoin	131-143	forkhead box O1	Homo sapiens	108-113
30397984-0	2018	The effect of continuous high versus low dose oral isotretinoin regimens on dermcidin expression in patients with moderate to severe acne vulgaris.	Isotretinoin	51-63	dermcidin	Homo sapiens	76-85
30397984-8	2018	Both isotretinoin regimens significantly raised dermcidin levels compared to pre-treatment values (p &lt; .001).	Isotretinoin	5-17	dermcidin	Homo sapiens	48-57
30144329-7	2018	Isotretinoin enhanced FoxO1, p53 and p21 but inhibited p-FoxO1 and involucrin expression in HPKs.	Isotretinoin	0-12	tumor protein p53	Homo sapiens	29-32
30144329-7	2018	Isotretinoin enhanced FoxO1, p53 and p21 but inhibited p-FoxO1 and involucrin expression in HPKs.	Isotretinoin	0-12	H3 histone pseudogene 16	Homo sapiens	37-40
30144329-7	2018	Isotretinoin enhanced FoxO1, p53 and p21 but inhibited p-FoxO1 and involucrin expression in HPKs.	Isotretinoin	0-12	forkhead box O1	Homo sapiens	57-62
30144329-9	2018	IGF-1 may reduce keratinocyte differentiation through PI3K/Akt/FoxO1 pathway, while isotretinoin can reinforce FoxO1 expression.	Isotretinoin	84-96	forkhead box O1	Homo sapiens	111-116
30677858-5	2018	We report one case of a severe acneiform eruption associated with vemurafenib with a good response to isotretinoin allowing continuation of the BRAF inhibitor.	Isotretinoin	102-114	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	144-148
30210158-0	2018	Comparison of Efficacy of Doxycycline and Isotretinoin on Cutaneous Human Beta-Defensin-1 and -2 Levels in Acne Vulgaris.	Isotretinoin	42-54	defensin beta 1	Homo sapiens	74-96
30210158-7	2018	Doxycycline therapy achieved a decrease in hBD-1 levels (P&lt;0.05), whereas isotretinoin therapy achieved a reduction in hBD-2 levels when compared with pretreatment levels (P&lt;0.05).	Isotretinoin	77-89	defensin beta 4A	Homo sapiens	122-127
30210158-10	2018	Our results showing a significant reduction in hBD-1 staining with doxycycline treatment and in hBD-2 with isotretinoin suggested that some part of their anti-acne effect worked through these mechanisms.	Isotretinoin	107-119	defensin beta 4A	Homo sapiens	96-101
29476041-3	2018	CYP26C1 was found to effectively metabolize all-trans retinoic acid (atRA), 9-cis-retinoic acid (9-cis-RA), 13-cis-retinoic acid, and 4-oxo-atRA with the highest intrinsic clearance toward 9-cis-RA.	Isotretinoin	108-128	cytochrome P450 family 26 subfamily C member 1	Homo sapiens	0-7
29872305-0	2018	Association between leptin gene rs7799039 polymorphism and lipid profile changes induced by isotretinoin treatment in acne patients.	Isotretinoin	92-104	leptin	Homo sapiens	20-26
29872305-4	2018	Thus, genetic polymorphisms in the leptin (LEP) gene may modulate the response to isotretinoin therapy.	Isotretinoin	82-94	leptin	Homo sapiens	35-41
29872305-4	2018	Thus, genetic polymorphisms in the leptin (LEP) gene may modulate the response to isotretinoin therapy.	Isotretinoin	82-94	leptin	Homo sapiens	43-46
29872305-5	2018	Here, we explore the contribution of rs7799039 polymorphism of the LEP gene in the adverse effects of the oral isotretinoin therapy among acne patients.	Isotretinoin	111-123	leptin	Homo sapiens	67-70
28238164-7	2018	CONCLUSION: Isotretinoin may affect the functioning of the RPE and can cause the development of subretinal fluid and serous retinal detachment.	Isotretinoin	12-24	ribulose-5-phosphate-3-epimerase	Homo sapiens	59-62
28833556-2	2018	This hypothesis predicts that isotretinoin (13-cis retinoic acid), the prodrug of all-trans retinoic acid (ATRA), exaggerates neural crest cell (NCC) apoptosis via upregulation of the pro-apoptotic transcription factor p53, the guardian of the genome.	Isotretinoin	30-42	tumor protein p53	Danio rerio	219-222
28833556-2	2018	This hypothesis predicts that isotretinoin (13-cis retinoic acid), the prodrug of all-trans retinoic acid (ATRA), exaggerates neural crest cell (NCC) apoptosis via upregulation of the pro-apoptotic transcription factor p53, the guardian of the genome.	Isotretinoin	44-64	tumor protein p53	Danio rerio	219-222
28833556-5	2018	Translational evidence implies that isotretinoin-stimulated overactivation of p53 during embryogenesis represents the molecular basis of isotretinoin"s teratogenicity.	Isotretinoin	36-48	tumor protein p53	Danio rerio	78-81
28833556-5	2018	Translational evidence implies that isotretinoin-stimulated overactivation of p53 during embryogenesis represents the molecular basis of isotretinoin"s teratogenicity.	Isotretinoin	137-149	tumor protein p53	Danio rerio	78-81
28927457-2	2017	All-trans retinoic acid (ATRA) and isotretinoin (13-cis retinoic acid) enhance p53 expression.	Isotretinoin	35-47	tumor protein p53	Homo sapiens	79-82
28786105-1	2017	BACKGROUND: 13-Cis retinoic acid (13-CRA) is a synthetic vitamin A derivative.	Isotretinoin	12-32	myotubularin related protein 11	Homo sapiens	37-40
29362686-7	2017	Isotretinoin is another example of a retinoid causing microcephaly in human babies via maternal exposure and activation of the retinoid X receptor in developing fetuses.	Isotretinoin	0-12	retinoid X receptor alpha	Homo sapiens	127-146
28746836-4	2017	The retinoic acid receptor alpha (RARalpha)-selective antagonist Ro 41-5253 inhibited the cystine perturbation caused by all-trans-retinoic acid, TTNPB, 13-cis-retinoic acid, 9-cis-retinoic acid, and acitretin.	Isotretinoin	153-173	retinoic acid receptor alpha	Homo sapiens	4-32
28746836-4	2017	The retinoic acid receptor alpha (RARalpha)-selective antagonist Ro 41-5253 inhibited the cystine perturbation caused by all-trans-retinoic acid, TTNPB, 13-cis-retinoic acid, 9-cis-retinoic acid, and acitretin.	Isotretinoin	153-173	retinoic acid receptor alpha	Homo sapiens	34-42
28927457-2	2017	All-trans retinoic acid (ATRA) and isotretinoin (13-cis retinoic acid) enhance p53 expression.	Isotretinoin	49-69	tumor protein p53	Homo sapiens	79-82
28927457-7	2017	p53 induces FoxO1, FoxO3, p21 and sestrin 1, sestrin 2, and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), the key inducer of isotretinoin-mediated sebocyte apoptosis explaining isotretinoin"s sebum-suppressive effect.	Isotretinoin	145-157	tumor protein p53	Homo sapiens	0-3
28927457-7	2017	p53 induces FoxO1, FoxO3, p21 and sestrin 1, sestrin 2, and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), the key inducer of isotretinoin-mediated sebocyte apoptosis explaining isotretinoin"s sebum-suppressive effect.	Isotretinoin	145-157	TNF superfamily member 10	Homo sapiens	60-116
28927457-7	2017	p53 induces FoxO1, FoxO3, p21 and sestrin 1, sestrin 2, and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), the key inducer of isotretinoin-mediated sebocyte apoptosis explaining isotretinoin"s sebum-suppressive effect.	Isotretinoin	145-157	TNF superfamily member 10	Homo sapiens	118-123
28927457-7	2017	p53 induces FoxO1, FoxO3, p21 and sestrin 1, sestrin 2, and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), the key inducer of isotretinoin-mediated sebocyte apoptosis explaining isotretinoin"s sebum-suppressive effect.	Isotretinoin	197-209	tumor protein p53	Homo sapiens	0-3
28927457-7	2017	p53 induces FoxO1, FoxO3, p21 and sestrin 1, sestrin 2, and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), the key inducer of isotretinoin-mediated sebocyte apoptosis explaining isotretinoin"s sebum-suppressive effect.	Isotretinoin	197-209	TNF superfamily member 10	Homo sapiens	60-116
28927457-7	2017	p53 induces FoxO1, FoxO3, p21 and sestrin 1, sestrin 2, and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), the key inducer of isotretinoin-mediated sebocyte apoptosis explaining isotretinoin"s sebum-suppressive effect.	Isotretinoin	197-209	TNF superfamily member 10	Homo sapiens	118-123
28643913-7	2017	However, the alveolar bone of the isotretinoin group revealed more medullary spaces with inflammatory, hematopoietic cells, blood vessels and intense immunolabeling for VEGF-C.	Isotretinoin	34-46	vascular endothelial growth factor C	Rattus norvegicus	169-175
27917684-1	2017	PURPOSE: To evaluate the long-term effect of oral isotretinoin therapy on macula ganglion cell complex (GCC) thickness by spectral domain optical coherence tomography (SD-OCT).	Isotretinoin	50-62	plexin A2	Homo sapiens	171-174
28932071-0	2017	Keratosis Follicularis Spinulosa Decalvans with Associated Mental Retardation: Response to Isotretinoin.	Isotretinoin	91-103	membrane bound transcription factor peptidase, site 2	Homo sapiens	0-42
27292185-9	2017	RESULTS: The changes in the mean AMH, OV and AFC were statistically significant between the sixth and eighteenth months (the end of systemic isotretinoin treatment and 12 months treatment free).	Isotretinoin	141-153	anti-Mullerian hormone	Homo sapiens	33-36
28591443-0	2017	Low-dose isotretinoin prevents digital amputation in loricrin keratoderma (Vohwinkel syndrome with ichthyosis).	Isotretinoin	9-21	loricrin cornified envelope precursor protein	Homo sapiens	53-61
28686773-7	2017	75% report stopping isotretinoin when AST or ALT values reach 3 times normal; 89% report stopping at 4 times normal.	Isotretinoin	20-32	solute carrier family 17 member 5	Homo sapiens	38-41
28659916-4	2017	In each trial, certain KIR/KIR-ligand genotypes were associated with clinical benefit for patients randomized to immunotherapy treatment (immunotherapy in COG; maintenance rituximab in ECOG) as compared to patients that did not receive the immunotherapy [isotretinoin alone (COG); no-maintenance (ECOG)].	Isotretinoin	255-267	killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1	Homo sapiens	23-26
28659916-4	2017	In each trial, certain KIR/KIR-ligand genotypes were associated with clinical benefit for patients randomized to immunotherapy treatment (immunotherapy in COG; maintenance rituximab in ECOG) as compared to patients that did not receive the immunotherapy [isotretinoin alone (COG); no-maintenance (ECOG)].	Isotretinoin	255-267	killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1	Homo sapiens	27-30
27853192-4	2016	Isotretinoin induced IL-10 signaling in Tregs and naive T-cells directly after treatment and reduced effector T-cell proliferation alone and in co-culture with Tregs.	Isotretinoin	0-12	interleukin 10	Mus musculus	21-26
27671426-2	2017	Its effect depends on sebocyte apoptosis, which results from isotretinoin-induced expression of the apoptotic protein tumour necrosis factor-related apoptosis-inducing ligand, insulin-like growth factor-binding protein-3 and neutrophil gelatinase-associated lipocalin.	Isotretinoin	61-73	lipocalin 2	Homo sapiens	225-267
27671426-5	2017	Genetic variants of components of the apoptotic signalling cascade, such as RARA polymorphisms, might explain variations in the magnitude of isotretinoin-induced apoptotic signalling and apparently identify subgroups of patients who experience either stronger adverse effects with isotretinoin therapy or resistance to treatment.	Isotretinoin	141-153	retinoic acid receptor alpha	Homo sapiens	76-80
27671426-5	2017	Genetic variants of components of the apoptotic signalling cascade, such as RARA polymorphisms, might explain variations in the magnitude of isotretinoin-induced apoptotic signalling and apparently identify subgroups of patients who experience either stronger adverse effects with isotretinoin therapy or resistance to treatment.	Isotretinoin	281-293	retinoic acid receptor alpha	Homo sapiens	76-80
28145501-4	2017	We have found that 13-cis-retinoic acid, retinol and retinyl-acetate inhibited the Pgp and ABCG2 mediated substrate transport as well as the substrate stimulated ATPase activity of these transporters.	Isotretinoin	19-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	91-96
28145501-7	2017	Thus, the mixed-type inhibition of both transporters by retinol and ABCG2 by 13-cis-retinoic acid may be the collective result of direct interactions of these retinoids with the substrate binding site(s) and of indirect interactions mediated by their membrane rigidifying effects.	Isotretinoin	77-97	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	68-73
29190629-0	2017	Suppressed Adiponectin Levels and Increased Adiponectin Response to Oral Glucose Load in Lean Women with Severe Acne Normalizes after Isotretinoin Treatment.	Isotretinoin	134-146	adiponectin, C1Q and collagen domain containing	Homo sapiens	44-55
29190629-3	2017	In this study, we aimed to investigate adiponectin levels in postadolescent severe acne and the effect of isotretinoin on adiponectin levels.	Isotretinoin	106-118	adiponectin, C1Q and collagen domain containing	Homo sapiens	122-133
29190629-8	2017	Isotretinoin treatment resulted in a significant increase in weight, BMI, and triglyceride and adiponectin levels.	Isotretinoin	0-12	adiponectin, C1Q and collagen domain containing	Homo sapiens	95-106
29190629-11	2017	Remarkably, this OGTT-induced adiponectin increment in acne patients was diminished after isotretinoin treatment.	Isotretinoin	90-102	adiponectin, C1Q and collagen domain containing	Homo sapiens	30-41
29190629-13	2017	Suppression of baseline adiponectin ameliorates after 6 months of isotretinoin treatment, reaching levels similar to those of healthy controls.	Isotretinoin	66-78	adiponectin, C1Q and collagen domain containing	Homo sapiens	24-35
29258098-0	2017	The Magnitude of mTORC1 Signalling May Predict the Response to Isotretinoin Treatment in Patients with Hidradenitis Suppurativa.	Isotretinoin	63-75	CREB regulated transcription coactivator 1	Mus musculus	17-23
28145501-4	2017	We have found that 13-cis-retinoic acid, retinol and retinyl-acetate inhibited the Pgp and ABCG2 mediated substrate transport as well as the substrate stimulated ATPase activity of these transporters.	Isotretinoin	19-39	ATP binding cassette subfamily B member 1	Homo sapiens	83-86
26886237-11	2017	Because 9cRA and 13-cis-retinoic acid, which is retinoic acid receptor-selective, prevent prostate carcinogenesis in rats, and 13-cis-retinoic acid also inhibits growth of human prostate cancer cells, the RAR is a potential molecular target for prostate cancer prevention and therapy.	Isotretinoin	17-37	retinoic acid receptor alpha	Homo sapiens	205-208
26886237-11	2017	Because 9cRA and 13-cis-retinoic acid, which is retinoic acid receptor-selective, prevent prostate carcinogenesis in rats, and 13-cis-retinoic acid also inhibits growth of human prostate cancer cells, the RAR is a potential molecular target for prostate cancer prevention and therapy.	Isotretinoin	127-147	retinoic acid receptor alpha	Homo sapiens	205-208
27071079-1	2017	BACKGROUND: The study aims to determine the detrimental effects of 7.5 mg/kg/day isotretinoin treatment on the anti-Mullerian hormone (AMH) levels in an experimental study to see whether the effects on ovarian reserve are reversible.	Isotretinoin	81-93	anti-Mullerian hormone	Rattus norvegicus	135-138
27071079-7	2017	The mean AMH levels significantly decreased (p = 0.02) immediately after isotretinoin administration.	Isotretinoin	73-85	anti-Mullerian hormone	Rattus norvegicus	9-12
27071079-8	2017	The mean AMH levels 1 month after the last dose of isotretinoin therapy were higher than the levels immediately after the medication; however, the difference was not statistically significant.	Isotretinoin	51-63	anti-Mullerian hormone	Rattus norvegicus	9-12
27071079-9	2017	CONCLUSION: This study indicates that exposure to isotretinoin is responsible for decreased AMH levels in experimental rat model and this effect seems to be reversible.	Isotretinoin	50-62	anti-Mullerian hormone	Rattus norvegicus	92-95
29429508-3	2016	In addition, the treatment of cyclin-resistant papulopustular rosacea was also the subject of a large French controlled randomized controlled trial that could modify our therapeutic approach by the use of isotretinoin.	Isotretinoin	205-217	proliferating cell nuclear antigen	Homo sapiens	30-36
27324482-4	2016	Here we demonstrate that the essential type IVb effector, CirA, stimulates GTPase activity of RhoA.	Isotretinoin	58-62	ras homolog family member A	Homo sapiens	94-98
27719722-15	2016	(5) Comparing with negative control group, IFNalpha-2b combined with each dose of 13cRA significantly decreased the levels of cycling D1 and procaspase-9, while increased the level of cleaved caspase-9 (P&lt;0.05), which were similar to the positive control group (P&gt;0.05).	Isotretinoin	82-87	deiodinase, iodothyronine, type I	Mus musculus	134-153
27719722-15	2016	(5) Comparing with negative control group, IFNalpha-2b combined with each dose of 13cRA significantly decreased the levels of cycling D1 and procaspase-9, while increased the level of cleaved caspase-9 (P&lt;0.05), which were similar to the positive control group (P&gt;0.05).	Isotretinoin	82-87	caspase 9	Mus musculus	144-153
27324482-5	2016	Overexpression of CirA in mammalian cells results in cell rounding and stress fiber disruption, a phenotype that is rescued by overexpression of wild-type or constitutively active RhoA.	Isotretinoin	18-22	ras homolog family member A	Homo sapiens	180-184
26287661-11	2015	Notably, TA+RA combination also caused down regulation of AKT and ERK1/2 suggesting a distinct impact on survival and proliferation pathways via signaling cascades.	Isotretinoin	12-14	AKT serine/threonine kinase 1	Homo sapiens	58-61
27605902-7	2016	In addition, serum adiponectin and leptin levels were significantly increased following isotretinoin therapy while serum ghrelin levels were not different.	Isotretinoin	88-100	adiponectin, C1Q and collagen domain containing	Homo sapiens	19-30
27605902-7	2016	In addition, serum adiponectin and leptin levels were significantly increased following isotretinoin therapy while serum ghrelin levels were not different.	Isotretinoin	88-100	leptin	Homo sapiens	35-41
27605902-8	2016	CONCLUSIONS: Isotretinoin may exert its anti-inflammatory activity by increasing leptin and adiponectin levels.	Isotretinoin	13-25	leptin	Homo sapiens	81-87
27605902-8	2016	CONCLUSIONS: Isotretinoin may exert its anti-inflammatory activity by increasing leptin and adiponectin levels.	Isotretinoin	13-25	adiponectin, C1Q and collagen domain containing	Homo sapiens	92-103
27130733-4	2016	We also show marked synergy in tumor cell killing between MEK inhibitors (trametinib) and retinoids (isotretinoin) in primary nf1a-/- zebrafish neuroblastomas.	Isotretinoin	101-113	neurofibromin 1a	Danio rerio	126-130
27895437-9	2016	CONCLUSION: Isotretinoin treatment for four months significantly increased CIMT in acne patients.	Isotretinoin	12-24	CIMT	Homo sapiens	75-79
26985947-5	2016	After treatment with isotretinoin, acitretin, or adapalene at 0.010 mg/mL for 12 h, the expression of AQP3 was the highest in the isotretinoin group, followed by the acitretin group, with the lowest expression in the adapalene group.	Isotretinoin	21-33	aquaporin 3 (Gill blood group)	Homo sapiens	102-106
26985947-5	2016	After treatment with isotretinoin, acitretin, or adapalene at 0.010 mg/mL for 12 h, the expression of AQP3 was the highest in the isotretinoin group, followed by the acitretin group, with the lowest expression in the adapalene group.	Isotretinoin	130-142	aquaporin 3 (Gill blood group)	Homo sapiens	102-106
26985947-7	2016	Retinoic acid can increase AQP3 expression in HaCaT cells, with significant effects observed with 0.010 mg/mL isotretinoin treatment for 12 h. The side effects, namely skin and mucosa dryness caused by retinoic acid might be related to its effects on AQP3 expression.	Isotretinoin	110-122	aquaporin 3 (Gill blood group)	Homo sapiens	27-31
26985947-7	2016	Retinoic acid can increase AQP3 expression in HaCaT cells, with significant effects observed with 0.010 mg/mL isotretinoin treatment for 12 h. The side effects, namely skin and mucosa dryness caused by retinoic acid might be related to its effects on AQP3 expression.	Isotretinoin	110-122	aquaporin 3 (Gill blood group)	Homo sapiens	251-255
26287661-11	2015	Notably, TA+RA combination also caused down regulation of AKT and ERK1/2 suggesting a distinct impact on survival and proliferation pathways via signaling cascades.	Isotretinoin	12-14	mitogen-activated protein kinase 3	Homo sapiens	66-72
26245651-8	2015	Furthermore, both NGP and SK-N-DZ cells showed CHD5 upregulation and neuronal differentiation after 13cRA treatment.	Isotretinoin	100-105	chromodomain helicase DNA binding protein 5	Homo sapiens	47-51
26096596-4	2015	Here we show that all-trans and 13-cis retinoic acid appear to function through the heterodimer partners of TRs, retinoid-X receptors (RXRs), as RXR antagonists abrogated retinoid-induced activation.	Isotretinoin	35-52	retinoid X receptor alpha	Homo sapiens	135-138
26245651-9	2015	In contrast, 13cRA treatment of IMR5, LAN5, or SK-N-FI induced neither CHD5 expression nor neuronal differentiation.	Isotretinoin	13-18	chromodomain helicase DNA binding protein 5	Homo sapiens	71-75
26245651-13	2015	CONCLUSIONS: Treatment with 13cRA induces neuronal differentiation only in NB cells that upregulate CHD5.	Isotretinoin	28-33	chromodomain helicase DNA binding protein 5	Homo sapiens	100-104
25573071-1	2015	BACKGROUND: The effect of isotretinoin (ISO) on adipokines and insulin resistance has been investigated in a few studies, and the results are conflicting.	Isotretinoin	26-38	insulin	Homo sapiens	63-70
25410880-8	2015	The mixed cells showed a significant increase in the CYP3A4 and ABCB1 reporter activities following treatment with 1,25(OH)2 D3, ATRA, and 9-cis RA.	Isotretinoin	141-147	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	53-59
25410880-8	2015	The mixed cells showed a significant increase in the CYP3A4 and ABCB1 reporter activities following treatment with 1,25(OH)2 D3, ATRA, and 9-cis RA.	Isotretinoin	141-147	ATP binding cassette subfamily B member 1	Homo sapiens	64-69
25573071-8	2015	CONCLUSION: ISO may affect leptin and adiponectin levels.	Isotretinoin	12-15	leptin	Homo sapiens	27-33
24697846-0	2015	Oral isotretinoin therapy of acne patients decreases serum paraoxonase-1 activity through increasing oxidative stress.	Isotretinoin	5-17	paraoxonase 1	Homo sapiens	59-72
25573071-8	2015	CONCLUSION: ISO may affect leptin and adiponectin levels.	Isotretinoin	12-15	adiponectin, C1Q and collagen domain containing	Homo sapiens	38-49
24697846-7	2015	CONCLUSION: This study revealed that decreased PON1 activity and increased oxidative stress may have a crucial role in the pathogenesis of isotretinoin"s side effects.	Isotretinoin	139-151	paraoxonase 1	Homo sapiens	47-51
24947929-0	2014	PBX1 is a favorable prognostic biomarker as it modulates 13-cis retinoic acid-mediated differentiation in neuroblastoma.	Isotretinoin	57-77	PBX homeobox 1	Homo sapiens	0-4
25039756-1	2014	BACKGROUND AND PURPOSE: Isotretinoin (13-cis-retinoic acid; 13-cRA) is a differentiation inducer used to treat minimal residual disease after myeloablative therapy for high-risk neuroblastoma.	Isotretinoin	24-36	myotubularin related protein 11	Homo sapiens	63-66
25039756-1	2014	BACKGROUND AND PURPOSE: Isotretinoin (13-cis-retinoic acid; 13-cRA) is a differentiation inducer used to treat minimal residual disease after myeloablative therapy for high-risk neuroblastoma.	Isotretinoin	38-58	myotubularin related protein 11	Homo sapiens	63-66
25039756-12	2014	Plasma levels of both 13-cRA and 4-oxo-13-cRA should be evaluated in pharmacokinetic studies of isotretinoin in neuroblastoma.	Isotretinoin	96-108	myotubularin related protein 11	Homo sapiens	42-45
25304678-3	2014	The objective of this multi-institutional phase 2 trial was to evaluate the efficacy and toxicity of paclitaxel and bcl-2 modulators (13-cis retinoic acid and interferon alfa-2b) in patients with advanced-stage or recurrent cervical cancer.	Isotretinoin	134-154	BCL2 apoptosis regulator	Homo sapiens	116-121
24916439-4	2014	While relative expression levels of cathelicidin, HBD-2, lactoferrin, psoriasin (S100A7), and koebnerisin (S100A15) decreased during isotretinoin treatment, only those of cathelicidin and koebnerisin returned to normal after 6 months of isotretinoin therapy.	Isotretinoin	133-145	defensin beta 4A	Homo sapiens	50-55
24916439-4	2014	While relative expression levels of cathelicidin, HBD-2, lactoferrin, psoriasin (S100A7), and koebnerisin (S100A15) decreased during isotretinoin treatment, only those of cathelicidin and koebnerisin returned to normal after 6 months of isotretinoin therapy.	Isotretinoin	133-145	S100 calcium binding protein A7	Homo sapiens	81-87
24916439-4	2014	While relative expression levels of cathelicidin, HBD-2, lactoferrin, psoriasin (S100A7), and koebnerisin (S100A15) decreased during isotretinoin treatment, only those of cathelicidin and koebnerisin returned to normal after 6 months of isotretinoin therapy.	Isotretinoin	133-145	S100 calcium binding protein A7A	Homo sapiens	107-114
25660129-7	2015	CONCLUSION: Our study is the first to analyze the levels of serum AMH, AFC, and OV together in patients treated with oral isotretinoin for acne.	Isotretinoin	122-134	anti-Mullerian hormone	Homo sapiens	66-69
24720725-0	2014	Avascular necrosis of the hip and diffuse idiopathic skeletal hyperostosis during long-term isotretinoin treatment of epidermolytic ichthyosis due to a novel deletion mutation in KRT10.	Isotretinoin	92-104	keratin 10	Homo sapiens	179-184
24966012-9	2014	Iso caused significant increases in serum levels of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, cholesterol, triglycerides, and high-density lipids content.	Isotretinoin	0-3	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	78-104
24852785-8	2014	TNFB can succeed when isotretinoin fails, either as monotherapy, or as a bridge to aggressive surgical treatment, but long term data is lacking.	Isotretinoin	22-34	lymphotoxin alpha	Homo sapiens	0-4
25079382-14	2014	Nevertheless, when primary monocytes were in vitro differentiated into macrophages and treated with 13-cis-retinoic acid, we observed a fourfold induction of ABCD2.	Isotretinoin	100-120	ATP binding cassette subfamily D member 2	Homo sapiens	158-163
24858462-0	2014	Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501).	Isotretinoin	22-42	BCL2 apoptosis regulator	Homo sapiens	57-62
24858462-3	2014	We conducted a phase II study to evaluate if modulation of Bcl-2 with 13-cis-retinoic acid (13-CRA) and interferon alpha could improve response rates when combined with paclitaxel in patients with recurrent SCLC.	Isotretinoin	70-90	BCL2 apoptosis regulator	Homo sapiens	59-64
24858462-3	2014	We conducted a phase II study to evaluate if modulation of Bcl-2 with 13-cis-retinoic acid (13-CRA) and interferon alpha could improve response rates when combined with paclitaxel in patients with recurrent SCLC.	Isotretinoin	70-90	myotubularin related protein 11	Homo sapiens	95-98
25079382-11	2014	In THP-1 cells, 13-cis-retinoic acid reached the highest, fivefold, increase in ABCD2 expression.	Isotretinoin	16-36	ATP binding cassette subfamily D member 2	Homo sapiens	80-85
25008440-2	2014	OBJECTIVE: This study was performed to detect possible toxic effects of oral isotretinoin treatment on the retinal nerve fiber layer (RNFL) and ganglion cell layer (GCL).	Isotretinoin	77-89	germ cell-less 2, spermatogenesis associated	Homo sapiens	165-168
23338233-1	2013	To evaluate the effect of oral isotretinoin therapy on retinal nerve fiber layer (RNFL) and ganglion cell layer (GCL) thickness by spectral domain optical coherence tomography (OCT).	Isotretinoin	31-43	germ cell-less 2, spermatogenesis associated	Homo sapiens	113-116
24683393-10	2014	CONCLUSIONS: Measurements of IL-1alpha, IL-1beta and TNF-alpha sera concentrations could be assessed in parallel to the improvement of the clinical condition and can constitute a good indication of the efficiency of the isotretinoin treatment.	Isotretinoin	220-232	interleukin 1 alpha	Homo sapiens	29-38
24683393-10	2014	CONCLUSIONS: Measurements of IL-1alpha, IL-1beta and TNF-alpha sera concentrations could be assessed in parallel to the improvement of the clinical condition and can constitute a good indication of the efficiency of the isotretinoin treatment.	Isotretinoin	220-232	interleukin 1 beta	Homo sapiens	40-48
24683393-10	2014	CONCLUSIONS: Measurements of IL-1alpha, IL-1beta and TNF-alpha sera concentrations could be assessed in parallel to the improvement of the clinical condition and can constitute a good indication of the efficiency of the isotretinoin treatment.	Isotretinoin	220-232	tumor necrosis factor	Homo sapiens	53-62
24599963-6	2014	Here, we report that retinoic acid (RA) isomers, including all-trans-RA, 9-cis-RA, and 13-cis-RA, significantly increase apoE secretion to ~4-fold of control through retinoid X receptor (RXR) and RA receptor.	Isotretinoin	87-96	apolipoprotein E	Mus musculus	121-125
24256373-10	2014	Decrease in AMH levels following exposure to isotretinoin may suggest that it has a detrimental effect on the ovaries.	Isotretinoin	45-57	anti-Mullerian hormone	Homo sapiens	12-15
24034378-0	2013	Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions.	Isotretinoin	0-12	epidermal growth factor receptor	Homo sapiens	42-74
23610147-11	2013	De novo synthesis of BAFF-R and up-regulation of BCMA were observed in NB cell lines upon treatment with IFN-gamma or 13-cis retinoic acid.	Isotretinoin	118-138	TNF receptor superfamily member 13C	Homo sapiens	21-27
22188511-2	2013	The aim of this study is to determine the changes in prothrombin time (PT), international normalized ratio (INR), and activated partial thromboplastin time (aPTT) during isotretinoin treatment.	Isotretinoin	170-182	coagulation factor II, thrombin	Homo sapiens	53-64
23782583-0	2013	The effect of genetic polymorphisms of RARA gene on the adverse effects profile of isotretinoin-treated acne patients.	Isotretinoin	83-95	retinoic acid receptor alpha	Homo sapiens	39-43
23782583-3	2013	In this study, we examined the association between rs9303285, rs2715554 and rs4890109 genetic polymorphisms in the retinoic acid receptor alpha (RARA), one of the main targets of isotretinoin, and the adverse effects of oral isotretinoin therapy.	Isotretinoin	179-191	retinoic acid receptor alpha	Homo sapiens	115-143
23782583-3	2013	In this study, we examined the association between rs9303285, rs2715554 and rs4890109 genetic polymorphisms in the retinoic acid receptor alpha (RARA), one of the main targets of isotretinoin, and the adverse effects of oral isotretinoin therapy.	Isotretinoin	179-191	retinoic acid receptor alpha	Homo sapiens	145-149
23782583-11	2013	CONCLUSIONS: Our findings suggest an association between polymorphisms of RARA gene and some of some common adverse effects of oral isotretinoin.	Isotretinoin	132-144	retinoic acid receptor alpha	Homo sapiens	74-78
23768617-7	2013	The serum AMH concentrations were found to be lower in both isotretinoin groups.	Isotretinoin	60-72	anti-Mullerian hormone	Rattus norvegicus	10-13
23768617-9	2013	The number of PCNA-positive granulosa cells was decreased in the isotretinoin groups.	Isotretinoin	65-77	proliferating cell nuclear antigen	Rattus norvegicus	14-18
23610147-11	2013	De novo synthesis of BAFF-R and up-regulation of BCMA were observed in NB cell lines upon treatment with IFN-gamma or 13-cis retinoic acid.	Isotretinoin	118-138	TNF receptor superfamily member 17	Homo sapiens	49-53
22714752-2	2012	OBJECTIVE: The objective of this study was to evaluate the profile of changes in alanine aminotransferase (ALT), aspartate aminotransferase (AST) and triglyceride levels in patients who had been treated with oral isotretinoin dispensed by the Sao Mateus/ES pharmacy for special drugs.	Isotretinoin	213-225	glutamic--pyruvic transaminase	Homo sapiens	81-105
23096714-7	2013	In prespecified secondary analyses, isotretinoin was associated with IBD among individuals aged 12-19 years (RR 1.39; 95% CI 1.03-1.87) and topical acne medications were associated with ulcerative colitis (RR 1.19; 95% CI 1.00-1.42).	Isotretinoin	36-48	ribonucleotide reductase catalytic subunit M1	Homo sapiens	109-113
23096714-7	2013	In prespecified secondary analyses, isotretinoin was associated with IBD among individuals aged 12-19 years (RR 1.39; 95% CI 1.03-1.87) and topical acne medications were associated with ulcerative colitis (RR 1.19; 95% CI 1.00-1.42).	Isotretinoin	36-48	ribonucleotide reductase catalytic subunit M1	Homo sapiens	206-210
23335538-0	2012	In vitro increased natural killer cell activity of metastatic melanoma patients with interferon-alpha alone as opposed to its combination with 13-cis retinoic acid is associated with modulation of NKG2D and CD161 activating receptor expression.	Isotretinoin	143-163	killer cell lectin like receptor K1	Homo sapiens	197-202
23335538-0	2012	In vitro increased natural killer cell activity of metastatic melanoma patients with interferon-alpha alone as opposed to its combination with 13-cis retinoic acid is associated with modulation of NKG2D and CD161 activating receptor expression.	Isotretinoin	143-163	killer cell lectin like receptor B1	Homo sapiens	207-212
22435970-7	2012	TNF-alpha and IL-4 values after isotretinoin treatment were similar to those of the control group.	Isotretinoin	32-44	tumor necrosis factor	Homo sapiens	0-9
22435970-7	2012	TNF-alpha and IL-4 values after isotretinoin treatment were similar to those of the control group.	Isotretinoin	32-44	interleukin 4	Homo sapiens	14-18
22435970-8	2012	However, levels of IL-17 (P&lt;0.0001) after isotretinoin treatment were higher than those of the control group, despite a significant decline after treatment.	Isotretinoin	45-57	interleukin 17A	Homo sapiens	19-24
22435970-9	2012	Levels of IFN-gamma (P&lt;0.0001) after isotretinoin treatment were lower than those of the control group.	Isotretinoin	40-52	interferon gamma	Homo sapiens	10-19
22435970-10	2012	CONCLUSIONS: This study shows that isotretinoin treatment significantly decreases TNF, IL-4, IL-17 and IFN-gamma levels in patients with acne.	Isotretinoin	35-47	tumor necrosis factor	Homo sapiens	82-85
22435970-10	2012	CONCLUSIONS: This study shows that isotretinoin treatment significantly decreases TNF, IL-4, IL-17 and IFN-gamma levels in patients with acne.	Isotretinoin	35-47	interleukin 4	Homo sapiens	87-91
22435970-10	2012	CONCLUSIONS: This study shows that isotretinoin treatment significantly decreases TNF, IL-4, IL-17 and IFN-gamma levels in patients with acne.	Isotretinoin	35-47	interleukin 17A	Homo sapiens	93-98
22435970-10	2012	CONCLUSIONS: This study shows that isotretinoin treatment significantly decreases TNF, IL-4, IL-17 and IFN-gamma levels in patients with acne.	Isotretinoin	35-47	interferon gamma	Homo sapiens	103-112
22988651-0	2012	Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.	Isotretinoin	96-108	epidermal growth factor receptor	Homo sapiens	31-63
22988651-3	2012	We report 3 cases of severe acneiform eruptions induced by EGFR inhibitors that were successfully treated with oral isotretinoin.	Isotretinoin	116-128	epidermal growth factor receptor	Homo sapiens	59-63
22988651-5	2012	We recommend oral isotretinoin for the management of acneiform reactions to EGFR inhibitors when the lesions persist or worsen despite antibiotic treatment.	Isotretinoin	18-30	epidermal growth factor receptor	Homo sapiens	76-80
23475749-0	2013	Interplay between EGR1 and SP1 is critical for 13-cis retinoic acid-mediated transcriptional repression of angiotensin type 1A receptor.	Isotretinoin	47-67	early growth response 1	Rattus norvegicus	18-22
23475749-1	2013	Recently, we have demonstrated that 13-cis retinoic acid (13cRA) downregulates rat angiotensin type 1A receptor (Agtr1a) gene transcription through a MAP kinase (ERK1/2)-dependent mechanism in rat liver epithelial and aortic smooth muscle cells.	Isotretinoin	36-56	angiotensin II receptor, type 1a	Rattus norvegicus	113-119
23475749-1	2013	Recently, we have demonstrated that 13-cis retinoic acid (13cRA) downregulates rat angiotensin type 1A receptor (Agtr1a) gene transcription through a MAP kinase (ERK1/2)-dependent mechanism in rat liver epithelial and aortic smooth muscle cells.	Isotretinoin	36-56	mitogen activated protein kinase 3	Rattus norvegicus	162-168
23475749-1	2013	Recently, we have demonstrated that 13-cis retinoic acid (13cRA) downregulates rat angiotensin type 1A receptor (Agtr1a) gene transcription through a MAP kinase (ERK1/2)-dependent mechanism in rat liver epithelial and aortic smooth muscle cells.	Isotretinoin	58-63	angiotensin II receptor, type 1a	Rattus norvegicus	113-119
23475749-1	2013	Recently, we have demonstrated that 13-cis retinoic acid (13cRA) downregulates rat angiotensin type 1A receptor (Agtr1a) gene transcription through a MAP kinase (ERK1/2)-dependent mechanism in rat liver epithelial and aortic smooth muscle cells.	Isotretinoin	58-63	mitogen activated protein kinase 3	Rattus norvegicus	162-168
23475749-3	2013	In this study, we determined the signaling intermediates activated by ERK1/2 involved in 13cRA-mediated Agtr1a downregulation.	Isotretinoin	89-94	mitogen activated protein kinase 3	Rattus norvegicus	70-76
23475749-3	2013	In this study, we determined the signaling intermediates activated by ERK1/2 involved in 13cRA-mediated Agtr1a downregulation.	Isotretinoin	89-94	angiotensin II receptor, type 1a	Rattus norvegicus	104-110
23475749-7	2013	Studies showed that 13cRA treatment maximally phosphorylates ERK1/2 within 5-10 min, which translocates to the nucleus, activating early growth response protein 1 (Egr1) mRNA expression at 20 min followed by de novo protein synthesis, leading to an EGR1/SP1 interaction.	Isotretinoin	20-25	mitogen activated protein kinase 3	Rattus norvegicus	61-67
23475749-7	2013	Studies showed that 13cRA treatment maximally phosphorylates ERK1/2 within 5-10 min, which translocates to the nucleus, activating early growth response protein 1 (Egr1) mRNA expression at 20 min followed by de novo protein synthesis, leading to an EGR1/SP1 interaction.	Isotretinoin	20-25	early growth response 1	Rattus norvegicus	131-162
23475749-7	2013	Studies showed that 13cRA treatment maximally phosphorylates ERK1/2 within 5-10 min, which translocates to the nucleus, activating early growth response protein 1 (Egr1) mRNA expression at 20 min followed by de novo protein synthesis, leading to an EGR1/SP1 interaction.	Isotretinoin	20-25	early growth response 1	Rattus norvegicus	164-168
23475749-7	2013	Studies showed that 13cRA treatment maximally phosphorylates ERK1/2 within 5-10 min, which translocates to the nucleus, activating early growth response protein 1 (Egr1) mRNA expression at 20 min followed by de novo protein synthesis, leading to an EGR1/SP1 interaction.	Isotretinoin	20-25	early growth response 1	Rattus norvegicus	249-253
23475749-8	2013	siRNA silencing of Egr1 restored Agtr1a mRNA and protein expression in 13cRA-treated cells, and Sp1 silencing results in complete loss of Agtr1a expression.	Isotretinoin	71-76	early growth response 1	Rattus norvegicus	19-23
23475749-8	2013	siRNA silencing of Egr1 restored Agtr1a mRNA and protein expression in 13cRA-treated cells, and Sp1 silencing results in complete loss of Agtr1a expression.	Isotretinoin	71-76	angiotensin II receptor, type 1a	Rattus norvegicus	33-39
22513780-0	2012	Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients.	Isotretinoin	9-21	toll like receptor 2	Homo sapiens	53-58
22513780-5	2012	Treatment of patients with isotretinoin significantly decreased monocyte TLR-2 expression and subsequent inflammatory cytokine response to P. acnes after 1 week of therapy.	Isotretinoin	27-39	toll like receptor 2	Homo sapiens	73-78
22513780-6	2012	This effect was sustained 6 months following cessation of therapy, indicating that TLR-2 modulation may be involved in the durable therapeutic response to isotretinoin.	Isotretinoin	155-167	toll like receptor 2	Homo sapiens	83-88
22577058-2	2012	The 13-cis-Retinoic acid (13-cRA) has been tested as a chemoprevention agent in clinical trials with mixed results.	Isotretinoin	4-24	myotubularin related protein 11	Homo sapiens	29-32
22714752-2	2012	OBJECTIVE: The objective of this study was to evaluate the profile of changes in alanine aminotransferase (ALT), aspartate aminotransferase (AST) and triglyceride levels in patients who had been treated with oral isotretinoin dispensed by the Sao Mateus/ES pharmacy for special drugs.	Isotretinoin	213-225	solute carrier family 17 member 5	Homo sapiens	113-139
22714752-8	2012	After treatment with oral isotretinoin, triglyceride levels had increased beyond the normal range in 11% of the patients, while 8.6% had elevated AST levels and 7.3% had increased ALT levels.	Isotretinoin	26-38	solute carrier family 17 member 5	Homo sapiens	146-149
22714752-9	2012	CONCLUSION: The results in this population show that the use of oral isotretinoin for the treatment of acne may result in altered triglyceride, AST and ALT levels.	Isotretinoin	69-81	solute carrier family 17 member 5	Homo sapiens	144-147
21628419-5	2011	13-cis-RA and 9-cis-RA also significantly increased mRNA levels of Abca1 (maximal induction 7.3 +- 0.42 and 2.7 +- 0.17, respectively) and Abcg1 (maximal induction 2.0 +- 0.18 and 1.8 +- 0.09, respectively), and the levels of membrane-bound Abca1 (2.5 +- 0.3 and 2.5 +- 0.40-fold increase, respectively), whereas they significantly decreased intracellular cholesterol content without affecting cholesterol synthesis.	Isotretinoin	0-9	ATP binding cassette subfamily A member 1	Rattus norvegicus	67-72
22510008-1	2012	PURPOSE: Evaluation of changes in anterior chamber parameters with the Pentacam rotating Scheimpflug and axial length measurements (Alx) by ultrasound in patients who use isotretinoin for the treatment of acne vulgaris.	Isotretinoin	171-183	hematopoietic SH2 domain containing	Homo sapiens	132-135
22180636-4	2012	Therefore, we hypothesized that 13-cis-retinoic acid (13cRA), an antioxidant, enhances insulin-sensitive glucose-mediated down-regulation of the AT1.	Isotretinoin	32-52	angiotensin II receptor, type 1a	Rattus norvegicus	145-148
22180636-4	2012	Therefore, we hypothesized that 13-cis-retinoic acid (13cRA), an antioxidant, enhances insulin-sensitive glucose-mediated down-regulation of the AT1.	Isotretinoin	54-59	angiotensin II receptor, type 1a	Rattus norvegicus	145-148
22180636-9	2012	Treatment with 13cRA resulted in phosphorylation of p42/p44 MAP kinases in these cells.	Isotretinoin	15-20	mitogen activated protein kinase 3	Rattus norvegicus	56-59
22180636-11	2012	Furthermore, 13cRA-mediated inhibitory effects on AT1 were validated in primary rat aortic smooth muscle cells.	Isotretinoin	13-18	angiotensin II receptor, type 1a	Rattus norvegicus	50-53
22180636-12	2012	In summary, our results demonstrate for the first time that 13cRA has a glucose- and RAR/RXR-independent mechanism for transcriptional inhibition of AT1, suggesting its therapeutic potential in systems in which AT1 expression is deregulated in insulin-sensitive and -insensitive tissues.	Isotretinoin	60-65	angiotensin II receptor, type 1a	Rattus norvegicus	149-152
22180636-12	2012	In summary, our results demonstrate for the first time that 13cRA has a glucose- and RAR/RXR-independent mechanism for transcriptional inhibition of AT1, suggesting its therapeutic potential in systems in which AT1 expression is deregulated in insulin-sensitive and -insensitive tissues.	Isotretinoin	60-65	angiotensin II receptor, type 1a	Rattus norvegicus	211-214
21992189-5	2012	Oral treatment with 13cis retinoic acid (13cRA) was found to selectively ameliorate the dysregulation of the Hh and canonical Wnt pathways associated with CAD, and lead to a general preservation of cilial structures.	Isotretinoin	20-39	Wnt family member 2	Rattus norvegicus	126-129
21992189-5	2012	Oral treatment with 13cis retinoic acid (13cRA) was found to selectively ameliorate the dysregulation of the Hh and canonical Wnt pathways associated with CAD, and lead to a general preservation of cilial structures.	Isotretinoin	41-46	Wnt family member 2	Rattus norvegicus	126-129
21564055-0	2011	TRAIL contributes to the apoptotic effect of 13-cis retinoic acid in human sebaceous gland cells.	Isotretinoin	45-65	TNF superfamily member 10	Homo sapiens	0-5
21564055-2	2011	13-cis RA induces key genes in sebocytes that are involved in apoptosis, including Tumor necrosis factor Related Apoptosis Inducing Ligand (TRAIL).	Isotretinoin	2-9	TNF superfamily member 10	Homo sapiens	83-138
21564055-2	2011	13-cis RA induces key genes in sebocytes that are involved in apoptosis, including Tumor necrosis factor Related Apoptosis Inducing Ligand (TRAIL).	Isotretinoin	2-9	TNF superfamily member 10	Homo sapiens	140-145
21564055-7	2011	Furthermore, TRAIL expression increased in the skin of patients with acne after 1 week of isotretinoin therapy compared with baseline.	Isotretinoin	90-102	TNF superfamily member 10	Homo sapiens	13-18
22870349-8	2012	Future research should investigate the effects of isotretinoin on sebocyte mTORC1 activity.	Isotretinoin	50-62	CREB regulated transcription coactivator 1	Mus musculus	75-81
22870349-9	2012	It is conceivable that isotretinoin may downregulate mTORC1 in sebocytes by upregulation of nuclear levels of FoxO1.	Isotretinoin	23-35	CREB regulated transcription coactivator 1	Mus musculus	53-59
22870349-9	2012	It is conceivable that isotretinoin may downregulate mTORC1 in sebocytes by upregulation of nuclear levels of FoxO1.	Isotretinoin	23-35	forkhead box O1	Homo sapiens	110-115
21628419-5	2011	13-cis-RA and 9-cis-RA also significantly increased mRNA levels of Abca1 (maximal induction 7.3 +- 0.42 and 2.7 +- 0.17, respectively) and Abcg1 (maximal induction 2.0 +- 0.18 and 1.8 +- 0.09, respectively), and the levels of membrane-bound Abca1 (2.5 +- 0.3 and 2.5 +- 0.40-fold increase, respectively), whereas they significantly decreased intracellular cholesterol content without affecting cholesterol synthesis.	Isotretinoin	0-9	ATP binding cassette subfamily G member 1	Rattus norvegicus	139-144
21628419-5	2011	13-cis-RA and 9-cis-RA also significantly increased mRNA levels of Abca1 (maximal induction 7.3 +- 0.42 and 2.7 +- 0.17, respectively) and Abcg1 (maximal induction 2.0 +- 0.18 and 1.8 +- 0.09, respectively), and the levels of membrane-bound Abca1 (2.5 +- 0.3 and 2.5 +- 0.40-fold increase, respectively), whereas they significantly decreased intracellular cholesterol content without affecting cholesterol synthesis.	Isotretinoin	0-9	ATP binding cassette subfamily A member 1	Rattus norvegicus	241-246
21628419-5	2011	13-cis-RA and 9-cis-RA also significantly increased mRNA levels of Abca1 (maximal induction 7.3 +- 0.42 and 2.7 +- 0.17, respectively) and Abcg1 (maximal induction 2.0 +- 0.18 and 1.8 +- 0.09, respectively), and the levels of membrane-bound Abca1 (2.5 +- 0.3 and 2.5 +- 0.40-fold increase, respectively), whereas they significantly decreased intracellular cholesterol content without affecting cholesterol synthesis.	Isotretinoin	14-22	ATP binding cassette subfamily A member 1	Rattus norvegicus	67-72
21628419-5	2011	13-cis-RA and 9-cis-RA also significantly increased mRNA levels of Abca1 (maximal induction 7.3 +- 0.42 and 2.7 +- 0.17, respectively) and Abcg1 (maximal induction 2.0 +- 0.18 and 1.8 +- 0.09, respectively), and the levels of membrane-bound Abca1 (2.5 +- 0.3 and 2.5 +- 0.40-fold increase, respectively), whereas they significantly decreased intracellular cholesterol content without affecting cholesterol synthesis.	Isotretinoin	14-22	ATP binding cassette subfamily G member 1	Rattus norvegicus	139-144
21628419-5	2011	13-cis-RA and 9-cis-RA also significantly increased mRNA levels of Abca1 (maximal induction 7.3 +- 0.42 and 2.7 +- 0.17, respectively) and Abcg1 (maximal induction 2.0 +- 0.18 and 1.8 +- 0.09, respectively), and the levels of membrane-bound Abca1 (2.5 +- 0.3 and 2.5 +- 0.40-fold increase, respectively), whereas they significantly decreased intracellular cholesterol content without affecting cholesterol synthesis.	Isotretinoin	14-22	ATP binding cassette subfamily A member 1	Rattus norvegicus	241-246
21521770-5	2011	9-cis-RA and 13-cis-RA were also substrates of CYP26A1.	Isotretinoin	13-22	cytochrome P450 family 26 subfamily A member 1	Homo sapiens	47-54
21466536-0	2011	Isotretinoin increases skin-surface levels of neutrophil gelatinase-associated lipocalin in patients treated for severe acne.	Isotretinoin	0-12	lipocalin 2	Homo sapiens	46-88
21466536-3	2011	Recently, the protein neutrophil gelatinase-associated lipocalin (NGAL) has been identified as a mediator of the apoptotic effect of isotretinoin on sebocytes.	Isotretinoin	133-145	lipocalin 2	Homo sapiens	22-64
21466536-3	2011	Recently, the protein neutrophil gelatinase-associated lipocalin (NGAL) has been identified as a mediator of the apoptotic effect of isotretinoin on sebocytes.	Isotretinoin	133-145	lipocalin 2	Homo sapiens	66-70
21466536-5	2011	METHODS: Methods were developed to isolate and quantify skin-surface levels of NGAL from normal subjects and patients with acne undergoing treatment with isotretinoin.	Isotretinoin	154-166	lipocalin 2	Homo sapiens	79-83
21466536-8	2011	In patients, isotretinoin increases NGAL levels by 2 4-fold on the skin surface and this increase precedes decreases in sebum and P. acnes counts.	Isotretinoin	13-25	lipocalin 2	Homo sapiens	36-40
21466536-9	2011	CONCLUSIONS: These data support the hypothesis that NGAL is an important mediator of the early effects of isotretinoin on the sebaceous glands and provide insights into the mechanisms that regulate NGAL expression in the skin.	Isotretinoin	106-118	lipocalin 2	Homo sapiens	52-56
21292632-1	2011	The study reported by Lee and colleagues in this issue of the journal (beginning on page 185) incorporated global genetic variation within a new assessment of the outcome of a previously reported phase-III trial of low-dose 13-cis-retinoic acid (13-cRA) for preventing second primary tumors (SPT) or the recurrence of head-and-neck cancer.	Isotretinoin	224-244	myotubularin related protein 11	Homo sapiens	249-252
21235714-1	2011	13-cis Retinoic acid (13cRA), a stereoisomeric form of retinoic acid, is naturally generated in the body and is also used clinically to treat acute promyelocytic leukemia, some skin diseases and cancer.	Isotretinoin	0-20	myotubularin related protein 11	Homo sapiens	24-27
21235714-4	2011	The present study identified and characterized a novel enzyme in zebrafish brain, 13-cis isomerohydrolase (13cIMH) (EC 5.2.1.7), which exclusively generated 13-cis retinol and can be oxidized to 13cRA.	Isotretinoin	195-200	retinoid isomerohydrolase RPE65 b	Danio rerio	107-113
21292633-2	2011	13-cis-retinoic acid (13-cRA) has been tested in chemoprevention clinical trials, but the results have been inconclusive.	Isotretinoin	0-20	myotubularin related protein 11	Homo sapiens	25-28
21159604-0	2010	Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteins.	Isotretinoin	68-88	BCL2 apoptosis regulator	Homo sapiens	122-127
21159604-9	2010	Thus, combining 13-cis-RA with cytotoxic chemotherapy significantly reduced the cytotoxicity for neuroblastoma in vitro, mediated at least in part via the antiapoptotic Bcl-2 family of proteins.	Isotretinoin	16-25	BCL2 apoptosis regulator	Homo sapiens	169-174
20833146-8	2010	Raldh3 catalyzes the conversion of 13-cis retinal to 13-cis retinoic acid and we revealed that 13-cis retinoic acid significantly reduces cell viability in MIN6 and alphaTC1 clone 9 cells, but not in cells of H4IIEC3, 3T3-L1, and COS-1 cell lines.	Isotretinoin	53-73	aldehyde dehydrogenase family 1, subfamily A3	Mus musculus	0-6
20708044-9	2010	To determine if 13-cis-RA was acting via retinoic acid receptors (RARs) to decrease cell number, GT1-7 cells were treated with 13-cis-RA and the RAR pan-antagonist, AGN 193109.	Isotretinoin	16-25	retinoic acid receptor, alpha	Mus musculus	66-69
20833146-8	2010	Raldh3 catalyzes the conversion of 13-cis retinal to 13-cis retinoic acid and we revealed that 13-cis retinoic acid significantly reduces cell viability in MIN6 and alphaTC1 clone 9 cells, but not in cells of H4IIEC3, 3T3-L1, and COS-1 cell lines.	Isotretinoin	95-115	aldehyde dehydrogenase family 1, subfamily A3	Mus musculus	0-6
20930691-1	2010	It is the purpose of this review to demonstrate that oral isotretinoin treatment restores all major pathogenetic factors of acne vulgaris by upregulation of the nuclear transcription factor FoxO1, which will be shown to be the major target of retinoid action.	Isotretinoin	58-70	forkhead box O1	Homo sapiens	190-195
20930691-4	2010	Isotretinoin-induced upregulation of nuclear FoxO1 is proposed to be responsible for the mode of action of isotretinoin on all major pathogenetic factors in acne.	Isotretinoin	0-12	forkhead box O1	Homo sapiens	45-50
20930691-4	2010	Isotretinoin-induced upregulation of nuclear FoxO1 is proposed to be responsible for the mode of action of isotretinoin on all major pathogenetic factors in acne.	Isotretinoin	107-119	forkhead box O1	Homo sapiens	45-50
20930691-6	2010	All major events in acne pathogenesis as well as all major effects of isotretinoin treatment appear to be related to modifications of the PI3K/Akt/FoxO1 signaling pathway, the well-known oncogenic pathway.	Isotretinoin	70-82	AKT serine/threonine kinase 1	Homo sapiens	143-146
20930691-6	2010	All major events in acne pathogenesis as well as all major effects of isotretinoin treatment appear to be related to modifications of the PI3K/Akt/FoxO1 signaling pathway, the well-known oncogenic pathway.	Isotretinoin	70-82	forkhead box O1	Homo sapiens	147-152
20421446-0	2010	Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation.	Isotretinoin	51-71	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	27-33
20084480-0	2010	Antiproliferative effect of 13-cis-retinoic acid is associated with granulocyte differentiation and decrease in cyclin B1 and Bcl-2 protein levels in G0/G1 arrested HL-60 cells.	Isotretinoin	28-48	cyclin B1	Homo sapiens	112-121
20084480-0	2010	Antiproliferative effect of 13-cis-retinoic acid is associated with granulocyte differentiation and decrease in cyclin B1 and Bcl-2 protein levels in G0/G1 arrested HL-60 cells.	Isotretinoin	28-48	BCL2 apoptosis regulator	Homo sapiens	126-131
20084480-2	2010	In this study we demonstrate that 13-cis-RA has a dose and time-dependent antiproliferative effect on HL-60 PML cell line, that it induces cell accumulation in resting G0/G1 phase of the cell cycle followed by an increase in CD11b granulocyte differentiation antigen expression.	Isotretinoin	34-43	PML nuclear body scaffold	Homo sapiens	108-111
20084480-2	2010	In this study we demonstrate that 13-cis-RA has a dose and time-dependent antiproliferative effect on HL-60 PML cell line, that it induces cell accumulation in resting G0/G1 phase of the cell cycle followed by an increase in CD11b granulocyte differentiation antigen expression.	Isotretinoin	34-43	integrin subunit alpha M	Homo sapiens	225-230
20421446-1	2010	CYP2C8 has a major role in the metabolism of the anticancer agents 13-cis retinoic acid (13cisRA) and paclitaxel.	Isotretinoin	67-87	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
20421446-1	2010	CYP2C8 has a major role in the metabolism of the anticancer agents 13-cis retinoic acid (13cisRA) and paclitaxel.	Isotretinoin	89-96	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
20421446-4	2010	In the current study, the effect of two common nonsynonymous CYP2C8 polymorphisms, CYP2C8*3 (R139K and K399R) and *4 (I264M), on the metabolism of 13cisRA and paclitaxel was examined using an Escherichia coli expression system with coexpression of human cytochrome P450 reductase.	Isotretinoin	147-154	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	61-67
20421446-4	2010	In the current study, the effect of two common nonsynonymous CYP2C8 polymorphisms, CYP2C8*3 (R139K and K399R) and *4 (I264M), on the metabolism of 13cisRA and paclitaxel was examined using an Escherichia coli expression system with coexpression of human cytochrome P450 reductase.	Isotretinoin	147-154	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	83-89
20128787-0	2010	Short-term isotretinoin treatment decreases insulin-like growth factor-1 and insulin-like growth factor binding protein-3 levels: does isotretinoin affect growth hormone physiology?	Isotretinoin	11-23	insulin like growth factor 1	Homo sapiens	44-121
20394627-0	2010	Is nuclear deficiency of FoxO1 due to increased growth factor/PI3K/Akt-signalling in acne vulgaris reversed by isotretinoin treatment?	Isotretinoin	111-123	forkhead box O1	Homo sapiens	25-30
20225331-0	2010	A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid.	Isotretinoin	189-209	epidermal growth factor receptor	Homo sapiens	99-131
19533139-1	2010	We report a case of acute sacroiliitis with severe disability after only 3 weeks of isotretinoin therapy with graduate reduction of pain, limitation and muscle incompetence after discontinuation of the drug and ACTH-depo injection and Ethodolac therapy.	Isotretinoin	84-96	proopiomelanocortin	Homo sapiens	211-215
20346742-1	2010	We document an EGFR mutation in a patient with papillary renal cell cancer with a history of multiple therapies, including interferon-alpha, interleukin-2, 5-fluorouracil, and interferon-alpha together with 13-cis-retinoic acid, to which floxuridine was later added, and thalidomide maintenance therapy for six years.	Isotretinoin	207-227	epidermal growth factor receptor	Homo sapiens	15-19
20308471-2	2010	13cisRA is known to undergo cytochrome P450-mediated oxidation, mainly by CYP2C8, but phase II metabolic pathways have not been characterized.	Isotretinoin	0-7	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	74-80
20308471-4	2010	Both HLM and, to a greater extent, HIM catalyzed the glucuronidation of 13cisRA and 4-oxo 13cisRA.	Isotretinoin	72-79	oxysterol binding protein 2	Homo sapiens	5-8
20308471-8	2010	UGT1A3 exhibited the highest rate of activity toward both substrates, and a high rate of activity toward 13cisRA glucuronidation was also observed with UGT1A7.	Isotretinoin	105-112	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	0-6
20308471-8	2010	UGT1A3 exhibited the highest rate of activity toward both substrates, and a high rate of activity toward 13cisRA glucuronidation was also observed with UGT1A7.	Isotretinoin	105-112	UDP glucuronosyltransferase family 1 member A7	Homo sapiens	152-158
20128787-0	2010	Short-term isotretinoin treatment decreases insulin-like growth factor-1 and insulin-like growth factor binding protein-3 levels: does isotretinoin affect growth hormone physiology?	Isotretinoin	11-23	growth hormone 1	Homo sapiens	155-169
20128787-3	2010	It was previously reported that serum growth hormone (GH) levels decreased with isotretinoin treatment.	Isotretinoin	80-92	growth hormone 1	Homo sapiens	38-52
20128787-3	2010	It was previously reported that serum growth hormone (GH) levels decreased with isotretinoin treatment.	Isotretinoin	80-92	growth hormone 1	Homo sapiens	54-56
20128787-10	2010	CONCLUSIONS: Isotretinoin therapy may have an effect on GH physiology, and further studies are needed to understand this association.	Isotretinoin	13-25	growth hormone 1	Homo sapiens	56-58
20178647-1	2010	BACKGROUND: To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid (CRA)/interferon-alpha2b (IFN) with paclitaxel (TAX), or mitoxantrone, estramustine and vinorelbine (MEV) will have clinical activity in men with metastatic castrate-resistant prostate cancer (CRPC).	Isotretinoin	65-85	BCL2 apoptosis regulator	Homo sapiens	54-59
20178647-1	2010	BACKGROUND: To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid (CRA)/interferon-alpha2b (IFN) with paclitaxel (TAX), or mitoxantrone, estramustine and vinorelbine (MEV) will have clinical activity in men with metastatic castrate-resistant prostate cancer (CRPC).	Isotretinoin	87-90	BCL2 apoptosis regulator	Homo sapiens	54-59
21058193-2	2010	Cox proportional hazards models describe the relationship between dose quartiles of isotretinoin and retinol use and time to first occurrence of squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) in crude and adjusted models.	Isotretinoin	84-96	serpin family B member 3	Homo sapiens	170-173
19880164-2	2010	Previously, we showed that low-dose interleukin-2 (IL-2) and 13-cis-retinoic acid (RA) improved the tumor-associated immunodeficiency and decreased VEGF in patients with AOC.	Isotretinoin	61-81	vascular endothelial growth factor A	Homo sapiens	148-152
19880164-2	2010	Previously, we showed that low-dose interleukin-2 (IL-2) and 13-cis-retinoic acid (RA) improved the tumor-associated immunodeficiency and decreased VEGF in patients with AOC.	Isotretinoin	83-85	vascular endothelial growth factor A	Homo sapiens	148-152
20465648-9	2010	Slight but significant difference between A/B for p53 with major reduction post isotretinoin [0.66+/-0.31 vs. 0.94+/-0.34 respectively (P = 0.04) was observed.	Isotretinoin	80-92	tumor protein p53	Homo sapiens	50-53
20150637-2	2010	PATIENTS AND METHODS: With the aim of increasing patient"s lymphocyte count and reducing VEGF, wich could translate into an improved immune function and a better clinical outcome, patients with HRBC, received HDCT, PBPCT and immunotherapy with interleukin-2 (IL-2) and 13-cis retinoic acid (RA).	Isotretinoin	269-289	vascular endothelial growth factor A	Homo sapiens	89-93
19552718-3	2010	MATERIALS AND METHODS: HNP 1-3 expression was investigated in 35 acne patients treated with isotretinoin and in 25 healthy subjects.	Isotretinoin	92-104	HNP1	Homo sapiens	23-28
19552718-7	2010	Isotretinoin treatment achieved a decrease in the perivascular and interstitial HNP 1-3 expression of pustular lesions (P = 0.01, P = 0.001, respectively).	Isotretinoin	0-12	HNP1	Homo sapiens	80-85
19646277-4	2009	PATIENTS AND METHODS: In this prospective study, 53 patients with radioiodine non avid metastatic disease (45) or hyperthyroglobulinemia (8) were treated with 13-cis-retinoic acid (13-CRA) [1.0 mg/kg/day over 1st week and then 1.5 mg/kg] for six weeks prior to I-131 treatment performed under rhTSH stimulation.	Isotretinoin	159-179	myotubularin related protein 11	Homo sapiens	184-187
19331204-2	2009	The primary endpoint evaluated in this study was whether interleukin-2 (IL-2) and 13-cisretinoic acid (RA) treatment reduced VEGF and improved immune function in such patients.	Isotretinoin	82-101	interleukin 2 receptor subunit alpha	Homo sapiens	103-105
19331204-2	2009	The primary endpoint evaluated in this study was whether interleukin-2 (IL-2) and 13-cisretinoic acid (RA) treatment reduced VEGF and improved immune function in such patients.	Isotretinoin	82-101	vascular endothelial growth factor A	Homo sapiens	125-129
18792915-11	2009	Incubation of 13-cis-retinoic acid (RA)-treated aHSCs with superoxide increased their GSH content significantly, and prevented superoxide-induced p38-MAPK and caspase-3 activation while dramatically reducing the extent of apoptosis.	Isotretinoin	14-34	mitogen activated protein kinase 14	Rattus norvegicus	146-149
19041696-0	2009	Different mRNA expression profiling of nuclear retinoid, thyroid, estrogen and PPARgamma receptors, their coregulators and selected genes in rat liver and spleen in response to short-term in vivo administration of 13-cis retinoic acid.	Isotretinoin	214-234	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	79-88
19041696-2	2009	In this work we describe different effects of short-term treatment of Wistar male rats with 13-cis retinoic acid on the regulation of retinoic acid receptors (RARs), retinoid-X receptors (RXRs), thyroid hormone receptors (TRs), ERs, 5"-DI, EGFR and erb-B2/neu genes in liver and/or spleen.	Isotretinoin	92-112	epidermal growth factor receptor	Rattus norvegicus	240-244
19041696-2	2009	In this work we describe different effects of short-term treatment of Wistar male rats with 13-cis retinoic acid on the regulation of retinoic acid receptors (RARs), retinoid-X receptors (RXRs), thyroid hormone receptors (TRs), ERs, 5"-DI, EGFR and erb-B2/neu genes in liver and/or spleen.	Isotretinoin	92-112	erb-b2 receptor tyrosine kinase 2	Rattus norvegicus	249-255
19041696-3	2009	Using RT-PCR analysis we have found that administration of 13-cis retinoic acid enhanced expression of RARbeta and PPARgamma mRNA, and decreased expression of RARalpha, RARgamma, RXRbeta and TRbeta mRNA in liver.	Isotretinoin	59-79	retinoic acid receptor, beta	Rattus norvegicus	103-110
19041696-3	2009	Using RT-PCR analysis we have found that administration of 13-cis retinoic acid enhanced expression of RARbeta and PPARgamma mRNA, and decreased expression of RARalpha, RARgamma, RXRbeta and TRbeta mRNA in liver.	Isotretinoin	59-79	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	115-124
19041696-3	2009	Using RT-PCR analysis we have found that administration of 13-cis retinoic acid enhanced expression of RARbeta and PPARgamma mRNA, and decreased expression of RARalpha, RARgamma, RXRbeta and TRbeta mRNA in liver.	Isotretinoin	59-79	retinoic acid receptor, alpha	Rattus norvegicus	159-167
19041696-3	2009	Using RT-PCR analysis we have found that administration of 13-cis retinoic acid enhanced expression of RARbeta and PPARgamma mRNA, and decreased expression of RARalpha, RARgamma, RXRbeta and TRbeta mRNA in liver.	Isotretinoin	59-79	retinoid X receptor beta	Rattus norvegicus	179-186
19041696-3	2009	Using RT-PCR analysis we have found that administration of 13-cis retinoic acid enhanced expression of RARbeta and PPARgamma mRNA, and decreased expression of RARalpha, RARgamma, RXRbeta and TRbeta mRNA in liver.	Isotretinoin	59-79	thyroid hormone receptor beta	Rattus norvegicus	191-197
20726329-4	2009	This work aimed to study the degree of expression of TLR2 on peripheral blood monocytes (PBM) from patients with non-inflammatory and inflammatory acne and to investigate the influence of systemic isotretinoin therapy on TLR2 expression.	Isotretinoin	197-209	toll like receptor 2	Homo sapiens	221-225
18792915-11	2009	Incubation of 13-cis-retinoic acid (RA)-treated aHSCs with superoxide increased their GSH content significantly, and prevented superoxide-induced p38-MAPK and caspase-3 activation while dramatically reducing the extent of apoptosis.	Isotretinoin	14-34	caspase 3	Rattus norvegicus	159-168
18792915-11	2009	Incubation of 13-cis-retinoic acid (RA)-treated aHSCs with superoxide increased their GSH content significantly, and prevented superoxide-induced p38-MAPK and caspase-3 activation while dramatically reducing the extent of apoptosis.	Isotretinoin	36-38	mitogen activated protein kinase 14	Rattus norvegicus	146-149
18792915-11	2009	Incubation of 13-cis-retinoic acid (RA)-treated aHSCs with superoxide increased their GSH content significantly, and prevented superoxide-induced p38-MAPK and caspase-3 activation while dramatically reducing the extent of apoptosis.	Isotretinoin	36-38	caspase 3	Rattus norvegicus	159-168
18795249-13	2009	The dichotomous effects of isotretinoin are at least in part due to time- and dose-dependent alterations of transforming growth factor beta1 and collagen IV gene expression as also suggested by cell-culture studies in vascular smooth muscle cells.	Isotretinoin	27-39	transforming growth factor, beta 1	Rattus norvegicus	108-140
18795249-14	2009	In addition, isotretinoin affected the systemic and the renal renin-angiotensin system (which was further analyzed in a model of angiotensin II infusion of the rat).	Isotretinoin	13-25	angiotensinogen	Rattus norvegicus	129-143
18769122-9	2008	Combination treatment of cells with both SAHA and cRA induced several transcripts with known anti-cancer/immunomodulatory effects, including dhrs9, gata3, il1beta, phlda1, txk and vhl.	Isotretinoin	50-53	dehydrogenase/reductase 9	Homo sapiens	141-146
18368485-4	2009	Indeed, treatment of cells with 1 muM all-trans retinoic acid (ATRA) or 1 muM 13-cis retinoic acid (13-CRA) for 7 days induced astrocytic differentiation with upregulation of glial fibrillary acidic protein (GFAP) and down regulation of telomerase activity.	Isotretinoin	78-98	LUC7 like 3 pre-mRNA splicing factor	Homo sapiens	103-106
18368485-4	2009	Indeed, treatment of cells with 1 muM all-trans retinoic acid (ATRA) or 1 muM 13-cis retinoic acid (13-CRA) for 7 days induced astrocytic differentiation with upregulation of glial fibrillary acidic protein (GFAP) and down regulation of telomerase activity.	Isotretinoin	78-98	glial fibrillary acidic protein	Homo sapiens	175-206
18368485-4	2009	Indeed, treatment of cells with 1 muM all-trans retinoic acid (ATRA) or 1 muM 13-cis retinoic acid (13-CRA) for 7 days induced astrocytic differentiation with upregulation of glial fibrillary acidic protein (GFAP) and down regulation of telomerase activity.	Isotretinoin	78-98	glial fibrillary acidic protein	Homo sapiens	208-212
19212007-0	2008	Short term 13-cis-retinoic acid treatment at therapeutic doses elevates expression of leptin, GLUT4, PPARgamma and aP2 in rat adipose tissue.	Isotretinoin	11-31	leptin	Rattus norvegicus	86-92
19212007-0	2008	Short term 13-cis-retinoic acid treatment at therapeutic doses elevates expression of leptin, GLUT4, PPARgamma and aP2 in rat adipose tissue.	Isotretinoin	11-31	solute carrier family 2 member 4	Rattus norvegicus	94-99
19212007-0	2008	Short term 13-cis-retinoic acid treatment at therapeutic doses elevates expression of leptin, GLUT4, PPARgamma and aP2 in rat adipose tissue.	Isotretinoin	11-31	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	101-110
19212007-0	2008	Short term 13-cis-retinoic acid treatment at therapeutic doses elevates expression of leptin, GLUT4, PPARgamma and aP2 in rat adipose tissue.	Isotretinoin	11-31	fatty acid binding protein 4	Rattus norvegicus	115-118
19212007-6	2008	Short-term treatment with therapeutic doses of 13cRA caused significant increase of the aP2, PPARgamma and moderately RXRalpha gene expression.	Isotretinoin	47-52	fatty acid binding protein 4	Rattus norvegicus	88-91
19212007-6	2008	Short-term treatment with therapeutic doses of 13cRA caused significant increase of the aP2, PPARgamma and moderately RXRalpha gene expression.	Isotretinoin	47-52	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	93-102
19212007-6	2008	Short-term treatment with therapeutic doses of 13cRA caused significant increase of the aP2, PPARgamma and moderately RXRalpha gene expression.	Isotretinoin	47-52	retinoid X receptor alpha	Rattus norvegicus	118-126
19212007-7	2008	Similarly, the relative amount of mRNA for leptin and GLUT4 was increased, while the TNFa transcript was decreased after treatment with 13cRA.	Isotretinoin	136-141	tumor necrosis factor	Rattus norvegicus	85-89
19288903-15	2008	The effect of acupuncture is stronger than that of Isotretinoin Capsules in lowering serum IL-6 content and has fewer adverse effects.	Isotretinoin	51-63	interleukin 6	Homo sapiens	91-95
18769122-9	2008	Combination treatment of cells with both SAHA and cRA induced several transcripts with known anti-cancer/immunomodulatory effects, including dhrs9, gata3, il1beta, phlda1, txk and vhl.	Isotretinoin	50-53	GATA binding protein 3	Homo sapiens	148-153
18769122-9	2008	Combination treatment of cells with both SAHA and cRA induced several transcripts with known anti-cancer/immunomodulatory effects, including dhrs9, gata3, il1beta, phlda1, txk and vhl.	Isotretinoin	50-53	interleukin 1 beta	Homo sapiens	155-162
18769122-9	2008	Combination treatment of cells with both SAHA and cRA induced several transcripts with known anti-cancer/immunomodulatory effects, including dhrs9, gata3, il1beta, phlda1, txk and vhl.	Isotretinoin	50-53	pleckstrin homology like domain family A member 1	Homo sapiens	164-170
18769122-9	2008	Combination treatment of cells with both SAHA and cRA induced several transcripts with known anti-cancer/immunomodulatory effects, including dhrs9, gata3, il1beta, phlda1, txk and vhl.	Isotretinoin	50-53	TXK tyrosine kinase	Homo sapiens	172-175
18769122-9	2008	Combination treatment of cells with both SAHA and cRA induced several transcripts with known anti-cancer/immunomodulatory effects, including dhrs9, gata3, il1beta, phlda1, txk and vhl.	Isotretinoin	50-53	von Hippel-Lindau tumor suppressor	Homo sapiens	180-183
18458045-4	2008	13-cis-RA increased the release of prostaglandin I(2) (PGI(2)), both spontaneous and thrombin-induced, in terms of 6-oxo-PGF(1alpha) analyzed by enzyme-immunoassay.	Isotretinoin	0-9	coagulation factor II, thrombin	Homo sapiens	85-93
18466335-3	2008	The present experiments were performed to see whether 13-cis-RA and all-trans-RA could alter the dendritic morphology of cultured hippocampal neurons via RA receptors: retinoic acid receptor (RAR) and retinoid X receptor (RXR).	Isotretinoin	54-63	retinoic acid receptor, alpha	Mus musculus	168-190
18466335-3	2008	The present experiments were performed to see whether 13-cis-RA and all-trans-RA could alter the dendritic morphology of cultured hippocampal neurons via RA receptors: retinoic acid receptor (RAR) and retinoid X receptor (RXR).	Isotretinoin	54-63	retinoic acid receptor, alpha	Mus musculus	192-195
18466335-5	2008	The negative changes induced by 13-cis-RA and all-trans-RA were antagonized by RXR antagonists and RAR antagonists, respectively.	Isotretinoin	32-41	retinoic acid receptor, alpha	Mus musculus	99-102
18466335-6	2008	The positive changes induced by a low dose of 13-cis-RA were blocked by both RXR antagonists and RAR antagonists.	Isotretinoin	46-55	retinoic acid receptor, alpha	Mus musculus	97-100
18280804-6	2008	Moreover, generation of ATRA- or cis-retinoic acid (cis-RA)-antiproliferative responses is enhanced in 4E-BP1 knockout cells.	Isotretinoin	33-50	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	103-109
18280804-6	2008	Moreover, generation of ATRA- or cis-retinoic acid (cis-RA)-antiproliferative responses is enhanced in 4E-BP1 knockout cells.	Isotretinoin	52-58	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	103-109
18166465-3	2008	We found that the combination of four HDIs (CI-994, MS-275, SAHA, and TSA) with retinoids all-trans-retinoic acid (ATRA) or 13-cis-retinoic acid (13-CRA) or our atypical retinoic acid metabolism blocking agents (RAMBAs) 1 (VN/14-1) or 2 (VN/66-1) produced synergistic anti-neoplastic activity on human LNCaP prostate cancer cells.	Isotretinoin	124-144	myotubularin related protein 11	Homo sapiens	149-152
18416830-2	2008	Here, we have demonstrated that the observed effects using ATRA and 9-cis RA are shared with the clinically useful RAR ligand, 13-cis retinoic acid (13-cis RA), and the retinoic acid receptor-alpha (RAR-alpha)-selective agonist, AM580 but not with the RAR-beta/gamma ligand, 4-hydroxyphenylretinamide (4-HPR).	Isotretinoin	127-147	retinoic acid receptor beta	Homo sapiens	252-260
18317594-0	2008	Neutrophil gelatinase-associated lipocalin mediates 13-cis retinoic acid-induced apoptosis of human sebaceous gland cells.	Isotretinoin	52-72	lipocalin 2	Homo sapiens	0-42
18317594-7	2008	Increased immunolocalization of NGAL was noted in patients" sebaceous glands following treatment with 13-cis RA, and recombinant NGAL induced apoptosis in SEB-1 sebocytes.	Isotretinoin	102-111	lipocalin 2	Homo sapiens	32-36
18317594-9	2008	These data indicate that NGAL mediates the apoptotic effect of 13-cis RA and suggest that agents that selectively induce NGAL expression in sebaceous glands might represent therapeutic alternatives to the use of 13-cis RA to treat individuals with acne.	Isotretinoin	63-72	lipocalin 2	Homo sapiens	25-29
18181979-1	2008	BACKGROUND: In the last two decades, there has been an increasing use of isotretinoin (13-cis-retinoic acid or 13-CRA) for treatment of severe, and recently mild and moderate, acne in Westernized populations.	Isotretinoin	73-85	myotubularin related protein 11	Homo sapiens	114-117
17987264-2	2008	Treatment of cells with 1 microM all-trans retinoic acid (ATRA) or 1 microM 13-cis retinoic acid (13-CRA) for 7 days induced astrocytic differentiation, overexpression of glial fibrillary acidic protein (GFAP), and also down regulated telomerase expression and activity, thereby increased sensitivity to TXL for apoptosis.	Isotretinoin	76-96	myotubularin related protein 11	Homo sapiens	101-104
17987264-2	2008	Treatment of cells with 1 microM all-trans retinoic acid (ATRA) or 1 microM 13-cis retinoic acid (13-CRA) for 7 days induced astrocytic differentiation, overexpression of glial fibrillary acidic protein (GFAP), and also down regulated telomerase expression and activity, thereby increased sensitivity to TXL for apoptosis.	Isotretinoin	76-96	glial fibrillary acidic protein	Homo sapiens	171-202
17987264-2	2008	Treatment of cells with 1 microM all-trans retinoic acid (ATRA) or 1 microM 13-cis retinoic acid (13-CRA) for 7 days induced astrocytic differentiation, overexpression of glial fibrillary acidic protein (GFAP), and also down regulated telomerase expression and activity, thereby increased sensitivity to TXL for apoptosis.	Isotretinoin	76-96	glial fibrillary acidic protein	Homo sapiens	204-208
18652567-0	2008	13-cis-retinoic acid induces apoptosis by modulating caspase-3, bcl-2, and p53 gene expression and regulates the activation of transcription factors in B16F-10 melanoma cells.	Isotretinoin	0-20	caspase 3	Mus musculus	53-62
18652567-0	2008	13-cis-retinoic acid induces apoptosis by modulating caspase-3, bcl-2, and p53 gene expression and regulates the activation of transcription factors in B16F-10 melanoma cells.	Isotretinoin	0-20	B cell leukemia/lymphoma 2	Mus musculus	64-69
18181979-8	2008	RESULTS: In both groups, isotretinoin supplementation caused a dramatic increase in the circulating concentration of 13-CRA and its derivatives.	Isotretinoin	25-37	myotubularin related protein 11	Homo sapiens	120-123
18652567-0	2008	13-cis-retinoic acid induces apoptosis by modulating caspase-3, bcl-2, and p53 gene expression and regulates the activation of transcription factors in B16F-10 melanoma cells.	Isotretinoin	0-20	transformation related protein 53, pseudogene	Mus musculus	75-78
17916647-7	2007	RA, in combination with 22-hydroxycholesterol, could induce apo A-I gene expression without any impact on apo A-I mass.	Isotretinoin	0-2	apolipoprotein A1	Homo sapiens	60-67
18652567-4	2008	13-cis-retinoic acid treatment also showed an inhibitory effect on bcl-2 expression and upregulated p53 and caspase-3 gene expression in B16F-10 melanoma cells.	Isotretinoin	0-20	B cell leukemia/lymphoma 2	Mus musculus	67-72
18652567-4	2008	13-cis-retinoic acid treatment also showed an inhibitory effect on bcl-2 expression and upregulated p53 and caspase-3 gene expression in B16F-10 melanoma cells.	Isotretinoin	0-20	transformation related protein 53, pseudogene	Mus musculus	100-103
18652567-4	2008	13-cis-retinoic acid treatment also showed an inhibitory effect on bcl-2 expression and upregulated p53 and caspase-3 gene expression in B16F-10 melanoma cells.	Isotretinoin	0-20	caspase 3	Mus musculus	108-117
18652567-5	2008	The study also reveals that 13-cis-retinoic acid treatment could alter the production and expression of proinflammatory cytokines and could inhibit the activation and nuclear translocation of p65, p50, and c-Rel subunits of nuclear factor-kappaB, and other transcription factors such as c-fos, activated transcription factor-2, and cyclic adenosine monophosphate response element-binding protein in B16F-10 melanoma cells.	Isotretinoin	28-48	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	192-195
18652567-5	2008	The study also reveals that 13-cis-retinoic acid treatment could alter the production and expression of proinflammatory cytokines and could inhibit the activation and nuclear translocation of p65, p50, and c-Rel subunits of nuclear factor-kappaB, and other transcription factors such as c-fos, activated transcription factor-2, and cyclic adenosine monophosphate response element-binding protein in B16F-10 melanoma cells.	Isotretinoin	28-48	dynactin 2	Mus musculus	197-200
18652567-5	2008	The study also reveals that 13-cis-retinoic acid treatment could alter the production and expression of proinflammatory cytokines and could inhibit the activation and nuclear translocation of p65, p50, and c-Rel subunits of nuclear factor-kappaB, and other transcription factors such as c-fos, activated transcription factor-2, and cyclic adenosine monophosphate response element-binding protein in B16F-10 melanoma cells.	Isotretinoin	28-48	reticuloendotheliosis oncogene	Mus musculus	206-211
18652567-5	2008	The study also reveals that 13-cis-retinoic acid treatment could alter the production and expression of proinflammatory cytokines and could inhibit the activation and nuclear translocation of p65, p50, and c-Rel subunits of nuclear factor-kappaB, and other transcription factors such as c-fos, activated transcription factor-2, and cyclic adenosine monophosphate response element-binding protein in B16F-10 melanoma cells.	Isotretinoin	28-48	FBJ osteosarcoma oncogene	Mus musculus	289-292
19066126-6	2008	The differential elevation is further evidenced by the increased production of IL-2 and tissue inhibitor of metalloprotease-1 (TIMP-1) in the 13-cis-retinoic acid treated animals.	Isotretinoin	142-162	interleukin 2	Mus musculus	79-83
19066126-6	2008	The differential elevation is further evidenced by the increased production of IL-2 and tissue inhibitor of metalloprotease-1 (TIMP-1) in the 13-cis-retinoic acid treated animals.	Isotretinoin	142-162	tissue inhibitor of metalloproteinase 1	Mus musculus	88-125
19066126-6	2008	The differential elevation is further evidenced by the increased production of IL-2 and tissue inhibitor of metalloprotease-1 (TIMP-1) in the 13-cis-retinoic acid treated animals.	Isotretinoin	142-162	tissue inhibitor of metalloproteinase 1	Mus musculus	127-133
19066126-9	2008	Furthermore, 13-cis-retinoic acid treatment could inhibit the activation and nuclear translocation of p65, p50, c-Rel subunits of nuclear factor-KB, and other transcription factors such as c-fos, activated transcription factor-2, and cyclic adenosine monophosphate response element-binding protein in B16F-10 melanoma cells.	Isotretinoin	13-33	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	102-105
19066126-9	2008	Furthermore, 13-cis-retinoic acid treatment could inhibit the activation and nuclear translocation of p65, p50, c-Rel subunits of nuclear factor-KB, and other transcription factors such as c-fos, activated transcription factor-2, and cyclic adenosine monophosphate response element-binding protein in B16F-10 melanoma cells.	Isotretinoin	13-33	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	107-110
19066126-9	2008	Furthermore, 13-cis-retinoic acid treatment could inhibit the activation and nuclear translocation of p65, p50, c-Rel subunits of nuclear factor-KB, and other transcription factors such as c-fos, activated transcription factor-2, and cyclic adenosine monophosphate response element-binding protein in B16F-10 melanoma cells.	Isotretinoin	13-33	FBJ osteosarcoma oncogene	Mus musculus	191-194
19746216-6	2007	RESULTS: All-trans retinoic acid and 13-cis retinoic acid induced a reduction of NF-kappaB activity up to 64% and 65%, respectively, compared to the control.	Isotretinoin	37-57	nuclear factor kappa B subunit 1	Homo sapiens	81-90
17694433-3	2007	We found that all-trans retinoic acid (ATRA) or 13-cis retinoic acid (13-CRA) induced astrocytic differentiation with down regulation of telomerase activity in rat glioblastoma C6 cells and enhanced sensitivity of the cells to interferon-gamma (IFN-gamma) or taxol (TXL) for apoptosis.	Isotretinoin	48-68	interferon gamma	Rattus norvegicus	227-243
17694433-3	2007	We found that all-trans retinoic acid (ATRA) or 13-cis retinoic acid (13-CRA) induced astrocytic differentiation with down regulation of telomerase activity in rat glioblastoma C6 cells and enhanced sensitivity of the cells to interferon-gamma (IFN-gamma) or taxol (TXL) for apoptosis.	Isotretinoin	48-68	interferon gamma	Rattus norvegicus	245-254
17694433-3	2007	We found that all-trans retinoic acid (ATRA) or 13-cis retinoic acid (13-CRA) induced astrocytic differentiation with down regulation of telomerase activity in rat glioblastoma C6 cells and enhanced sensitivity of the cells to interferon-gamma (IFN-gamma) or taxol (TXL) for apoptosis.	Isotretinoin	70-76	interferon gamma	Rattus norvegicus	227-243
17694433-3	2007	We found that all-trans retinoic acid (ATRA) or 13-cis retinoic acid (13-CRA) induced astrocytic differentiation with down regulation of telomerase activity in rat glioblastoma C6 cells and enhanced sensitivity of the cells to interferon-gamma (IFN-gamma) or taxol (TXL) for apoptosis.	Isotretinoin	70-76	interferon gamma	Rattus norvegicus	245-254
17916375-7	2007	The tTG activity in PBMCs reflected a trend to be enhanced after 13-cis retinoic acid supplementation.	Isotretinoin	65-85	transglutaminase 2	Homo sapiens	4-7
17895527-0	2007	13-cis-Retinoic acid alters intracellular serotonin, increases 5-HT1A receptor, and serotonin reuptake transporter levels in vitro.	Isotretinoin	0-20	solute carrier family 6 member 4	Rattus norvegicus	84-114
18194936-7	2007	CONCLUSION: 13-cis-Retinoic acid likely causes insulin resistance through its role as an agonist of retinoid A and X receptors.	Isotretinoin	12-32	insulin	Homo sapiens	47-54
18194936-8	2007	Although elevated levels of serum triglycerides are well documented with use of this drug, to the best of our knowledge this is the first report of a patient in whom polycystic ovary syndrome, a condition known to be associated with insulin resistance, manifested during isotretinoin therapy.	Isotretinoin	271-283	insulin	Homo sapiens	233-240
17895527-10	2007	SERT protein levels were significantly increased to 142.5 +/- 11.1% and 119.2 +/- 3.6% of control by 48 hrs of treatment with 2.5 and 10 microM of 13-cis-RA respectively.	Isotretinoin	147-156	solute carrier family 6 member 4	Rattus norvegicus	0-4
17514648-4	2007	Quantitative real-time PCR showed significant inhibition of 13-cis RA-induced HOXB7 expression by thalidomide with IC(50) approximately 0.1-0.2 microg/ml when given simultaneously with 13-cis RA but not when administered 18 h later (p &lt; 0.0001).	Isotretinoin	60-69	homeobox B7	Homo sapiens	78-83
17486130-2	2007	As intracellular metabolism of ATRA by CYP26 may result in clinical resistance to 13cisRA, an increase in efficacy may be achieved through modulation of this metabolic pathway.	Isotretinoin	82-89	cytochrome P450, family 26, subfamily a, polypeptide 1	Mus musculus	39-44
17486130-9	2007	These data suggest considerable potential for CYP26 inhibitors in the future treatment of neuroblastoma with 13cisRA.	Isotretinoin	109-116	cytochrome P450, family 26, subfamily a, polypeptide 1	Mus musculus	46-51
19746216-7	2007	For the treatment of the human transfectant cells with chemical carcinogens, all-trans retinoic acid (5 mM) and 13-cis retinoic acid (5 mM) downregulated the cellular NF-kappaB activation up to 83% and 85% compared to the NF-kappaB activity that was upregulated by NMU (5microM) and NEU (5microM), respectively.	Isotretinoin	112-132	nuclear factor kappa B subunit 1	Homo sapiens	167-176
19746216-7	2007	For the treatment of the human transfectant cells with chemical carcinogens, all-trans retinoic acid (5 mM) and 13-cis retinoic acid (5 mM) downregulated the cellular NF-kappaB activation up to 83% and 85% compared to the NF-kappaB activity that was upregulated by NMU (5microM) and NEU (5microM), respectively.	Isotretinoin	112-132	nuclear factor kappa B subunit 1	Homo sapiens	222-231
19746216-7	2007	For the treatment of the human transfectant cells with chemical carcinogens, all-trans retinoic acid (5 mM) and 13-cis retinoic acid (5 mM) downregulated the cellular NF-kappaB activation up to 83% and 85% compared to the NF-kappaB activity that was upregulated by NMU (5microM) and NEU (5microM), respectively.	Isotretinoin	112-132	neuralized E3 ubiquitin protein ligase 1	Homo sapiens	283-286
17512125-4	2007	Isotretinoin causes loss of night vision by slowing rhodopsin regeneration and chromophore recycling by the inhibition of 11-cis retinol dehydrogenase.	Isotretinoin	0-12	retinol dehydrogenase 5	Homo sapiens	122-150
17163463-1	2007	BACKGROUND: We have previously conducted phase II trials with a combination of 13-cis-retinoic acid (13-cRA), interferon-alpha2a (IFN-alpha2a), and alpha-tocopherol (alpha-TF) in patients with advanced oral premalignant lesions and locally advanced head and neck cancer in the adjuvant settings and achieved promising outcomes.	Isotretinoin	79-99	myotubularin related protein 11	Homo sapiens	104-107
16333837-1	2007	We report a neonate with 4S neuroblastoma and MYCN amplification, but favorable Shimada histology, successfully treated with chemotherapy and 13-cis-retinoic acid without stem cell transplantation.	Isotretinoin	142-162	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	46-50
17305640-0	2007	Effects of cisplatin, alpha-interferon, and 13-cis retinoic acid on the expression of Fas (CD95), intercellular adhesion molecule-1 (ICAM-1), and epidermal growth factor receptor (EGFR) in oral cancer cell lines.	Isotretinoin	44-64	Fas cell surface death receptor	Homo sapiens	91-95
17305640-0	2007	Effects of cisplatin, alpha-interferon, and 13-cis retinoic acid on the expression of Fas (CD95), intercellular adhesion molecule-1 (ICAM-1), and epidermal growth factor receptor (EGFR) in oral cancer cell lines.	Isotretinoin	44-64	intercellular adhesion molecule 1	Homo sapiens	98-131
17305640-0	2007	Effects of cisplatin, alpha-interferon, and 13-cis retinoic acid on the expression of Fas (CD95), intercellular adhesion molecule-1 (ICAM-1), and epidermal growth factor receptor (EGFR) in oral cancer cell lines.	Isotretinoin	44-64	intercellular adhesion molecule 1	Homo sapiens	133-139
17305640-0	2007	Effects of cisplatin, alpha-interferon, and 13-cis retinoic acid on the expression of Fas (CD95), intercellular adhesion molecule-1 (ICAM-1), and epidermal growth factor receptor (EGFR) in oral cancer cell lines.	Isotretinoin	44-64	epidermal growth factor receptor	Homo sapiens	146-178
18380168-2	2007	Treatment of Dalton"s lymphoma ascites cells (DLA)-induced experimental solid tumor tumor cells with 13 cis-retinoic acid, at concentrations of 25 microg/mL and 50 microg/mL, produced apoptotic morphologic changes, such as nuclear condensation and DNA-ladder formation after 48h incubation at 37 degrees C. in addition, the compound upregulated caspase-3 expression and downregulated bcl-2 gene expression.	Isotretinoin	104-121	caspase 3	Mus musculus	345-354
18380168-2	2007	Treatment of Dalton"s lymphoma ascites cells (DLA)-induced experimental solid tumor tumor cells with 13 cis-retinoic acid, at concentrations of 25 microg/mL and 50 microg/mL, produced apoptotic morphologic changes, such as nuclear condensation and DNA-ladder formation after 48h incubation at 37 degrees C. in addition, the compound upregulated caspase-3 expression and downregulated bcl-2 gene expression.	Isotretinoin	104-121	B cell leukemia/lymphoma 2	Mus musculus	384-389
18380168-4	2007	In conclusion, the results suggest that the anti-tumor activity of 13 cis-retinoic acid in DLA cells is due to apoptosis mediated by the regulation of bcl-2 and caspase-3 gene expression.	Isotretinoin	70-87	B cell leukemia/lymphoma 2	Mus musculus	151-156
18380168-4	2007	In conclusion, the results suggest that the anti-tumor activity of 13 cis-retinoic acid in DLA cells is due to apoptosis mediated by the regulation of bcl-2 and caspase-3 gene expression.	Isotretinoin	70-87	caspase 3	Mus musculus	161-170
17512311-0	2007	13-cis-Retinoic acid therapy induces insulin resistance, regulates inflammatory parameters, and paradoxically increases serum adiponectin concentration.	Isotretinoin	0-20	insulin	Homo sapiens	37-44
17512311-0	2007	13-cis-Retinoic acid therapy induces insulin resistance, regulates inflammatory parameters, and paradoxically increases serum adiponectin concentration.	Isotretinoin	0-20	adiponectin, C1Q and collagen domain containing	Homo sapiens	126-137
17512311-1	2007	13-cis-Retinoic acid treatment causes insulin resistance and disturbances in lipid and glucose metabolism.	Isotretinoin	0-20	insulin	Homo sapiens	38-45
17512311-2	2007	We studied how 13-cis-retinoic acid affects inflammatory factors and adiponectin.	Isotretinoin	15-35	adiponectin, C1Q and collagen domain containing	Homo sapiens	69-80
17512311-6	2007	Treatment with 13-cis-retinoic acid resulted in a significantly elevated serum adiponectin concentration (from 24.9 +/- 2.5 to 29.4 +/- 3.6 mg/L, P &lt; .05), hemoglobin A(1c) (from 5.27% +/- 0.05% to 5.42% +/- 0.06%, P &lt; .01), C-peptide area under the curve (from 314.2 +/- 16.6 to 350.0 +/- 21.0 (nmol .	Isotretinoin	15-35	adiponectin, C1Q and collagen domain containing	Homo sapiens	79-90
17512311-8	2007	The increase in adiponectin during 13-cis-retinoic acid therapy correlated with baseline triglycerides (r = 0.51, P &lt; .02).	Isotretinoin	35-55	adiponectin, C1Q and collagen domain containing	Homo sapiens	16-27
17513803-1	2007	PURPOSE: To conduct a phase III trial of adjuvant 13-cis-retinoic acid (13cRA) plus interferon alfa (IFN-alpha) for preventing tumor recurrence and second primary tumors (SPTs) of skin squamous cell carcinoma (SCC) among patients with aggressive skin SCC.	Isotretinoin	50-70	serpin family B member 3	Homo sapiens	210-213
17513803-1	2007	PURPOSE: To conduct a phase III trial of adjuvant 13-cis-retinoic acid (13cRA) plus interferon alfa (IFN-alpha) for preventing tumor recurrence and second primary tumors (SPTs) of skin squamous cell carcinoma (SCC) among patients with aggressive skin SCC.	Isotretinoin	72-77	serpin family B member 3	Homo sapiens	210-213
17536261-4	2007	RESULT: AR mRNA was downregulated by 13-cis-retinoic acid of 1 x 10(-5) mol/L and 1 x 10(-6) mol/L, and by baicalin of 1 x 10(-4) mol/L (P &lt; 0.05).	Isotretinoin	37-57	androgen receptor	Homo sapiens	8-10
17536261-5	2007	CONCLUSION: 13-cis-retinoic acid and baicalin may exert antiandrogenitic action by inhibiting AR mRNA expression in human sebocytes.	Isotretinoin	12-32	androgen receptor	Homo sapiens	94-96
17184907-5	2007	The ligands 9-cisRA and at-RA yielded an overall higher fold-change in D22 recruitment to RXRbeta LBD suggesting that more RXRbeta LBD-D22 complex was formed in the presence of these ligands under the assay conditions tested.	Isotretinoin	13-19	retinoid X receptor beta	Homo sapiens	90-97
17184907-5	2007	The ligands 9-cisRA and at-RA yielded an overall higher fold-change in D22 recruitment to RXRbeta LBD suggesting that more RXRbeta LBD-D22 complex was formed in the presence of these ligands under the assay conditions tested.	Isotretinoin	13-19	retinoid X receptor beta	Homo sapiens	123-130
17512125-6	2007	Since the photochemistry of melanopsin is very similar to other opsin photopigments, and it is known that melanopsin uses the same retinaldehyde chromophore, it is hypothesized here that isotretinoin may exert inhibitory effect on chromophore regeneration in ipRGCs similar to what is seen in rod and cone cells, thus enabling to alter circadian and circannual rhythms.	Isotretinoin	187-199	opsin 4	Homo sapiens	28-38
17512125-6	2007	Since the photochemistry of melanopsin is very similar to other opsin photopigments, and it is known that melanopsin uses the same retinaldehyde chromophore, it is hypothesized here that isotretinoin may exert inhibitory effect on chromophore regeneration in ipRGCs similar to what is seen in rod and cone cells, thus enabling to alter circadian and circannual rhythms.	Isotretinoin	187-199	opsin 4	Homo sapiens	106-116
16837623-8	2006	Direct comparison of other inhibitors such as fenretinide and 13-cis-retinoic acid showed multiple advantages of Ret-NH2 and its amides, including a higher potency, specificity, and lower transcription activation.	Isotretinoin	62-82	ret proto-oncogene	Mus musculus	113-116
17020619-7	2006	CONCLUSION: Isotretinoin may play a role in the treatment of ALHE due to its antiangiogenic properties via a reduction of vascular endothelial growth factor (VEGF) production by keratinocytes.	Isotretinoin	12-24	vascular endothelial growth factor A	Homo sapiens	122-156
17020619-7	2006	CONCLUSION: Isotretinoin may play a role in the treatment of ALHE due to its antiangiogenic properties via a reduction of vascular endothelial growth factor (VEGF) production by keratinocytes.	Isotretinoin	12-24	vascular endothelial growth factor A	Homo sapiens	158-162
16575387-5	2006	Although not previously demonstrated in sebocytes, we report that 13-cis RA induces apoptosis in SEB-1 sebocytes as shown by increased Annexin V-FITC staining, increased TUNEL staining, and increased cleaved caspase 3 protein.	Isotretinoin	66-75	annexin A5	Homo sapiens	135-144
16380803-1	2006	AIMS/HYPOTHESIS: We previously reported that treatment of acne with 13-cis-retinoic acid causes insulin resistance and disturbances in lipid metabolism resembling those of the insulin-resistance syndrome.	Isotretinoin	68-88	insulin	Homo sapiens	96-103
16899508-12	2006	Isotretinoin reduced Ca2+ entry in HaCaT cells and decreased survival of HaCaT and DD keratinocytes.	Isotretinoin	0-12	carbonic anhydrase 2	Homo sapiens	21-24
16391896-1	2006	In a phase II clinical trial, we sought to determine if combining celecoxib with 13-cis-retinoic acid (13-cRA, Accutane) was efficacious in the treatment of recurrent (progressive) glioblastoma multiforme (GBM).	Isotretinoin	81-101	myotubularin related protein 11	Homo sapiens	106-109
16983322-5	2006	Isotretinoin-induced apoptosis was shown to be an RAR-independent mechanism.	Isotretinoin	0-12	RAB40B, member RAS oncogene family	Homo sapiens	50-53
17006844-3	2006	MATERIAL AND METHODS: Between 1999 and 2005, 13-cis-retinoic acid was used in 11 patients with disseminated PTC and high serum level of thyroglobulin (Tg) before (131)I treatment (2 patients were treated twice - 13 treatment cycles in total).	Isotretinoin	45-65	thyroglobulin	Homo sapiens	136-149
17006844-10	2006	The possibility should be considered to use cis-retinoic acid as an independent therapeutic approach in patients with radioiodine non-avid foci of thyroid carcinoma especially those showing high expression of RARb and RXRg receptors.	Isotretinoin	44-61	retinoic acid receptor beta	Homo sapiens	209-213
16918296-2	2006	PATIENTS AND METHODS: Following prior systemic treatment with 8-week cycles of subcutaneous interferon- alpha2a (s.c. IFN-alpha2a) and subcutaneous interleukin-2 (s.c. IL-2)-based immunotherapy (5-day standard Atzpodien regimen), patients received prolonged maintenance treatment consisting of intermittent s.c. IFN-alpha2a and s.c. IL-2, combined with long-term daily peroral 13-cis-retinoic acid (p.o.	Isotretinoin	377-397	interleukin 2	Homo sapiens	148-161
16380803-5	2006	RESULTS: There was a reversible reduction in whole-body insulin sensitivity during therapy with 13-cis-retinoic acid.	Isotretinoin	96-116	insulin	Homo sapiens	56-63
16380803-9	2006	CONCLUSIONS/INTERPRETATION: There is a paradoxical increase in fasting serum adiponectin concentration during the 13-cis-retinoic acid-induced reduction in insulin sensitivity.	Isotretinoin	114-134	adiponectin, C1Q and collagen domain containing	Homo sapiens	77-88
16380803-9	2006	CONCLUSIONS/INTERPRETATION: There is a paradoxical increase in fasting serum adiponectin concentration during the 13-cis-retinoic acid-induced reduction in insulin sensitivity.	Isotretinoin	114-134	insulin	Homo sapiens	156-163
16365604-2	2006	We have previously shown that low-dose interleukin (IL)-2 and 13-cis retinoic acid (RA) decreased VEGF and improved the immune function of patients with advanced tumors treated with chemotherapy.	Isotretinoin	62-82	vascular endothelial growth factor A	Homo sapiens	98-102
16142321-1	2005	The primary objective was to assess whether low-dose Interleukin-2 (IL-2) and 13-cis-retinoic acid (RA) could decrease serum vascular endothelial growth factor (VEGF) and improve the immune function of patients with advanced ovarian cancer (AOC) responsive to chemotherapy.	Isotretinoin	78-98	vascular endothelial growth factor A	Homo sapiens	125-159
15975960-0	2005	All-trans and 9-cis retinoic acids, retinol and beta-carotene chemopreventive activities during the initial phases of hepatocarcinogenesis involve distinct actions on glutathione S-transferase positive preneoplastic lesions remodeling and DNA damage.	Isotretinoin	15-34	hematopoietic prostaglandin D synthase	Rattus norvegicus	167-192
16225983-4	2005	We studied the effect of 13-cis-retinoic acid on the gene expression of mentioned elements of the renin-angiotensin system in tumour tissue.	Isotretinoin	25-45	renin	Rattus norvegicus	98-103
16142321-1	2005	The primary objective was to assess whether low-dose Interleukin-2 (IL-2) and 13-cis-retinoic acid (RA) could decrease serum vascular endothelial growth factor (VEGF) and improve the immune function of patients with advanced ovarian cancer (AOC) responsive to chemotherapy.	Isotretinoin	78-98	vascular endothelial growth factor A	Homo sapiens	161-165
16142321-1	2005	The primary objective was to assess whether low-dose Interleukin-2 (IL-2) and 13-cis-retinoic acid (RA) could decrease serum vascular endothelial growth factor (VEGF) and improve the immune function of patients with advanced ovarian cancer (AOC) responsive to chemotherapy.	Isotretinoin	100-102	vascular endothelial growth factor A	Homo sapiens	125-159
16142321-1	2005	The primary objective was to assess whether low-dose Interleukin-2 (IL-2) and 13-cis-retinoic acid (RA) could decrease serum vascular endothelial growth factor (VEGF) and improve the immune function of patients with advanced ovarian cancer (AOC) responsive to chemotherapy.	Isotretinoin	100-102	vascular endothelial growth factor A	Homo sapiens	161-165
16185265-5	2005	Sebum also contains MMP-1, MMP-13, TIMP-1, and TIMP-2, as assessed by ELISA and western blot, but only MMP-13 was decreased following treatment with isotretinoin.	Isotretinoin	149-161	matrix metallopeptidase 1	Homo sapiens	20-25
16185265-5	2005	Sebum also contains MMP-1, MMP-13, TIMP-1, and TIMP-2, as assessed by ELISA and western blot, but only MMP-13 was decreased following treatment with isotretinoin.	Isotretinoin	149-161	matrix metallopeptidase 13	Homo sapiens	27-33
16185265-9	2005	These data indicate that MMP and TIMP of epithelial origin may be involved in acne pathogenesis, and that isotretinoin-induced reduction in MMP-9 and -13 may contribute to the therapeutic effects of the agent in acne.	Isotretinoin	106-118	matrix metallopeptidase 9	Homo sapiens	140-145
16185265-5	2005	Sebum also contains MMP-1, MMP-13, TIMP-1, and TIMP-2, as assessed by ELISA and western blot, but only MMP-13 was decreased following treatment with isotretinoin.	Isotretinoin	149-161	TIMP metallopeptidase inhibitor 1	Homo sapiens	35-41
16185265-5	2005	Sebum also contains MMP-1, MMP-13, TIMP-1, and TIMP-2, as assessed by ELISA and western blot, but only MMP-13 was decreased following treatment with isotretinoin.	Isotretinoin	149-161	TIMP metallopeptidase inhibitor 2	Homo sapiens	47-53
16185265-5	2005	Sebum also contains MMP-1, MMP-13, TIMP-1, and TIMP-2, as assessed by ELISA and western blot, but only MMP-13 was decreased following treatment with isotretinoin.	Isotretinoin	149-161	matrix metallopeptidase 13	Homo sapiens	103-109
16185265-8	2005	Isotretinoin inhibited the arachidonic acid-induced secretion and mRNA expression of proMMP-2 and -9 in both cell types and of MMP-13 in HaCaT keratinocytes.	Isotretinoin	0-12	matrix metallopeptidase 13	Homo sapiens	127-133
16194896-4	2005	Other retinoids (retinol, 9-cis-RA, and 13-cis-RA) also induced significant CYP26A1 expression in HepG2 and NB4 cells.	Isotretinoin	40-49	cytochrome P450 family 26 subfamily A member 1	Homo sapiens	76-83
16038410-10	2005	Despite a weak increase in cytosolic Hsp70, the percentage of Hsp70 membrane-positive cells dropped significantly after repeated treatments with 13-RA and ATRA in CX+ and ML-1 but not in CX- tumor cells.	Isotretinoin	145-150	heat shock protein family A (Hsp70) member 4	Homo sapiens	62-67
15972972-6	2005	In vitro, activated peritoneal macrophages of 13cRA-treated rats showed a pronounced decrease in protein secretion of inflammatory cytokines (eg, tumor necrosis factor-alpha, interleukin-6).	Isotretinoin	46-51	tumor necrosis factor	Rattus norvegicus	146-173
15972972-6	2005	In vitro, activated peritoneal macrophages of 13cRA-treated rats showed a pronounced decrease in protein secretion of inflammatory cytokines (eg, tumor necrosis factor-alpha, interleukin-6).	Isotretinoin	46-51	interleukin 6	Rattus norvegicus	175-188
15777839-7	2005	Both 9-cis-retinoic acid (9-cis-RA) and 13-cis-retinoic acid (13-cis-RA), which are stereo-isomers of ATRA, showed a modulatory effect on HGF induction similar to that of ATRA.	Isotretinoin	40-60	hepatocyte growth factor	Homo sapiens	138-141
15961764-1	2005	PURPOSE: A randomized phase II/III trial was conducted to determine whether combination treatment with 13-cis-retinoic acid (13-CRA) plus interferon alfa-2a (IFN-alpha-2a) was superior to IFN-alpha-2a alone in patients with progressive metastatic renal cell carcinoma.	Isotretinoin	103-123	myotubularin related protein 11	Homo sapiens	128-131
15806132-2	2005	We performed a pilot study to assess the efficacy and tolerability of 13cis retinoic acid (13cRA) and dexamethasone (Dex), when added to interferon alpha (IFNalpha) as maintenance therapy post autologous stem cell transplantation.	Isotretinoin	70-89	myotubularin related protein 11	Homo sapiens	93-96
15899809-10	2005	The combination of low-dose MK886, ciglitazone, and 13-cis-retinoic acid interacted at least in a superadditive fashion to inhibit the growth of lung cancer cell lines A549 and H1299, suggesting that targeting PPARgamma and AA action is a promising approach to lung cancer growth with a favorable therapeutic index.	Isotretinoin	52-72	peroxisome proliferator activated receptor gamma	Homo sapiens	210-219
15777839-7	2005	Both 9-cis-retinoic acid (9-cis-RA) and 13-cis-retinoic acid (13-cis-RA), which are stereo-isomers of ATRA, showed a modulatory effect on HGF induction similar to that of ATRA.	Isotretinoin	62-71	hepatocyte growth factor	Homo sapiens	138-141
15714209-7	2005	Both ATRA and 13cisRA dramatically induced the expression of CYP26A1 in SH-SY5Y cells, and treatment with R116010, but not acitretin, potentiated the RA-induced expression of a reporter gene and CYP26A1.	Isotretinoin	14-21	cytochrome P450 family 26 subfamily A member 1	Homo sapiens	61-68
15714209-7	2005	Both ATRA and 13cisRA dramatically induced the expression of CYP26A1 in SH-SY5Y cells, and treatment with R116010, but not acitretin, potentiated the RA-induced expression of a reporter gene and CYP26A1.	Isotretinoin	14-21	cytochrome P450 family 26 subfamily A member 1	Homo sapiens	195-202
15943494-5	2005	A combination of systemic isotretinoin and interferon-alpha-2a may provide a more potent effect than isotretinoin alone in the prevention and treatment of skin cancers.Systemic isotretinoin may be considered as an alternative drug in some dermatologic diseases unresponsive to conventional treatment modalities.	Isotretinoin	101-113	interferon alpha 2	Homo sapiens	43-62
15943494-5	2005	A combination of systemic isotretinoin and interferon-alpha-2a may provide a more potent effect than isotretinoin alone in the prevention and treatment of skin cancers.Systemic isotretinoin may be considered as an alternative drug in some dermatologic diseases unresponsive to conventional treatment modalities.	Isotretinoin	101-113	interferon alpha 2	Homo sapiens	43-62